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1. Introduction 
1.1. Immunity- an overview 
Host defense against invading microbial pathogens is elicted by two different types of 
immune responses: innate and adaptive immunity. There is a synergistic interplay 
between these two divisions. The innate immune system is an evolutionarily conserved 
form of host defense found in most multicellular organisms, which provides the first line of 
defense against infections. Innate defense mechanisms, then, initiate and provide time for 
the development of adaptive immune responses, which are characterized by high 
diversity, specificity and memory. Adaptive immunity is only found in vertebrates and is 
based on the activation of B and T lymphocytes. The enormous diversity of mature 
lymphocytes is generated by the rearrangement of different gene segments in individual 
lymphocytes. 
1.1.1. Innate immunity 
The main components of innate immunity are as follows: (1) The epithelium, which serves 
as a physical barrier to invading microbial pathogens and also secretes cytokines and 
antimicrobial peptides (see 1.2). (2) The cellular fraction, which is composed of circulating 
cells like phagocytic cells (neutrophils, macrophages), natural killer (NK) cells and 
dendritic cells. These cells combat infections by phagocytic destruction. Moreover, 
macrophages and dendritic cells are able to present detected microbial pathogens on their 
surface, thereby activating the adaptive immune system. They serve an important 
interface function, linking the innate and adaptive immune responses. (3) Blood proteins, 
including members of the complement system and other mediators of inflammation; and 
(4) Proteins called cytokines and chemokines, which lead to the recruitment of further 
immune cells.  
The innate immune system uses a limited number of germline-encoded pattern 
recognition receptors (PRRs) to recognize conserved structures originally called 
pathogen-associated molecular patterns (PAMPs). PAMPs are generated by microbes 
and are not present on mammalian cells, suggesting that PAMPs are good targets for 
innate immunity to discriminate between self and non-self (Janeway and Medzhitov 2002; 
Janeway 2005; Abbas 2007; Uematsu and Akira 2008). 
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1.1.2. Pattern recognition receptors (PRRs) 
PRRs are either located on the cell membrane, localized in intracellular compartments like 
the endosome or present in the cytosol. Due to their molecular structure, they can be 
subdivided into Toll-like receptors (TLRs), Retinoic acid-inducible gene I (RIG-I)-like 
receptors (RLRs) and Nucleotide-binding and oligomerization domain (NOD)-like 
receptors (NLRs), the latter of which are described in the discussion section below. These 
receptors show modular domain architecture with ligand-binding and signaling domains, 
the latter being regulated either through dimerization and oligomerization or through 
conformational changes by enzymatic activities. Subsequently, signaling domains recruit 
adaptor proteins that initiate intracellular signaling (Lee and Kim 2007). 
1.1.2.1. Toll-like receptors (TLRs) 
Toll was originally identified as a Drosophila gene involved in establishing the dorsal-
ventral axis during the embryogenesis of the fly, but then it was discovered that the Toll 
protein was required to explain the resistance of flies to fungal infection (Lemaitre et al. 
1996). The TLRs represent the human homolog to the Toll protein. TLRs are able to 
recognize microbes in different cellular locations. They are either expressed on the cell 
surface (TLR 1, 2, 3, 4, 5, and 6) or in intracellular compartments, namely endosomes 
(TLRs 3, 7, 8, and 9) (Ahmad-Nejad et al. 2002). Based on their primary sequences, TLRs 
can be divided into several subfamilies, each of which recognizes related PAMPs: the 
subfamily of TLR1, TLR2, and TLR6 recognizes lipids, whereas the closely-related TLR7, 
TLR8, and TLR9 recognize nucleic acids and nucleoside analogs (Akira et al. 2006). The 
major ligands for TLRs are shown in Table 1. 
TLRs consist of a leucine-rich-repeat-containing extracellular domain (LRRs), which 
mediates ligand binding and a cytoplasmic signaling domain homologous to that of the 
interleukin 1 receptor (IL-1R), termed the Toll/IL-1R homology (TIR) (Akira et al. 2006). 
Ligand-induced TLR dimerization permits the binding of TIR-domain-containing adaptor 
molecules. Four of these adaptors are MyD88 (myeloid differentiation protein 88), TIRAP 
(TIR domain-containing adaptor protein), TRIF (TIR domain-containing adaptor inducing 
IFN-ß), and TRAM (TRIF-related adaptor molecule) (Akira et al. 2006). The TLR signaling 
pathways are shown in Figure 1. MyD88 is utilized by all TLRs except TLR3 and leads to 
the activation of the IKK complex (inhibitor of nuclear factor-κB (IКB)-kinase complex), so 
that NF-κB is realesed from its inhibitor and translocates to the nucleus, where it induces 
the expression of inflammatory cytokines (Akira et al. 2006). 
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Table 1: Mammalian pattern recognition receptors: their major ligands and cell types 
(modified after (Lee and Kim 2007)). 

















Triacyl lipopeptides from bacteria and mycobacteria 
LTA from gram-positive bacteria, yeast zymosan, lipopeptides 
(Pam3CSK4, MALP2), lipoarabinomannan from mycobacteria 
Viral dsRNA, Poly (I:C) 
LPS from gram-negative bacteria, mannan from Candida albicans, 
GIPLs from Trypanosoma, viral envelope proteins from RSV and MMTV 
Bacterial flagellin 
Diacyl lipopeptides from Mycoplasma, LTA from gram-positive bacteria, 
yeast zymosan 
ssRNA from RNA viruses, imiquimod, resiquimod (R848), synthetic poly 
U RNA, certain siRNAs 
Resiquimod (R848), viral ssRNA 
Bacterial and viral CpG DNA, Hemozoin from Plasmodium 
Unknown 
Profilin-like molecule from Toxoplasma gondii, unknown ligand(s) from 
uropathogenic bacteria 
 
TLR3 does not bind MyD88 but rather utilizes the TRIF adaptor protein and mediates the 
activation of the transcription factor IRF-3 (interferon response factor-3) (Akira et al. 
2006). TLR4 engages two different signaling pathways. MyD88 and TIRAP lead to NF-κB 
activation, while TRAM and TRIF lead to activation of IRF-3. The main role of the MyD88-
dependent pathway downstream of TLR4 is to induce the expression of inflammatory 
cytokines such as IL-6, IL-12, and TNF-α, whereas the main role of the TRIF-dependent 
pathway is to induce the expression of type-I IFNs (Akira et al. 2006).  
TLRs within the endosomes recruit MyD88, leading to the activation of IRF-7, a 
transcription factor that, like IRF-3, induces type-I interferon gene expression. 
Plasmacytoid dendritic cells (pDCs) represent a subset of immune cells that specializes in 
the detection of viruses. These cells express TLR7 and TLR9 and produce large amounts 
of type-I interferons upon the detection of viruses (Akira et al. 2006; Fitzgerald-Bocarsly et 
al. 2008).  














1.1.2.2. Cytoplasmic PRRs 
The RLR family is composed of three members RIG-I (retinoic acid-inducible gene I), 
MDA-5 (melanoma-differentiation-associated gene 5) and LPG2 (laboratory of physiology 
and genetics 2) which were originally described as RNA helicases (Yoneyama et al. 
2004). These cytosolic RNA receptors are also expressed ubiquitously in non-immune 
Figure 1: TLR signaling pathway (modified after (Akira and Takeda 2004; Saito and Gale 
2008)). Simplified representation of the major pathways leading to the expression of cytokines and
type-I interferons. All TLRs apart from TLR3 share a common pathway called the MyD88-
dependent pathway that induces inflammatory cytokine production. The TIR domain-containing 
adaptor, MyD88, associates with the cytoplasmic TIR domain of TLRs, leading to the activation of 
the IКК complex (inhibitor of nuclear factor-КB (IКB)-kinase complex), which consists of IKK-α, 
IKK-ß and IKK-γ, so that NF-κB is realesed from its inhibitor and translocates to the nucleus.
TIRAP, a second TIR domain-containing adaptor, specifically mediates the MyD88-dependent 
pathway via TLR2 and TLR4. In the TLR4- and TLR3-mediated signaling pathways, a MyD88-
independent pathway exists that leads to activation of IRF-3. A third TIR domain-containing 
adaptor, TRIF, mediates this MyD88-independent pathway. A fourth TIR-domain containing 
adaptor, TRAM, is specific to the TLR4-mediated MyD88-independent/TRIF-dependent pathway. 
TLR7/8/9 act in pDCs cells via a unique pathway to induce IFN-α. TLR2 is shown to form a 
heterophilic dimer with TLR1 or TLR6, but the other TLRs are believed to form homodimers. 
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cells. The amino termini of RIG-I and MDA-5 contain two CARDs (caspase activation and 
recruitment domains), that interact with downstream adaptor molecules. LPG2 does not 
harbor this amino-terminal domain and has therefore been reported to be a negative 
regulator for RIG-I/MDA-5 signaling (Rothenfusser et al. 2005; Yoneyama et al. 2005; 
Pippig et al. 2009). However, recent studies observed that LPG2 act as a positive 
regulator of RIG-I- and MDA-5-mediated viral recognition, except for the influenza virus 
(Satoh et al. 2010). The central portion of all three family members shows homologies 
with the DexD/H box RNA helicase family and is implicated in dsRNA binding and ATP-
dependent unwinding (Cordin et al. 2006). The carboxy-terminus harbors a regulatory or 
repression domain (RD) that interacts with the helicase domain and inhibits signaling by 
the amino-terminal CARDs (Saito et al. 2007). The C-terminal regulatory domain (RD) of 
RIG-I acts as a sensor for 5`-triphosphates in RNA and dsRNA, and the binding of these 
structures induce an ATP-dependent conformational change (Cui et al. 2008; Takahasi et 
al. 2008; Takahasi et al. 2009; Yoneyama and Fujita 2010) that damasks the N-terminal 
CARDs for interaction with the CARD-containing adaptor IPS-1 (IFN-ß promoter stimulator 
1) also termed CARDIF (CARD-adaptor inducing IFN-ß), MAVS (mitochondrial antiviral 
signaling), and VISA (virus-induced signaling adaptor), which is localized within the 
mitochondrial membrane, for NF-κB and IRF-3 activation and subsequent production of 
IFN-ß (Kawai et al. 2005; Meylan et al. 2005; Seth et al. 2005; Xu et al. 2005; Kumar et al. 
2006; Sun et al. 2006). Recently it was discovered that MITA, also termed STING 
(stimulator of interferon genes), functions downstream of RIG-I and IPS-1 (Ishikawa and 
Barber 2008; Zhong et al. 2008). Besides its immunostimulatory activity, RIG-I and MDA-5 
ligands also initiate a proapoptotic signaling and have therapeutic potential for virus 
infection or tumor therapy (Besch et al. 2009). For enteroviral infection, it was shown that 
the RIG-I pathway is active in beta cells and could contribute to the induction of insulitis 
(Garcia et al. 2009). 
1.1.2.3. Cooperative recognition in innate immunity 
PAMP recognition is rendered additionally complex by cell-type-specific expression of 
different sets of PRRs. In conventional dendritic cells (cDCs) and fibroblasts virus 
protection is mediated by the cytosolic residing RLRs, whereas in plasmacytoid dendritic 
cells (pDCs) virus recognition is mediated by TLRs (Kato et al. 2005; Koyama et al. 2007; 
McCartney and Colonna 2009): Therefore, TLRs and RLRs function cooperatively to 
provide ubiquitous immune protection. Kumagai et al. showed that alveolar macrophages 
and cDCs act as the first-line sensor for invading viruses, producing IFN-α at the site of 
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infection. In contrast, pDCs are not activated until the initial defense line is broken by the 
viruses. Given that several viruses (e.g., the influenza virus) suppress the RLR-mediated 
signaling pathway, it is tempting to speculate that hosts have evolved two different type-I 
production systems to make it more difficult for viruses to escape the antiviral response 
(Kumagai et al. 2007; Kumagai et al. 2009). 
1.1.3. Nucleic acids recognition 
1.1.3.1. Recognition of DNA 
Unmethylated CpG motifs present in bacterial DNA (Hemmi et al. 2000; Bauer et al. 2001) 
have been shown to trigger the endosomally-located TLR9. The low frequency and high 
rate of methylation of CpG motifs prevent recognition of mammalian DNA by TLR9 under 
physiological circumstances.  
Further, non-self DNA is also capable of triggering cytosolic receptors (Hochrein et al. 
2004; Krug et al. 2004; Hornung and Latz 2010), as is evidenced in the recently 
discovered DNA sensors, DAI (DNA-dependent activator of IRFs) (Ishii et al. 2006; 
Stetson and Medzhitov 2006; Takaoka et al. 2007), the inflammasome (Muruve et al. 
2008) and AIM2 (absent in melanoma 2) (Hornung et al. 2009). A role in detecting DNA 
was also ascribed to STING (Ishikawa et al. 2009). Moreover, it was shown that the DNA-
dependent RNA polymerase III converts microbial DNA in the cytosol to 5`-triphosphates 
RNA to induce IFN-β through the RIG-I pathway (Ablasser et al. 2009; Cao 2009; Chiu et 
al. 2009; Choi et al. 2009). 
1.1.3.2. Recognition of RNA 
RNA recognition by TLR3 
TLR3 recognizes long dsRNAs, as was demonstrated by a high sensitivity for Poly I:C 
(Polyinosine-deoxycytidylic acid), a synthetic analogue to dsRNA (Alexopoulou et al. 
2001). Long dsRNAs are naturally absent in eukaryotic cells, but viral RNA has been 
observed to form long dsRNA intermediates during the process of replication. Eukaryotic 
messenger RNA, which tends to form intermolecular duplex-structures, has been 
characterized as a further target structure for TLR3 when entering the endosomal 
compartments as described for messenger RNA of necrotic or apoptotic cells (Kariko et al. 
2004). Cellular localization of TLR3 differs depending on cell type. TLR3 localizes to 
endosomal compartments in cDCs, whereas it is expressed on the cell surface of 
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fibroblasts (Matsumoto et al. 2003). Additionally, instances of TLR3-independent 
recognition of viral dsRNA via RNA-helicases exist (compare 1.1.2.2). 
RNA recognition by TLR7 & 8 
Mouse TLR7 and human TLR7 & 8 recognize synthetic antiviral imidazoquinoline 
components (R848 and imiquimod) which are structurally related to nucleic acids, as well 
as uridine-rich or uridine/guanosine-rich ssRNA of both viral and host origins (Jurk et al. 
2002; Heil et al. 2003; Lee et al. 2003; Diebold et al. 2004; Heil et al. 2004; Lund et al. 
2004; Diebold et al. 2006). Although both TLR7 & 8 are expressed in mice, mouse TLR8 
appears to be non-functional (Heil et al. 2004). IFN-α production by pDCs from TLR7-
deficient mice is impaired after infection with the influenza virus or vesicular stomatitis 
virus (VSV) (Diebold et al. 2004; Lund et al. 2004). TLR7 & 8 are exclusively expressed in 
endosomal compartments. Therefore, the differentiation between endogenous and non-
self-RNA molecules has been linked to the localization of the ligands within the cell. Unlike 
virus particles whose genomes are sheltered in the capsid, self-RNAs are degraded by 
extracellular RNases when they are released from the cell, and are not delivered to the 
endosome (Akira et al. 2006). Furthermore, mammalian RNA contains many modified 
nucleosides making them significantly less stimulatory via TLR7 & 8 (Ishii and Akira 2005; 
Kariko et al. 2005; Kariko and Weissman 2007). Studying various modification patterns, it 
has been shown that the 2`-position of the ribose is relevant for immunorecognition 
principles. Methylation led to an abrogation of cytokine secretion. Bacterial RNA is also 
recognized by TLR7 due to its lower content of nucleotide modifications (Eberle et al. 
2009). In addition, TLR7 detects short dsRNA such as small interfering RNA (siRNA) in a 
sequence-dependent manner (Hornung et al. 2005). The expression of TLR7 & 8 is 
restricted to pDCs, which are known to produce vast amounts of type-I interferons upon 
viral infections (Liu 2005; Fitzgerald-Bocarsly et al. 2008). 
Discrimination between self (host) and viral nucleic acids occurs on the basis of 
modifications and structural features, as well as on cellular compartments where viral but 
not host-derived nucleic acids are normally found. Endogenous RNA molecules (e.g. 
messenger RNA) reside either in the cytosol or in the nucleus and do not enter endosomal 
locations that participate in the uptake of exogenous substances. A failure of this 
discrimination results in the development of autoimmune diseases (Rifkin et al. 2005). 
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RNA recognition by RLRs  
Whereas TLRs detect viral components in specific cells such as dendritic cells and 
macrophages, RLRs sense viral infections in the cytoplasm of most cell-types. RIG-I and 
MDA-5 recognize different types of viral RNA (Kato et al. 2006; Loo et al. 2008). RIG-I 
detects negative-strand viruses (e.g., paramyxovirus, influenza virus), ssRNA containing 
5`-triphosphate (Hornung et al. 2006; Pichlmair et al. 2006) and short dsRNA (Hausmann 
et al. 2008; Kato et al. 2008), whereas MDA-5 senses positive-strand RNA viruses (e.g., 
encephalomyocarditis virus) and the dsRNA-mimic Poly I:C (Gitlin et al. 2006). However, 
viruses have developed the ability to circumvent these innate antiviral defenses. For 
example, it was shown that RIG-I is degraded during encephalomyocarditis virus infection 
(Barral et al. 2009; Papon et al. 2009) or inhibited by the Ebola viral protein 35 (VP35) 
(Leung et al. 2010). Even Poly I:C was reported to promote RIG-I degradation (Kim et al. 
2008). Furthermore, the V proteins of many paramyxoviruses inhibit the function of MDA-
5. However, it was shown that V protein-deficient viruses are in addition to RIG-I 
recognized by MDA-5 (Ikegame et al. 2010). This ligand-induced inhibition or degradation 
of the receptor makes it difficult to find a relation between nucleic acid structure and the 
dependent sensor. A specific RNA-sequence or structure activating MDA-5 has not yet 
been identified. Pichelmair et al. have found that MDA-5 activation requires a RNA web 
rather than merely long molecules of dsRNA (Pichlmair et al. 2009). Interestingly, the 
length of dsRNA is important for differential recognition by RIG-I and MDA-5. The MDA-5 
ligand can be converted to a RIG-I ligand by shortening its length (Kato et al. 2008). 
However, the aforementioned structural features are absent from self-RNA. 5`-
triphosphate and dsRNA are two molecular patterns that enable RIG-I to discriminate 
pathogenic from self-RNA. The dsRNA translocation activity on RNA that contains 5`-
triphosphate serves as a signal verification mechanism by activating the ATPase only 
when the RNA features both PAMPs, the 5`-triphosphate and dsRNA. Integration of more 
than one PAMP in a single activation mechanism could be important for the selective 
discrimination of host- from viral-RNA (Myong et al. 2009). However, the exact structure of 
RNA detected by RIG-I remains controversial (Schlee et al. 2009). One study on 
activating ligands for RIG-I demonstrated that 5`-triphosphate with homopulyuridine or 
homopolyriboadenine motifs present in the genomes of hepatitis C virus (HCV) is a key 
feature for RIG-I-mediated RNA recognition (Saito et al. 2008; Uzri and Gehrke 2009). 
Cellular RNAs also contain poly-U and poly-A motifs, but self-RNAs are typically capped 
and bound by proteins (Afonina et al. 1998; Yusupov et al. 2001). In the past, most 
studies demonstrated that single-stranded 5`-triphosphate RNA is sufficient to bind to and 
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activate RIG-I (Pichlmair et al. 2006). These studies used in vitro transcription for 
generation of 5`-triphosphate RNAs without analyzing the purity of those RNA molecules. 
In fact, an unintended formation of dsRNA was the cause of RIG-I activity of the in vitro 
transcribed RNA (Schlee et al. 2009; Schmidt et al. 2009). Even for negative-strand RNA 
viruses known to activate RIG-I, it was shown by Schlee et al. that they contain 5`- and 3`-
sequences that form a short double-strand with a perfectly blunt end ("panhandle") 
(Schlee et al. 2009). Furthermore, products of host RNA cleavage by RNase L, which 
bear 5`-hydroxyl- and 3`-monophosphate ends, were suggested to contribute to RIG-I 
activation (Malathi et al. 2007; Rehwinkel and Reis e Sousa 2010). Figure 2 presents an 
overview of the important nucleic acid sensor molecules described above, their respective 














Figure 2: Sensors for nucleic acids (modified after (Seth et al. 2006; Saito and Gale 2008; 
Barral et al. 2009; McCartney and Colonna 2009)). Toll-like receptors are expressed in cellular 
membranes at the cell surface or intracellular. Besides Toll-like receptors, there are helicases in 
the cytosol. MDA-5 and RIG-I distinguish their ligands by size; MDA-5 binds to long dsRNA,
whereas RIG-I binds short dsRNA and ssRNA bearing a 5`-triphosphate end. Among the TLRs, 
TLR3 recognizes dsRNA, TLR7 & 8 recognize ssRNA, and TLR9 binds to CpG DNA. Upon 
binding of nucleic acids, intracellular adaptor molecules are recruited and initiate the activation of 
NF-κB and IRF-dependent target genes. IPS is a mitochondrial protein that participates in the
signaling pathway downstream of RIG-I and MDA-5. Not mentioned in this figure is the negative 
regulator of RIG-I/MDA-5: LGP2 and the cytosolic DNA receptor DAI. 
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1.2. Antimicrobial peptides (AMPs) 
Antimicrobial peptides are important effector molecules of innate immunity. They are 
ubiquitous defense biomolecules found in virtually all forms of life (Jenssen et al. 2006). 
Currently, about 900 different AMPs and proteins have been described (Brogden 2005). 
Although AMPs are diverse in their amino-acid sequence, structure and size, they are 
mostly amphipathic, containing both cationic and hydrophobic faces (Molhoek et al. 2009).  
In mammals, there are two main families of AMPs, the defensins and the cathelicidins 
(Zasloff 2002; Yang et al. 2004). This work will concentrate on cathelicidins. Cathelicidins 
consist of an N-terminal anionic signal peptide (preregion), a highly conserved cathelin-
like domain (proregion) and a structurally variable cationic antimicrobial peptide at the C-
terminus (hence the name "cathelicidin") as shown in Figure 3 (Zanetti et al. 1995). The 
anionic prosegment neutralizes the cationic peptide and maintains an inactive propetide 
















The only known human cathelicidin LL-37 or hCAP-18 (cationic antimicrobial peptide of 18 
kDa), was isolated from bone marrow (Larrick et al. 1995; Gudmundsson et al. 1996). 
Cathelicidins are usually stored in the granules of neutrophils. They are also produced by 
various epithelial cells and keratinocytes (Agerberth et al. 2000; Dorschner et al. 2001) 
Figure 3: Cathelicidins and their activities (modified after (Yang et al. 2004)). All cathelicidins
have a common primary structure that contains an N-terminal signal peptide, a highly conserved
cathelin-like domain in the middle, and a highly variable C-terminal antimicrobial domain. For the C-
terminal antimicrobial domain of cathelicidins, several activities have been identified. 
Functions
Sorting 1. Inhibiting protease
2. Antibacterial effect
1. Antimicrobial effect
2. LPS-binding and neutralizing
3. Chemotactic activity
4. Degranulating mast cells
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and by mononuclear cells (monocytes, NK cells, B cells, and γ-, δ- T cells) (Frohm et al. 
1997; Bals et al. 1998; Durr et al. 2006), as an inactive proform. They undergo processing 
to the mature peptides during or after secretion by proteases. The 18 kD human cationic 
antimicrobial protein (hCAP18) can be cleaved by either elastase (Gudmundsson et al. 
1996) or proteinase 3 (Sorensen et al. 2001) to liberate its C-terminal antimicrobial 
domain (Zanetti 2004). This peptide is called "LL-37" because it begins with two leucine 
residues and has 37 amino acid residues (Gudmundsson et al. 1996; Yang et al. 2004). 
The cathelicidins in mouse and rat have also been characterized and named CRAMP 
(cathelin-related antimicrobial peptide) (Gallo et al. 1997) and rCRAMP (Termen et al. 
2003). 
The gene encoding LL-37 consists of 4 exons of which the first three encode the signal 
peptide and the cathelin region. The cathelin domain is similar to members of the cystatin 
superfamily of protease inhibitors (Zaiou and Gallo 2002; Zaiou et al. 2003). The fourth 
exon encodes the processing site and the antimicrobial domain (Gudmundsson et al. 
1996) and is located on chromosome 3 (Gudmundsson et al. 1995), which is homologous 
to mouse chromosome 9, where the gene encoding CRAMP is located (Gallo et al. 1997). 
The C-terminal AMPs of cathelicidins are microbicidal against a broad spectrum of 
microorganisms (Zasloff 2002), including bacteria (Turner et al. 1998), fungi (Dorschner et 
al. 2004), parasites (Johansson et al. 1998) and viruses (Howell et al. 2004). The 
mechanism of cathelicidin-mediated microbial killing depends on the formation of ion 
channels or pores in the microbial cell membrane. AMPs preferentially interact with 
prokaryotic cells, although at high concentrations eukaryotic cells are also ruptured. The 
reason for this preference may be the presence of negatively-charged molecules in 
prokaryotic membranes, such as phospholipids, lipotechoic acid, and LPS. Eukaryotic 
membranes, on the other hand, are dominated by neutral zwitterions and cholesterol, 
resulting in a more neutral charge (Zasloff 2002). 
LL-37 also possesses a potent endotoxin-neutralizing activity due to interaction with a 
negatively-charged lipid A portion of the LPS molecule (Larrick et al. 1995; Nagaoka et al. 
2001; Kandler et al. 2006; Mookherjee et al. 2006). LL-37 was shown to protect mice and 
rats from LPS-mediated lethality in septic shock (Kirikae et al. 1998; Scott et al. 2002; 
Cirioni et al. 2006; Alalwani et al. 2010). LL-37 suppressed proinflammatory cytokine 
production induced by agonists of TLR4 and TLR2/1, while leaving TLR2/6, TLR5, TLR7 
and TLR8 responses unchanged (Molhoek et al. 2009).  
In addition to the antimicrobial effects, LL-37 exhibits a number of other host-defense and 
immunoregulatory functions. LL-37 has chemotactic activities on neutrophils, monocytes 
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and T cells. This activity was shown to be mediated via the formyl-peptide receptor-like 1 
(FPRL-1) (De et al. 2000). Mouse CRAMP (1-39) also exhibits a direct effect on the 
migration and function of leukocytes (Kurosaka et al. 2005). Furthermore, LL-37 has been 
shown to mediate release of IL-1ß from monocytes via an additional receptor, P2X(7) 
(Elssner et al. 2004). LL-37 additionally exhibited effects on the maturation of dendritic 
cells (Davidson et al. 2004). This shows a role for LL-37 as a potent immunomodulatory 
molecule, which acts as a link between the innate and adaptive immune systems. 
Furthermore, LL-37 exerts wound-healing functions (Heilborn et al. 2003) and induces 
angiogenesis by a direct effect on endothelial cells mediated by FPRL-1 (Koczulla et al. 
2003). 
1.3. TLR ligands as adjuvants 
The idea behind vaccines is to create a long-lasting immune reaction against a pathogen. 
Innate immunity does not provide long-lasting or protective immunity to the host 
(Pulendran and Ahmed 2006). In contrast, adaptive immunity relies on the clonal selection 
of lymphocytes with recombined highly affine receptors. This second immune response is 
more specific and leads to an increase in defense capabilities with every further exposure 
to the same antigen. Receptors of T cells recognize their antigens only in the form of 
peptides presented by specialized proteins that are encoded by genes in a locus called 
the major histocompatibility complex (MHC) (Janeway 2005; Abbas 2007). Thus, immunity 
must be associated with memory. This is achieved by introducing small amounts of non-
infectious antigen to the host; an event we call vaccination. However, the antigen alone is 
not sufficient to create an immunological memory. There is a need for an adjuvant. Alum 
has a good safety record but is only a weak adjuvant (O'Hagan et al. 2001). CpG-DNA 
has been proven to be one of the strongest Th1-immune-response-inducing adjuvants 
known in vivo (Lipford et al. 2000; Krieg 2002). But the utilization of DNA as an adjuvant 
might raise certain safety concerns, like the risk of DNA integration into the genome or 
overstimulation of the immune system. For this reason, RNA has been tested as an 
adjuvant. Since RNA is very prone to hydrolysis, the RNA molecules have to be protected 
from immediate degradation either through interaction with cationic proteins or through 
chemical modification of the phosphodiester backbone. With regard to RNA, it has been 
reported that mRNA molecules (Scheel et al. 2004) induce immune stimulation and 
specific antibody production (Westwood et al. 2006). Vaccination with mRNA combines 
two aspects of an immunization: Firstly, RNA induces immune stimulation; secondly, the 
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protein coding from the mRNA serves as an antigen. Hoerr at al. proposed that the 
application of mRNA coding for the model antigen ß-galactosidose leads to induction of 
cytotoxic T cells and antigen-specific antibodies (Hoerr et al. 2000). As adjuvant, RNA 
induces a Th2-type humoral response that means the antibody response was primarily of 
the IgG1 isotype. Recently, it was shown that the injection of single-stranded synthetic 
RNA, when complexed to the cationic transfection reagent DOTAP and OVA, works as 
adjuvant. In comparison with CpG-DNA, immunostimulatory RNA induced lower 
frequencies of cytotoxic T cells, but RNA did not induce splenomegaly, which is in contrast 
to the effect of CpG-DNA. RNA is a weaker but safer adjuvant than CpG-DNA (Hamm et 
al. 2007). Interestingly, some novel studies have confirmed that eukaryotic RNA can be a 
potent adjuvant for immune responses (Riedl et al. 2002; Scheel et al. 2004). 
1.4. Hydrolysis of RNA 
RNA represents a ligand for various immunorecognition principles. RNA degradation is 
catalyzed by enzymes, called ribonucleases. These enzymes are ubiquitous and are 
crucial for processing RNA into mature forms. They are not only important for RNA 
metabolism, cell maturation, physiological cell death, and promotion of blood vessel 
formation, but also for host defense against RNA viruses (Arnold and Ulbrich-Hofmann 
2006; Probst et al. 2006). Ribonucleases activate the phosphodiester group through basic 
amino acids, metal ions or a combination of both. Water is often used as an external 
nucleophile (Kurz 1998). Ribonucleases that preferentially degrade ssRNA are the 
following: RNase A, RNase T1, RNase T2, RNase I, and RNase L (Meador et al. 1990; 
Raines 1998; Deshpande and Shankar 2002; Czaja et al. 2004; Malathi et al. 2007; 
Luhtala and Parker 2010). These endoribonucleases hydrolyze RNA to 3`-
phosphomonoester via 2`,3`-cyclic nucleosides (Deshpande and Shankar 2002). RNase I 
cleaves every phosphodiester bond, unlike other ribonucleases, which cleave only after 
specific residues. For example, RNase A is a pyrimidine-specific (C and U) 
endoribonuclease (Raines 1998). RNase A is the founding member of a family of proteins, 
called the RNase A superfamily. Initially isolated from bovine pancreatic tissue, RNase A 
is a classic model system for protein studies, as a result of its thermostability and the 
relative abundance of its source tissue (Dyer and Rosenberg 2006; Rosenberg 2008). 
RNase A is a relatively small protein (124 residues, ~13.7 kDa) and it is a cationic protein 
at physiological pH, explaining its binding to RNA (poly-anion). RNase A has eight 
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cysteines that form four disulfide bonds, and the catalytic triade (Figure 4) consists of two 





The RNase A catalyzes the cleavage of the P-O 5`-bond of RNA, thereby catalyzing both 
the transphosphorylation of RNA to form a 2`,3`-cyclic phosphodiester intermediate and 
the hydrolysis of this cyclic intermediate to form a 3´-phosphomonoester. Figure 5 shows 
the mechanism of catalysis. The side chain of His12 acts as a base that abstracts a 
proton from the 2`-oxygen of a substrate molecule, and thereby facilitates its attack on the 
phosphorus atom. The side chain of His119 acts as an acid that protonates the 5`-oxygen 
to facilitate its displacement. The side chain of Lys41 and the main chain of Phe120 
enhance catalysis by stabilizing this transition state. RNase A primarily catalyses 
transphosphorylation of RNA rather than hydrolysis of the cyclic intermediate. The 2`,3`-
cyclic phosphodiester intermediate accumulates during catalysis by RNase A. It can be 
concluded that the 2`,3`-cyclic phosphodiester are true products of the 
transphosphorylation reaction and not intermediates as generally thought (Cuchillo et al. 








Figure 4: Active site of RNase A
(modified after (Raines 1998)). The
catalytic triade consist of two histidines
and one lysine. Further site chains like
phenylalanine stabilize the transition state
during RNA cleavage. 
















The endoribonuclease L (RNase L) is a latent enzyme expressed in nearly every 
mammalian cell type. Its activation requires it to bind to a small oligonucleotide, 2-5A. By 
regulating viral and cellular RNA expression, RNase L plays an important role in the 
antiviral and antiproliferative activities of IFN. RNase L cleaves RNAs at UpN (usually 
UpU and UpA) sequences in single-stranded regions of RNA. The products generated 
contain 5`-hydroxyl- and 3`-monophosphate ends (Bisbal and Silverman 2007; Silverman 
2007; Silverman 2007).  
Besides these nucleases, there are further single-stranded specific endoribonucleases, 
like the S1 nuclease from Aspergillus oryzae (Desai and Shankar 2003) and the P1 
nuclease from Penicillium citrinum (Volbeda et al. 1991; Desai and Shankar 2003), which 
hydrolyze RNA to 5`-phosphomonoester.  
Finally, a particular ds-specific endoribonuclease RNase III cannot be neglected. RNase 
III family members are divided into three structural classes. The first class is represented 
by Escheria coli RNase III, the second by Drosha, and the third by Dicer (Carmell and 
Hannon 2004). The bacterial RNase III, discovered in 1968 (Robertson et al. 1968), is the 
most studied member of this family (Gan et al. 2008). E. coli RNase III promotes 
maturation of ribosomal RNA (rRNA), tRNAs and mRNA, and can also initiate mRNA 
degradation (Nicholson 1999; Carmell and Hannon 2004). The products generated 
contain 5`-monophosphate and 3`-OH groups with two nucleotide 3`-overhangs (Conrad 
and Rauhut 2002; Carmell and Hannon 2004). Complete digestion of dsRNA results in 
ssRNA fragments of 12-15 bp. Class 2 and Class 3 RNases are essential for the 
biogenesis of miRNAs and siRNAs which are assembled into effector complexes to guide 
specific antiviral defenses via the RNA silencing pathway (Carmell and Hannon 2004; 
Figure 5: Hydrolysis of 
the P-O 5`-bond in RNA 
(modified after (Raines 
1998)). This reaction occurs 
in two steps: (A) 
transphosphorylation of 
RNA to a 2`,3`-cyclic 
phosphodiester 
intermediate and (B) 
hydrolysis of this cyclic 
intermediate to a 3`-
phosphomonoester. In both 
mechanisms, "B" is His12 
and "A" is His119. 
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Aliyari and Ding 2009). Dicer belongs to the same helicase family as do the RIG-I-like 
receptors (Deddouche et al. 2008). 
Metal-ion-induced hydrolysis of RNA 
Metal ions are an essential factor for the phosphodiester hydrolysis of nucleic acids by 
nucleases and ribozyms. For example, the aforementioned enzymes S1 nuclease and P1 
nuclease are zinc metalloproteins and contain three Zn2+ atoms per molecule of the 
enzyme (McCall et al. 2000).  
Pb2+-induced cleavage patterns have been used in the analysis of RNA structures. Pb2+-
induced cleavage occurs preferentially in bulges, loops and other ssRNA regions. DsRNA 
segments are essentially resistant to breakage, but cleavages are also observed in paired 
regions destabilized by the presence of non-canonical interactions, bulges or other 











The simplified mechanism shown in Figure 6 might account for all types of cleavage 
induced by metal ions. First, the ionized metal ion hydrate acts as a Brönsted base by 
accepting a proton from the 2`-OH group of the ribose. Then, the activated anionic 2`-O 
attacks the phosphorus atom, and a penta-coordinated intermediate is formed. The 
phosphodiester bond is cleaved generating 2`,3`-cyclic phosphate and 5`-hydroxyl groups 
as cleavage products (Matsuo et al. 1995; Yashiro et al. 2002; Hartmann et al. 2005; 
Wang et al. 2007). 




(Hartmann et al. 2005)). 
The metal ion facilitates 
deprotonation of the 2`-
OH, resulting in a 
nucleophilic attack on the 
phosphorus atom and 
subsequent cleavage of 
the phosphodiester bond. 
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2. Goal of the project 
RNA is present in abundance in host cells, but host cellular RNA fails to stimulate innate 
immune responses, unlike virus-derived RNA. TLRs as well as cytoplasmic receptors 
have been described to be triggered by non-self-RNA molecules. The immune system 
must possess mechanisms to discriminate molecular features between host and virus 
RNA species. Although some receptor ligand interactions could be identified already, 
essential parts of RNA immunorecognition remain unclear. This study intended to 
characterize the interaction of different RNA ligands with the respective immunoreceptors. 
The first part of the work analyzed the influence of nucleotide modifications of RNA for 
inducing an immune response. Self-RNA is not immunostimulatory due to RNA 
modifications such as base-methylation, pseudouridine and 2`-O-methyl ribose. The 
immunostimulatory potentials of purified ribosomal 18S rRNA and in vitro transcribed 18S 
rRNA, which lack modifications, are beeing compared on human PBMCs and murine Flt3-
derived immune cells. RNA oligonucleotides derived from the 18S rRNA with different 
modifications have been synthesized and should be tested for their behaviour concerning 
the induction of cytokines on immune cells. 
In the second part of the work, the ability of LL-37, a human antimicrobial peptide and its 
murine homolog cathelicidin-related antimicrobial peptide (CRAMP) to function as carrier 
for immunostimulatory RNA and to induce innate immune activation should be analyzed. 
Since naturally occurring cathelicidin is produced at mucosal sites, it should function as 
immune activator by targeting RNA from virus-infected cells to immune cells. The central 
issue was to find out, if cathelicidins/RNA complexes are potent vaccine formulations, if 
cathelicidins are crucial for antiviral immune response against influenza infections and if 
viral immune recognition can be manipulated by synthetic LL-37/CRAMP. Since DOTAP is 
toxic at higher concentrations, non-toxic or natural carriers for immunostimulatory RNA 
are desirable. 
Moreover, we set out to investigate the characteristics of RNA extracted from influenza-
infected cells that are recognized as non-self structures. RNA of the influenza virus, which 
contains a 5`-triphosphate, directly interacts with RIG-I and is responsible for the induction 
of type-I IFN. The immunostimulatory potential of influenza-infected RNA was to be 
assessed by measuring the induction of IFN-α in human PBMCs and in cells from various 
knockout mice. In parallel, influenza-infected RNA should be used for transfection of 
HEK293 cells overexpressing RIG-I. The influence of the terminal 5`-triphosphate as well 
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as the confirmation of the influenza-infected RNA (ssRNA or dsRNA) on RIG-I-mediated 
signaling should be investigated. 
 
Finally, immunorecogition of small self-RNAs should be analyzed. During viral infection 
cellular RNA serves as a ligand that stimulates the immune response. Viral RNA 
stimulates 2`-5` oligoadenylate synthetase (2`-5` OAS) to promote activation of an 
endonuclease, RNase L, which subsequently cleaves self-RNA to make small RNA 
species. The cleaved RNA, which contains a 3`-monophosphate group, serves as the 
ligand for RIG-I and MDA-5 to initiate signaling leading to type-I IFN production. This is 
surprising, since self-RNA is not stimulatory due to natural occurring RNA modifications. 
The aim of this study is to analyze the immunostimulatory nature of RNase treated self-
RNAs. Therefore, responsiveness to small self-RNAs should be examined in different 
immune cells. Furthermore, self-RNAs were degraded by using different methods, like 
ultrasonic treatment, metal-ion induced hydrolysis or treatment with different RNase types 
and the generated fragments were compared for their immunostimulatory abilities. It was 
intended to identify structures and sequences that presumably have interesting properties 
as therapeutics in vaccination protocols.  
Overall, the goal of the project is to discover novel basic viral and host immune 
mechanisms. Influenza viruses are a major concern for global public health. Therefore, 
new and efficient antiviral therapeutics and effective vaccine formulations are of major 
interest. Regarding autoimmune diseases, principle mechanism for recognizing self-RNAs 
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3. Material 
3.1. Machines and technical devices 
Equipment Manufacturer 
Agarose gel chamber OWL, Weilheim 
Apotome Zeiss, Jena 
CASY-1 TT Schärfe System, Reutlingen 
Centrifuges 
Pico Fuge-Stratagene, La Jolla USA 
Mikro 200R Centrifuge-Hettich, Tuttlingen 
Multifuge 1L-R Heraeus, Hanau  
Diavert Microscope Leitz, Bielefeld 
Elutriation Beckman J2-21M/E Centrifuge 
FACS Calibur Becton Dickinson, Basel 
Fine scale Sartorius, Göttingen 
Gel imaging system Fröbel, Lindau 
Gene Pulser x-cell Biorad, Hercules, USA 
Heating blocks PeqLab Biotechnologie GMbH TS-100 Thermo Shaker, Peqlab Erlangen 
HPLC "BioCAD Sprint" Applied Biosystems, USA 
Incubator 
HERA cell 240® (37°C / 5% CO2) 
HERA cell 240 ® (37°C / 7.5% CO2), Heraeus, Hanau
Heraeus Lamin Air® (37°C / 7.5% CO2) 
MACS Midi-Separator Miltenyi Biotec, Bergisch Gladbach 
MACS Multistand Miltenyi Biotec, Bergisch Gladbach 
Microplate Nunc Denmark Poly Sorte 
Microplate Spectrophotometer Molecular Devices, Ismaning 
Microplate Washer Molecular Devices, Ismaning 
Mini Opticon Bio-Rad, Hercules, USA 
Neubauer W. Schreck, Hofheim 
Normal scale Mettler, P1000 
Orion II Microplate Luminometer Berthold Detection System, Pforzheim 
PAA-gel chamber PeqLab, Erlangen 
pH-Meter WTW, Weilheim 
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Equipment Manufacturer 
Pipetus Hirschmann Laborgeräte,  IBS Integra Biosciences 
Spectrophotometer  NanoDrop® Spectrophotometer peQLab, Wilmington, USA 
Steril bench HERA Safe®, Heraeus Lamin Air® 
Thermocycler Elite Helena, Sunderland, UK 
Thermocycler Eppendorf Eppendorf, Hamburg 
TS–100 Thermoshaker Peqlab, Erlangen 
Ultrasonic Homogenizer Bandelin 
Vortexer, REAX 2000 Heidolph, Schwabach 
Water bad WTW, Weilheim Kottermann Labortechnik, Haake D8 
3.2. Software 
Software Manufacturer 
Microsoft Office Microsoft Corporation, Redmond, USA 
Sigma Plot Systat Software Inc., Chicago, USA 
CellQuest Pro BD Biosciences, San Jose, USA 
EndNote The Thomson Corporation, Stamford, USA 
Flowjo for Macintosh Tree Star, Inc., Ashland, USA 
AxioVision LE Carl Zeiss MicroImaging GmbH 
3.3. Equipment 
Equipment Manufacturer 
4 mm Electroporation cuvette Bio-Rad, Hercules, USA 
Flat Cap Strips Bio-Rad, Hercules, USA 
Low Tube Strip, WHT Bio-Rad, Hercules, USA 
Membrane Filter, pore size 25 mm Millipore 
Cell strainer BD Falcon, Franklin Lakes NY USA 




(MgCO3)4Mg(OH)2 x 5H2O Roth, Karlsruhe 
Acrylamide M-Bis Roth, Karlsruhe 
Agar Agar Roth, Karlsruhe 
Agarose Invitrogen, Karlsruhe 
Ammonium acetate Roth, Karlsruhe 
Ammoniumpersulfate Sigma Aldrich, Taufkirchen 
Bacto-Agar Becton Dickinson 
Bovine serum albumin (BSA) Roth, Karlsruhe 
CaCl Roth, Karlsruhe 
Chloroform Sigma Aldrich, Taufkirchen 
Citric acid Roth, Karlsruhe 
Crystal violet Serva, Heidelberg 
DAPI (4,6 Diamidin-2-phenylindol-dihydrochlorid) Roche, Mannheim 
Diethylpyrocarbonat (DEPC) Roth, Karlsruhe 
Dithiothreitol (DTT) AmpliScribe
TM T7, SP6 Transcription Kit 
Epicentre, Biozym, Hess. Oldendorf 
DMSO Merck, Ismaning 
EDTA (Etylendiamintetraacetacid) Roth, Karlsruhe 
Eosin Merk, Ismaning Roth, Karlsruhe 
Ethanol p.a. 99.8% Roth, Karlsruhe 
Ethidiumbromide Roth, Karlsruhe 
Glycerol ICN Biomedicals,  Inc, Aurora, Ohio 
HEPES Roth, Karlsruhe 
Hydrogen peroxide Roth, Karlsruhe 
Isopropanol Roth, Karlsruhe 
Kaliumchlorid Roth, Karlsruhe 
Kaliumdihydrogenphosphate Roth, Karlsruhe 
Lead (II) acetate trihydrate (316512-5G) Sigma-Aldrich, Taufkirchen 
Methanol Roth, Karlsruhe 
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Chemicals Manufacturer 
MgSO4 Roth, Karlsruhe 
MOPS (3-(N-Morpholino)-Propansulfonacid) Roth, Karlsruhe 
Mowiol Sigma Aldrich, Taufkirchen 
N,N,N`,N`-Tetraethylmethylenediamin (TEMED) Sigma Aldrich, Taufkirchen 
Na2HPO4 anhydrate Roth, Karlsruhe 
NaCl Roth, Karlsruhe 
Natriumacetat Roth, Karlsruhe 
Natriumazide Merk, Ismaning 
Natriumchlorid solution Merk, Ismaning 
Natriumhydroxid Merck, Darmstadt 
Phenol Roth, Karlsruhe 
Phenol:Chloroform:Isoamylalcohol (25:24:1) Roth, Karlsruhe 
Polyvinylalkohol-88 Sigma Aldrich, Taufkirchen 
HCl Merck, Darmstadt 
SDS (Natriumdodecylsulfate) Roth, Karlsruhe 
Sulphuric acid Roth, Karlsruhe 
Tetraethylammoniumchloride (TEACL) SIGMA, Spruce Street, Saint Louis, Missouir, USA 
TMB Microwell Peroxidase Substrate System KPL, Clopper Road, Gaithersburg, Maryland, USA 
Tris-(hydroxymethyl)-aminomethane Roth, Karlsruhe 
Tris-HCL Roth, Karlsruhe 
Trizol® Sigma-Aldrich, Munich 
Tween 20 Roth, Karlsruhe 
Ultra-pure water Biochrom AG, Berlin 
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3.5. Biochemicals, kits and enzymes 
Biochemicals Manufacturer 
5 x Lysing Solution Promega, Mannheim 
Alkaline Phosphatase Sigma Aldrich, Munich 
Alkaline Phosphatase, Calf Intestinal (CIAP) [1 U/µl] 
(M1821) Promega, Mannheim 
AmpliScribeTM T7, SP6 Transcription Kit Epicentre, Biozym, Hess. Oldendorf 
ATP Roth, Karlsruhe 
Benzonase 25 U/µl (M00047398) Novagen, Darmstadt 
Biotin (powder) Sigma, Munich 
Chicken egg albumin (OVA) Profos AG, Regensburg, Germany 
Coenzyme A PJL, Kleinblittersdorf 
D-Luciferin PJL, Kleinblittersdorf 
DNase I recombinant, RNase-free  [10 U/µl] 
(10776785001) Roche, Mannheim 
dNTPs Invitrogen, Karlsruhe 
Donkey-α-rabbit-IgG-HRP Dianova GmbH, Hamburg 
DTP PJL, Kleinblittersdorf 
Ficoll PAA Laboratories, Pasching 
FMS-like tyrosine kinase 3 Ligand (Flt3-L) From own cell line purified: TU Munich 
RNA Fragmentation Reagent Ambion 
Granulocyte macrophage colony stimulating factor (GM-
CSF) (315-03) Peprotech 
Heparin "Liquemin N 25000" Roche, Mannheim 
human AB Serum Sigma 
Klenow Fragment New England Biolabs, Frankfurt a.M. 
Macrophage colony stimulating factor (M-CSF) (416 ML) Tebu 
Micro Bio-Spin 30 Columns in RNase-Free Tris Bio-Rad, Hercules, USA  
Mini Elute DNA PCR Purification Kit PeqLab, Erlangen 
Mycoplasma Detection Kit  Lonza, Switzerland 
Nuclease P1 [0.3 U/µl] (N8630) Sigma Aldrich, Taufkirchen 
o-Phenylenediaminedihydrochloride (OPD), 20 mg tablet 
(P7288) Sigma-Aldrich, Munich 
  Material 
 24
Biochemicals Manufacturer 
Optimen (31985047) GIBCO, Invitrogen Corporation 
PeqGold Plasmid Mini Praep Kit PeqLab, Erlangen 
Proteinase K [10 mg/ml] Roche, Mannheim 
Pvu II New England Biolabs, Frankfurt a.M. 
Recombinant human IFN-α (300-02A) Peprotech 
Recombinant human IL-6 (200-06) R&D Biosystems, Wiesbaden 
Recombinant human TNF-α (300-01A) Peprotech 
Recombinant murine IFN-α (HC1040a) Hycult biotechnology b. v.  
Recombinant murine IL-6 (406-ML) R&D Biosystems, Wiesbaden 
Recombinant murine IFN-ß (12400-1) [100,000 U/ml] 
(12400-1) PBL Interferon Source, Piscataway, NJ 
Red blood cell lysing solution (RBL) Sigma, Munich 
RNase [500 µg/ml] [15 U/ml] (11119915001) 
called RNase A in the figures Roche, Mannheim 
RNase A [100 mg/ml] [7000 U/ml] (19101) 
not used for the figures Quiagen 
RNase I [10 U/µl] (N6901K) Epicentre 
RNase III [1 U/µl] (RN029050) Epicentre 
RNase III [1.3 U/µl] BioLabs 
RNase T1 from Aspergillus oryzae [1,46 mg protein/ml, 
300,000–600,000 U/mg protein] [657 U/µl] Sigma 
RNase T2 [34,000 U/ml] (R-6398) Sigma 
SvP (snake venom protease) [50ng/µl] [0,01 U/mg] 
(P3134) Sigma Aldrich, Munich 
Silencer® siRNA Construction Kit Ambion 
Streptavidin-beads Pierce 
Streptavidin-POD (11 089 153 001) Roche, Mannheim 
SuperScript III CellsDirect cDNA Synthesis System Invitrogen, Karlsruhe 
T4 Polynucleotide Kinase 10 U/µl (#EK0031) Fermentas 
Taq PCR Master Mix Kit Quiagen, Hilden 
Tricin Roth, Karlsruhe 
Waters C18 SepPak columns Waters Corporation, Milford/Massachusets 
XBRIDGETM OST C18 columns Waters Corporation, Milford/Massachusets 





Coating Antibody Human IFN-α (BMS216MST) Bender MedSystems, Vienna, Austria 
HRP-conjugate (23010-11) Bender MedSystems,Vienna, Austria 
Purified Rat Anti-Human IL-6 Monoclonal Antibody 
(554543) BD Pharmingen, Heidelberg 
Biotinylated Rat Anti-Human IL-6 (554546) BD Pharmingen, Heidelberg 
Purified Mouse Anti-Human TNF Monoclonal 
Antibody (551220) BD Pharmingen, Heidelberg 
Biotinylated Mouse Anti-Human TNF Monoclonal 
Antibody (554511) BD Pharmingen, Heidelberg 
Rat Monoclonal Antibody against Mouse Interferon 
Alpha (RMMA-1) (22100-1) PBL, New Brunswick,USA 
Rabbit Polyclonal Antibody against Mouse Interferon 
Alpha (32100-1) PBL, New Brunswick,USA 
Polyclonal rabbit anti-mouse IFN-ß  
(32 400-1) PBL, New Brunswick,USA 
Monoclonal rat anti-mouse IFN-ß  
(22 400-1) PBL, New Brunswick,USA 
Monoclonal Anti-mouse IL-6 Antibody (MAB 406) R&D, Biosystems, Wiesbaden 
Biotinylated Anti-mouse IL-6 Antibody (BAF406) R&D, Biosystems, Wiesbaden 
anti-rat IgG antibody H&L POD-conjugated (ab6734) Abcam, UK 
POD-conjuagated goat anti-rabbit IgG (111-035-
045) Immuno Research 
ELISA Immunization  
biotin-SP-conjugated AffiniPure goat anti-mouse IgG Jackson ImmunoResearch, Hamburg 
FACS  
Mouse anti-human BDCA-2-PE Miltenyi Biotec, Bergisch Gladbach 
Mouse anti-human CD11b-APC BD Pharmingen, Heidelberg 
Mouse anti-human CD14-FITC BD Pharmingen, Heidelberg 
Rat Anti murine B220-FITC  BD Pharmingen, Heidelberg  
Rat Anti murine CD11c-APC Rat BD Pharmingen, Heidelberg  
Anti murine CD11b-FITC BD Pharmingen, Heidelberg  
Rat IgG, Fc Blocking Jackson ImmunoResearch, Hamburg 
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Antibody Manufacturer 
Mouse IgG, Fc Blocking Jackson ImmunoResearch, Hamburg 
TO-PRO® iodide solution in DMSO [SKU#T3605] Invitrogen 
Apotome  
Lamp-1 (Purified Mouse Anti-Human CD107a) 
(555798) BD Pharmingen, Heidelberg 
Transferrin Conjugates (T2872) Invitrogen, Karlsruhe 
Lysotracker (L7528) Invitrogen, Karlsruhe 
Purified Mouse Anti-EEA-1 (610456) BD Biosciences 
Rhodamine (TRITC)-conjugated AffiniPure F (ab`)2 
Fragment Goat Anti-Mouse IgG (H+L) (115-026-003) Dianova 
DAPI Roche, Mannheim 
3.7. Size markers 
3.8. Buffers and media 
Name Compounds 
0.1% DEPC (Diethyl-Pyrocarbonat) solution 
Milli-Q-H20 
1/1000 Volume DEPC  
3 h stir  
2 x autoclave 
6 x loading dye solution 
(Fermentas) 
30% (v/v) Glycerin 
0.25% (w/v) Bromphenol blue 
0.25% (w/v) Xylenblau 
dissolved in water 
 
Markers Manufacturers
6 x DNA Marker Fermentas, St. Leon Rot 
6 x Loading Dye Solution Fermentas,  St. Leon Rot 
2 x RNA Loading Dye Solution Fermentas, St. Leon Rot 
Gene Ruler 100 bp DNA-Marker (SM0321) Fermentas, St. Leon Rot 
Gene Ruler 1 kbp DNA-Marker (SM0313) Fermentas, St. Leon Rot 
RiboRulerTM RNA Ladder (SM1821) Fermentas, St. Leon Rot 
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Name Compounds 
Blocking buffer 1%  10 g BSA 1 x; 0.5 ml Tween 20;  ad 1 l with PBS-deficient  
EDTA 0.5 M 
18.612 g EDTA; 50 ml H20,  
neutralize with NaOH pellets;  
ad 100 ml with ddH20 
ELISA substrate buffer 
 
7.3 g C6H8O7;  
11.87 g Na2HPO4 x 2H2O;  
ad at 1 l with ddH2O  
ELISA wash buffer 
 
500 ml 10 x PBS; 2.5 ml Tween 20;  
ad 5 l with ddH2O  
Eosin solution 
2 g Eosin, 250 mg Natriumazid,  
450 ml 0.9% Natriumchlorid, 50 ml FCS 
Mix well and filter through an paper filter 
storage: unsterile, 4°C 






2% stock solution: 
2 g Kristallviolett 
20 ml Ethanol 96% 
10 ml Formaldehyde at least 35% 
70 ml Aqua distilled 
0.2% working solution:  
10 ml stock solution 
10 ml Formaldehyde 
80 ml Aqua distilled. 
Liposomal buffer 
20 mM HEPES, 150 mM NaCl  
adjust ad pH 7.4 
1/1000 Volume DEPC 
3 h stir 
2 x autoclave 
Luciferase-Assay buffer 1 l  
132 mg D-Luciferin; 210 mg Coenzyme A; 
5140 mg DTT; 292 mg ATP;  
520 mg (MgCO3)4Mg(OH)2 x 5 H2O;  
322mg MgSO4; 3584 mg Tricin;  
37.2 mg EDTA  
MACS-buffer PBS def.; 3% FCS; 2 mM EDTA 
MOPS 
 
0.2 M MOPS (Morpholinopropansulfonsäure),  
50 mM Natriumacetat (trihydrate),  
10 mM EDTA adjust pH ad 7.0 
ad H20 ad 1 l 
 
 




2 g Polyvinylalcohol 4-88 (Mowiol), 
6 g Glycerin, 
6 ml H20 
shake over night at room temperature 
12 ml Tris pH 8.5 
2 g DABCO 
heat for 10 min at 50°C and shake 
centrifugation for 15 min at 5,000 g 
froze supernatant at -20°C 
NEB Restrictionsendonuclease buffer 10 x  Acquired from New England Biolabs,  Frankfurt a.M.  
PBS-deficient 10 x 
2 g KCl; 2 g KH2PO4; 80 g NaCl;  
11.5 g Na2HPO4 x 2H2O; 
ad 1 l with ddH2O  
Red blood cell lysis buffer 
(Sigma-Aldrich, Taufkirchen) 
8.3 g/l NH4Cl 
in 0.01 M Tris 
pH 7.5 
RNase III reaction buffer 
20 mM Hepes 
66 mM K-Acetate 
10 mM Mg-Acetate 
0.5 mM DTT 
DEPC 1:1000 
adjust pH ad 6.5 
Substrate solution 7.3 g citric acid x H20 (C6H8O7), 11.87 g Na2HPO4 x 2H20, ad 1 l H20 
TAE buffer for PAE Gel 4 mM Tris- Acetate, 1 mM EDTA 
TAE DNA-Gel Running buffer 50 x  242 g Tris Base; 57.1 ml acetic acid (100%);  100 ml 0.5 M EDTA (pH 8) ad 1 l with H20 
TAECL 3.6 M 14,9 g ad 25 ml (Mr = 165,7 g) 
TBE 0.089 M Tris OH, 0.089 M boric acid, 0.002 M EDTA 






C57/BL6 wild-type mice Animal Facility BMFZ, Marburg 
TLR7-deficient mice on a C57/BL6 background Prof. Dr. Shizo Akira; Osaka; Japan 
TLR3-deficient mice on a C57/BL6 background Prof. Dr. Shizo Akira; Osaka; Japan 
TLR3 & 7-deficient mice on a C57/BL6 background Animal Facility BMFZ, Marburg 
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Mice Source 
MyD88-deficient mice on a C57/BL6 background Prof. Dr. Shizo Akira; Osaka; Japan 
IPS-deficient mice on a C57/BL6 background Prof. Jürg Tschopp, Lausanne, Schweiz 
Unc-deficient mice on a C57/BL6 background Prof. Bruce Beutler, La Jolla, USA 
3.10. Embryonated chicken eggs 
Specific-pathogen-free (SPF) chicken eggs were purchased from Lohmann, Tierzucht 
Cuxhaven. 
3.11. Transfection reagents 
3.12. Peptides 
Transfection reagent Manufacturer Stimulation of
DOTAP (11811177001) Roche, Mannheim PBMCs, Mouse culture 
DOTAP Roth, Karlsruhe HEKs 
Lipofectamine 2000 (11668-019) Invitrogen UK PBMCs, Mouse culture 






















CRAMP GLLRKGGEKI GEKLKKIGQK IKNFFQKLVP QPEQ 
Innovagen, Lund, 
SWEDEN 
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3.13. Plasmids 
Plasmid Vector Source 
Luciferase Reporter Plasmid p-125 Luc Prof. Takashi Fujita, Kyoto University, Japan 
pEFflag RIG-I (full) Prof. Takashi Fujita, Kyoto University, Japan 
pEFflag MDA-5 (full) Prof. Takashi Fujita, Kyoto University, Japan 
pES BOS Prof. Takashi Fujita, Kyoto University, Japan 
Renilla reporter plasmids TU Munich 
Trif TU Munich 
pGEM-T Easy Promega, Madison, USA 
3.14. Oligonucleotides 
Stimulative Oligo Sequence Manufacturer 
18S rRNA anti bio 
5`-(BIO) TAA TGA TCC TTC CGC AGG TTC ACC 
TAC GGA AAC -3` 
MWG 
RIG-I ligand 3`-P RNA template  
5`-GGG ACC CTG AAG TTC ATC CCC TAT AGT 
GAG TCG TAC CTG TCT C-3` 
Metabion, 
Martinsried 
3.15. Ligands for stimulation 
S = Phosphothioate (PTO) 
Stimuli Sequence Source 
RNA 40 
5`-GCC CGU CUG UUG UGU GAC 
UsC-3` 
IBA, Göttingen 
RNA 63 5`-CAG GUC UGU GAU-3` IBA, Göttingen 
RNA 63-2`-O-
methyl 
5`-CAZ GUC UGU GAU-3` 
“Z” = 2`-O-Me guanosine 
IBA, Göttingen 
RNA 63-2`-deoxy 
5`-CAZ GUC UGU GAU-3` 
“Z” = 2` dG 
IBA, Göttingen 
RNA 63-2`-F 5`-CAZ GUC UGU GAU-3` IBA, Göttingen 
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Stimuli Sequence Source 
“Z” = 2`Fluoro dG 
R848 Resiquimod Coley Pharmaceuticals, Langenfeld 
Poly I:C 
(tlrl-pic) 
Polyinosinic-polycytidylic acid; synthetic 
analog of dsRNA 





TIB Molbiol, Berlin 







NNNNNN Metabion, Martinsried 
RIG-I L GAGCATGCACGAATGAAAGA Metabion, Martinsried 
RIG-I R CTTCCTCTGCCTCTGGTTTG Metabion, Martinsried 
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4. Methods 
4.1. Cell culture 
All work was done under a sterile bench, security grade two. All substances used in cell 
cultures were tested for mycoplasma and contaminations with endotoxin because such 
contaminations would lead to a mediator release. All media and buffers were sterilized for 
20 min at 121°C and 1 bar. Solutions that were unstable or sensitive to heat were filtered. 
4.1.1. Cell culture material 
Material Manufacturer 
24 G cannula  BD Microlance
TM
, BD, Heidelberg 
96-well flat bottom plates Greiner, Frickenhausen 
96-well round bottom plates Greiner, Frickenhausen 
8 chamber culture slides BD Falcon, Franklin Lakes NY USA 
Cell scrapers Greiner bio-one, Frickenhausen 
Cell lysis buffer  Sigma-Aldrich, Taufkirchen 
Combitipps Eppendorf, Hamburg 
Cryovials Nunc, Wiesbaden 
Eppendorf tubes (0.5 ml, 1.5 ml, 2 ml) Eppendorf, Hamburg 
Falcon (15 ml, 50 ml) Greiner bio-one, Frickenhausen 
Needle 24 G Becton Dickinson, Heidelberg 
Pasteur pipettes Roth, Karlsruhe 
Pipette tips Avant Guard, USA 
Plastic pipettes (2 ml, 5 ml, 10 ml, 25 ml) Greiner, Frickenhausen 
Syringe Braun Omnifix 10 ml 
Tissue culture dish BD Falcon, Heidelberg 
Tissue culture flash (175 cm2, 75 cm2, 25 cm2) Greiner, Frickenhausen 
Tube 15 ml Greiner, Frickenhausen 
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4.1.2. Cell lines 
Cell line Source 
Madin-Darby canine Kidney (MDCK) Institute for Immunology; BMFZ; Marburg 
Human embryonic kidney cells (HEK293) Institute for medical Microbiology; TU Munich; Munich 
MDCK (Madin-Darby Canine Kidney) 
The MDCK cell line was derived from the kidney of a normal female cocker spaniel in 
1958 (Gaush et al. 1966). Some continuous cell lines of epithelial origin support the 
growth of influenza viruses, in the presence of added trypsine. The addition of trypsine 
improves the yield in cell lines that lack specific host proteases necessary for the 
proteolytic cleavage of HA to produce infectious particles (Klenk et al. 1975). MDCK cells 
have a polarized morphology, forming two-sided asymmetrical sheets with distinct apical 
and basolateral surfaces (Cereijido et al. 1978). When grown on non-permeable supports, 
such as plastic cell culture plates, MDCK cells are not fully polarized, since only the apical 
surface is exposed to the culture medium. However, this does not affect influenza virus 
growth in anchorage-dependent cell culture as budding and release only takes place from 
the apical plasma membrane (Matlin and Simons 1984). MDCK cells were maintained in 
RPMI complete medium at 37°C in a 5% humidified CO2 environment. 
Human embryonic kidney cells (HEK293) 
HEK293 cells are adherent growing human cells from an embryonic kidney. HEK293 cells 




The utilized Influenza-A-Virus Puerto Rico (A/PR/8) from the eight isolation was made 
available from Dr. Marianne Nain, Institute for Immunology in Marburg (Nain et al. 1990). 
The original virus, isolated in 1934 in Puerto Rico, can be regarded as adapted because 
of the many passages. Individual strains of influenza are named according to their 
antigenic group, geographic origin, strain number, year of isolation and mostly the 
antigenic classification of hemagglutinin and neuraminidase mentioned in the parenthesis 
[e.g. A/Puerto Rico/8/34 (H1N1) (De Jong et al. 2000). 
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4.1.3. Culture media 
The employed media were from PAA (PAA Laboratories GmbH, Pasching, Austria), FCS 
(heat-inactivated fetal calf serum) from Biochrom (Biochrom Ag, Berlin), ß-
Mercaptoethanol from Gibco (Invitrogen, UK) and L-glutamine/ penicillin/ streptomycin 
from PAA (Cölbe).  
Media Manufacturer 
RPMI 1640 PAA, Cölbe 
DMEM  PAA, Cölbe 
Fetal Calf Serum (FCS) Biochrom, Berlin 
LSM 1077 Lymphocyte Separation Medium PAA, Cölbe 
ß-Mercaptoethanol Gibco Invitrogen, UK 
L-glutamine 200 mM (100 x) PAA, Cölbe 
Penicillin/Streptomycin (100 x) PAA, Cölbe 
Trypsine-EDTA (10 x) PAA, Cölbe 
human AB-Serum Sigma Aldrich, St. Louis USA 
Natriumpyruvate PAA, Cölbe 
non-essential amino acids PAA, Cölbe 
Dulbecco`s PBS++ (with Ca2+, Mg2+) PAA, Cölbe 
Dulbecco`s PBS def (1 x) PAA, Cölbe 
 
Cell line Media Compounds 




500 µl Mercaptoethanol 
PBMCs RPMI 1640 




1% Amino acids 
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Cell line Media Compounds 





500 µl Mercaptoethanol 
 
In the following the media with supplements are called DMEM complete and RPMI 
complete medium. 
4.1.4. Passage of eukaryotic cells 
Passage of MDCK cells and HEK293 cells 
Cells were grown to near-confluence either in 75 cm2 or 175 cm2 tissue culture flasks. 
They were passaged after being washed twice with PBSdef and being dispersed with 
sufficient trypsine to cover the cells. Flasks with MDCK cells were then returned to the 
37°C incubator until the cells had detached from the surface (7 min). HEK293 cells were 
incubated with trypsine at room temperature for a short while. After removing the trypsine 
solution, the cells were again incubated for 5 min in the 37°C incubator (MDCK cells) or 
for 3 min at room temperature (HEK293 cells) before being resuspended either in RPMI 
complete medium (MDCK cells) or in DMEM complete medium (HEK293 cells). HEK293 
cells were then centrifuged for 6 min at room temperature and 1,300 rpm. Then the cell 
pellet was resuspended in 10 ml DMEM complete medium. For further cultivation, cells 
were split 1:10, usually two times per week. 
4.1.5. A/PR/8 infection of MDCK cells 
The influenza virus was grown in MDCK cell cultures (Garcia-Sastre et al. 1998). Cells 
were grown to 70-80% confluence, washed with PBS++ and inoculated with virus in 15 ml 
RPMI complete medium without FCS. For the infection 10 MOIs / cell were used. After 
adsorption for 1 hour at 37°C, the medium was replaced by 30 ml RPMI complete medium 
with 10% FCS. After an incubation time of 7 hours, the RNA was isolated from the 
infected cells through Trizol-treatment (4.3.1). Cells were harvested if cytopathogenic 
effect occurred. The cytopathogenic effect was manifested by cell rounding, cell shrinkage 
and foci of cell destruction. 
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4.1.6. Viable cell counts 
For determination of cell number, an aliquot of cell suspension was diluted with eosin. The 
cells were then transferred to a neubauer hemocytometer, and viable cells were counted 
in 4 squares, each of 10-4 ml, and averaged. Vital cells remained unstained, while pink 
cytoplasm served as an indicator for a loss of cellular functionality due to the increased 
permeability of the membranes. Thus, dead cells could be distinguished from living cells, 
which appear yellow under the microscope. The following formula was used to calculate 
the viable cell number: 
Cell number/ml = average cell number x 104 x dilution factor  
The CASY cell counter was used as another method to determine cell number. Cells were 
suspended in an electrolyte buffer and aspirated through a precision-measuring capillary 
with a defined size. While passing through the measuring capillary, they were scanned in 
a low voltage field between two platinum electrodes. The resulting electrical signals 
generated by a cell passing the measuring capillary were analyzed by amplitude, pulse 
width, course of time and resulting pulse area. The analyzed pulse areas of cell signals 
were cumulated and assigned in a calibrated multi-channel analyzer (Handbook 
Schaerfe). 
4.1.7. Freezing and thawing of cells 
For long-term storage, cells were suspended in Cell Freezing Medium at a concentration 
of 3-5 x 106 cells/ml, and aliquots were added to cryovials, which were frozen slowly in 
foam racks. On the following day, the vials were transferred to liquid nitrogen for long-term 
storage. Cells were recovered from liquid nitrogen storage by quickly thawing a vial at 
37°C, transferring the contents to 10 ml medium following by centrifugation in order to 
minimize the toxic effects of DMSO in the cell freezing medium. Then cells were 
transferred to a 25 cm2 tissue culture flask containing fresh medium. 
4.1.8. Mycoplasma test 
Mycoplasma are one of the most common cell culture contaminations. Mycoplasma 
belong to the smallest known self-replicating microorganisms. Mycoplasma is a genus of 
bacteria largely characterized by the lack of a cell wall and a small genome with low GC 
content. 
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Cells were plated on a coverslip and rinsed with PBS. Then cells were subsequently 
stained with a DNA-binding fluorochrome stain (DAPI). Therefore, the DAPI stock solution 
in PBS was diluted 1:50 in methanol, and the cells were rinsed with this DAPI/Methanol 
solution (100 ng DAPI/ml). In the next step, the cells were stained and fixed with this 
solution for 15 min in an incubator. Again the cells were rinsed with methanol and were 
covered with glycerine. Then the cells were evaluated microscopically for the presence of 
the characteristic particulate or filamentous pattern of fluorescence on the cell surface, 
which is indicative of a mycoplasma infection. 
4.1.9. Generation of primary cells 
4.1.9.1. Generation of dendritic cells from bone marrow 
Bone marrow cells are pluripotent cells, from which each hämatopoetic cell can be 
generated. Mice were sacrificed by cervical dislocation and femurs were prepared by 
flushing with a syringe with a 24 G cannula until the bone was completely white. Marrow 
clumps were disintegrated by pipetting up and down with a 5 ml serological pipette. The 
resulting suspension was transferred to 50 ml tubes. To separate cells from other bone 
marrow components, suspensions were spun down at 1,300 rpm for 6 min at room 
temperature. Red blood cell contaminations were removed with 5 ml blood cell lysis 
buffer. After an incubation time of 5 min, the reaction was stopped with 10 ml RPMI 
complete medium followed by centrifugation for 6 min at room temperature and 1,300 
rpm. Then the marrow cells were resuspended in 5 ml RPMI complete medium and the 
cell number was determined in a Neubauer hemocytometer (4.1.6). 
Cultivation and differentiation of bone marrow derived Flt3 cultures 
The bone marrow cells were initially seeded at a density of 1.5 x 106/ml in RPMI complete 
medium in a cell culture bottle. Under the influence of a Flt3 ligand (FMS-like tyrosine 
kinase 3 ligand) with a concentration of 35 ng/ml, they differentiated into pDCs and cDCs. 
The cultures were maintained under an atmosphere of 37°C, 100% humidity and 7.5% 
CO2. Cells were harvested on day 7 and seeded at a density of 2 x 106/ml (4.1.6) for 
experiments. The phenotype of the generated dendritic cells was analyzed by FACS (4.7). 
These cultures typically contained 30-50% CD45RA+CD11c+ pDCs, 30-50% CD45RA-
CD11c+ cDCs and 15% CD11c-cells. 
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Cultivation and differentiation of bone marrow derived macrophages 
Cells were seeded at a density of 0.5 * 106/ml in RPMI complete medium in a 10 cm petri 
dish. Under the influence of a M-CSF ligand (Macrophage Colony Stimulating Factor) with 
a final end concentration of 20 ng/ml, they differentiated into macrophages. The cultures 
were maintained under an atmosphere of 37°C, 100% humidity and 7.5% CO2. After three 
days, 20 ng/ml M-CSF was additionally added. After 5 days, the non-adherent cells were 
first collected and then incubated for 10 min at 37°C with 5 ml PBSdef/3% FCS/ 2 mM 
EDTA to detach the adherent cells. Cells were seeded at a density of 1 x 106/ml (4.1.6) for 
experiments. The purity of the cells was analyzed by FACS analysis (4.7). 
Cultivation and differentiation of bone marrow derived GM-CSF cultures 
Cells were seeded at a density of 0.3 * 106/ml with RPMI complete medium in a cell 
culture bottle. Under the influence of a GM-CSF ligand (Granulocyte macrophage colony-
stimulating factor) with a final end concentration of 10 ng/ml, they differentiated into cDCs. 
After three days, 5 ng/ml GM-CSF was additionally added. The cultures were maintained 
under an atmosphere of 37°C, 100% humidity and 7.5% CO2. Cells were harvested on 
day 7 and seeded at a density of 2 x 106/ml (4.1.6) for experiments. These cultures 
typically contained more than 90% cDCs (CD11c+, CD11b+, B220-) (4.1.6). 
 
4.1.9.2. Isolation of PBMCs  
PBMC (peripheral blood mononuclear cells) (from the Department for transfusion 
medicine from the clinical centre at the Philipps University Marburg) were generated from 
heparinized blood of healthy donors by density centrifugation over the carbohydrate 
polymer Ficoll (LSM 1077, PAA). This yielded a population of mononuclear cells at the 
interface that was depleted of red blood cells and most polymorphonuclear leukocytes or 
granulocytes. The resulting PBMC population consisted mainly of lymphocytes and 
monocytes. The cells were layered over Ficoll and centrifuged over 30 min at 2,000 rpm 
without brake. Red blood cells and polymorphonuclear leukocytes or granulocytes are 
denser and were thus centrifuged through the Ficoll-Hypaque TM, while mononuclear 
cells consisting of lymphocytes together with some monocytes banded over it and could 
be recovered at the interface. 
PBMCs were harvested, washed two times with PBSdef and resuspended in 20 ml RPMI 
complete medium without FCS. Finally, cell numbers were determined in a Neubauer 
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hemocytometer (4.1.6), and cells were seeded with 4% human AB Serum (after 
stimulation the final end concentration is 2%) onto a 96 well plate at a density of 3 x 
106/well. Cells were maintained at 37°C in a 5% humidified CO2 environment. 
4.1.9.3. Isolation of monocytes from human blood 
Human monocytes were isolated from buffy coats of healthy blood donors (Pauligk et al. 
2004). The term ‘centrifugal elutriation’ describes a technique which involves the balance 
between a centrifugal force generated by the spinning rotor and a centripetal flow of liquid 
within a separation chamber. Cells present in the separation chamber are found in a 
position at which the two forces acting on them are at equilibrium. The position of each 
cell is determined by its size, shape and density. Because the chamber's geometry 
produces a gradient of flow rates from one end to the other, cells with a wide range of 
different sedimentation rates can be held in suspension. By increasing the flow rate of the 
elutriating fluid in steps, or by increasing the rotor speed, successive populations of 
relatively homogeneous cell sizes are washed from the chamber. Each population 
contains cells which are larger or more dense (i.e., faster sedimenting) than those of the 
previous fraction (Figdor et al. 1983). The following correlation exists between the flow 
rate and the rotor speed (Beckman, Instruction Manual): 
  F = X x D2 x (RPM x 10-3)-2 
  F = flow rate at the pump in ml/min 
  X = 0, 0511 (Standard chamber) 
  D = cell diameter in µm 
  RPM = rotor speed pro minute 
By using a constant rotor speed, some guidance is given from this expression in order to 
calculate the cell size elutriated at any flow rate. For the experiments, the JE-6B elutriation 
system with appropriated rotor and standard chamber was used. The standard chamber 
has a volume of 4.2 ml. Human peripheral blood mononuclear cells were isolated from 
blood on Ficoll-Paque gradients. The mononuclear cells (300–500 x 106), suspended in 35 
ml RPMI complete medium, were loaded into a Beckman elutriation centrifuge. Separation 
by counterflow centrifugal elutriation was performed at a constant rotor speed from (3,000 
rpm) and a variable flow rate (6-36 ml/min) at 4°C. Phosphate-buffered saline (PBSdef) 
supplemented with 0.1% bovine serum albumin and 0.01% EDTA was used as an 
elutriation medium. Cells were drawn in the separation chamber at flow rates of 7 ml/min, 
following flushing at 15 ml/min in order to remove trombozytes and erythrocytes. The 
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lymphocyte and NK-cell population was eluted at flow rates of 28.5 ml/min, whereas the 
monocytes population was eluted at flow rates of 36 ml/min. 
The purified cell population was centrifuged at 1,400 rpm for 10 min at 4°C and 
resuspended in culture medium.  
4.1.9.4. Isolation of untouched monocytes 
After elutriation, the monocytes population had a purity of 60-80%. Therefore, the cells 
had to be further purified to get a homogenous monocyte population by using a magnetic 
activated cell sorting (MACS) kit, "Monocyte Isolation Kit II (human)". All non-monocytes 
were indirectly magnetically labeled by using a cocktail of biotin-conjugated antibodies as 
the primary label reagent, followed by anti-biotin monoclonal antibodies conjugated to 
microbeads as a secondary labeling reagent. The cell suspension was loaded onto a 
MACS LS column that was placed in the magnetic field of a MidiMACS separator. The 
magnetically-labeled non-monocytes were retained on the column, whereas all cells that 
were not labeled passed through and could be collected as the purified and untouched 
monocyte population. The separation was performed as described in the manufacturer’s 
manual. The purity of the cultures was analyzed via FACS analysis (4.7) using antibodies 
against CD14, CD11b and BDCA2 and usually achieved 86-96% purity.  
The cell number was counted (4.1.6), and monocytes were seeded in medium with 4% AB 
at 3 x 106/ml in 96-well flat-bottom plates and could be used for further experiments 
(4.6/4.8). As a control, PBMC were also used for stimulation (0.3x106 cells/well). 
4.2. General nucleic acids techniques 
4.2.1. Nucleic acid gel electrophoresis 
Electrophoresis is the separation of charged particles within an electric field. Separation 
efficiency of macromolecules correlates with differences in size and charge. 
Electrophoretic mobility is proportional to the field strength and the net charge of the 
molecule. 
Agarose gel electrophoresis 
Agarose is a polysaccharide (composed of galactose and galactose derivatives); different 
pore size of the gel matrix are adjusted by varying the concentration of agarose. The 
pores in agarose gels are larger than in polyacrylamide gels. For RNA agarose gel 
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electrophoresis, it had to be ensured that no contaminating RNases were present. 
Therefore, the electrophoresis chamber and other accessories were incubated with 3% 
H2O2 for 30 minutes. 
For gel preparation, agarose was dissolved in 1 x MOPS buffer by heating (e.g., in a 
microwave). Once the gel solution had cooled down to about 50-60°C, the solution was 
poured into a prepared gel tray with a comb. The solid gel was placed in an 
electrophoresis chamber containing 1 x MOPS. The nucleic acid samples (diluted to a 
concentration of approximately 1 µg) mixed with 6 x loading dye solution (to 1 x final 
concentration) were loaded into the gel pockets. The loading dye solution contained two 
dyes, bromphenol blue and xylene cyanol FF, for easy visual tracking of DNA migration 
during electrophoresis. (In 1% agarose gels bromphenol blue comigrates with ~300 bp 
fragments and xylene cyanol FF- with ~ 4000 bp fragment). Gels were run at 70-100 volts 
(7.5 mA/cm2). Agarose concentrations were chosen according to the size of the expected 
fragments (Table 2). 
In these experiments, RNA was analyzed with the help of agarose gel electrophoresis. 
RNA forms because of intramolecular base-pairing secondary structures, changing their 
course behavior in the gel. For this reason, an exact analysis of RNA was only possible in 
a denatured gel. Because in this work gel electrophoresis was only used in order to check 
RNA preparations, non-denatured gels as described above were sufficient. 
Table 2: Separation range of DNA fragments in agarose gels of different concentrations. 







1.0 – 30 
0.8 – 12 
0.5 – 7 
0.4 – 6.0 
0.2 - 3.0 
0.1 – 2.0 
 
Polyacrylamide gel electrophoresis (PAGE) 
Polyacrylamide (PAA) gels were generated by crosslinking polymers of acrylamide with 
the co-monomer bis-acrylamide. Unpolymerized polyacrylamide is a neurotoxin and 
therefore must be handled extremely carefully. Polymerization of polyacrylamide was 
initiated by addition of APS (ammonium persulfate, (NH4)2S2O8) and TEMED (N,N,N,N,-
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Tetramethylethylendiamine). In an aqueous solution, APS forms radicals that react with 
PAA. TEMED also serves as a catalyst. Different concentrations of acrylamide used for 
gel electrophoresis correlate with different pore sizes. 
Denaturing PAGE 
Denaturing sample buffer  
6 x Loading Dye 
8 M Urea 
PAA gel solution 










ad 40 ml 
 
In denaturing gels, the native structure of macromolecules that run within the gel is disrupted. 
PAA gels are usually supplemented with 8 M urea or another denaturing substance (e.g., 
formamide) before polymerization.  
Table 3 indicates the fragment sizes of ssDNA that comigrate with the BPB and XCB dyes of 
the sample buffer in denaturing polyacrylamide gels of different percentages. 
 
Table 3: Size of ss nucleic acids fragments (given in nucleotides) comigrating with the dyes 
of the sample buffer in denaturing polyacrylamide gels. 

















For preparation of a PAA gel solution, urea was dissolved in the appropriate volume of 10 
x TBE and the required volume of acrylamide/bisacrylamide stock solution was added. For 
gel preparation, glass plates were cleaned with 70% ethanol and assembled with spacers. 
Polymerization was initiated by adding 1/100 volume 10% (w/v) APS and 1/1000 volume 
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TEMED to the PAA gel solution. The gel solution was poured between the clamped glass 
plates, and a comb was inserted between the glass plates at the top to create pockets for 
later sample loading. After polymerization (approximately 1 h), the comb was removed, 
and the pockets were immediately rinsed using a syringe with 1 x TBE buffer to remove 
urea that had diffused from the gel matrix (which tended to accumulate in the pockets) 
and to avoid later polymerization of unpolymerized acrylamide within the pockets. The 
glass plates containing the gel were fixed in the electrophoresis equipment to bridge the 
buffer reservoirs filled with 1 x TBE buffer (supplemented with 8 M urea), and 
electrophoresis was performed at 5–30 mA (depending on gel size and PAA 
concentration). 
4.2.2. Detection of nucleic acids from gels 
Ethidium bromide staining 
Ethidium bromide intercalates between the stacked bases of DNA and RNA. When 
excited by UV light between 254 nm (short wave) and 366 nm (long wave), it emits 
fluorescent light at 590 nm (orange). 
For staining nucleic acids in agarose or PAA gels, the gels were carefully inserted into 
ethidium bromide staining solution (0.5 µg/ml in H2O) and incubated while shaking for 10 
min at room temperature. Staining solution was carefully removed, and gels were 
analyzed using an UV transluminator, where a photo was taken. 
4.2.3. Photometric concentration determination of nucleic acids 
The concentration of nucleic acids was determined by measuring the absorbance at 260 
nm. Concentration could be calculated according to the Lambert-Beer law: 
A = ε * c * d 
(A: Absorbance; c: molar concentration of DNA/RNA [mol/l]; ε: molar extinction coefficient [1/(M*cm)]; d: path 
length of the cuvette [cm]) 
Samples were diluted in water (depending on the expected concentration), and the 
absorbance at 260 nm was measured against water using a UV spectrophotometer. The 
concentration was calculated using the known values c(1 A260) that represent the 
concentration corresponding to one absorbance unit at 260 nm (1  A260): 
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1 A260 ds DNA     corresponds to a c(1  A260) of ~ 50 µg / ml 
1 A260 ss DNA     corresponds to a c(1  A260) of ~ 33 µg / ml 
1 A260 RNA     corresponds to c(1  A260) of ~ 40 µg / ml 
 
This results in a general formula for RNA/DNA concentration calculation: 
 
(where c is concentration in µg/µl, Df is the dilution factor) 
The purity of the preparation can be determined by forming the quotient E260nm/E280nm. 
The absorption maximum of nucleic acids is 260 nm, while amino acids or proteins 
respectively absorb best at 280 nm. Thus, the quotient of the absorption measured at 
these two wave length determines the degree of purity. An adequate purity is given for 
RNA by a proportion of > 2.0 and for DNA by a proportion of > 1.7. 
4.2.4. Alcohol precipitation 
Ethanol precipitation 
Ethanol precipitation is a very common method of concentrating nucleic acids from 
aqueous solutions and removing salts. The precipitate of DNA/RNA, which was formed at 
a low temperature in the presence of moderate concentrations of monovalant cations, was 
recovered by centrifugation. Salts remained predominantly in the ethanol supernatant. For 
precipitation, 1/10 volume of 3 M NAOAc ph 5.0 was added to one volume of DNA/RNA 
solution, followed by mixing with 2.5 volumes of absolute ethanol. Samples were kept for 
at least 1 h at -80°C or overnight at -20°C and were then centrifuged for at least 30 min at 
4°C, 13,000 rpm. For a more efficient removal of salts, the pellet was washed with 70% 
(v/v) ethanol and centrifuged for another 15 min at 13,000 rpm. The supernatant was 
discarded, the pellet was dried at room temperature and finally dissolved in an appropriate 
volume of ultra-pure water. 
4.2.5. Phenol/chloroform extraction 
Phenol/chloroform extraction is a common technique used to purify DNA or RNA samples. 
Such extractions are used whenever it is necessary to inactivate or remove enzymes. The 
procedure takes advantage of the fact that deproteinisation is more efficient when two 
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different organic solvents are used instead of one. The final extraction with chloroform 
also removes residual phenol.  
An equal volume of phenol/chloroform was added to an aqueous DNA/RNA sample, 
vigorously vortexed (30 s) and then centrifuged (5 min, 13,000 rpm at room temperature) 
to achieve phase separation. The upper aqueous layer was removed carefully, avoiding 
the protein-containing interface, and transferred into a new tube. The lower organic layer 
and interface were discarded. The aqueous phase was extracted a second time using 
chloroform. The aqueous layer was also the upper layer in chloroform extractions. 
Afterwards DNA/RNA was concentrated by ethanol precipitation (4.2.4). 
4.2.6. Micro Bio-Spin® 30 Columns 
Micro Bio-Spin columns are designed for the rapid cleanup and purification of riboprobes, 
including the removal of unincorporated nucleotides or templates used for in vitro 
transcription. The columns are packed with a special grade of Bio-Gel P-30 
polyacrylamide gel matrix suspended in 10 mM Tris buffer (pH 7.4). This unique gel 
produces very efficient, noninteractive separation by size. The columns are used to purify 
nucleic acids larger than 20 bases. The cleanup was performed according to the protocol 
provided by the manufacturer. First, the column was inverted several times to resuspend 
the settled gel. The cap was removed, so that the excess packing buffer began to flow. 
After discarding the buffer, the column was centrifuged for 2 min at 1,000 x g to remove 
the remaining packing buffer. The speed was important to ensure proper performance of 
the columns. Then the sample (10 – 75 µl) was carefully applied onto the top center of the 
gel bed, and the column was centrifuged again for 4 min at 1,000 x g. The collected 
purified sample was received in 10 mM Tris buffer. 
4.2.7. XBRIDGETM OST C18 columns 
XBridgeTM OST C18 columns, used for separations of detritylated synthetic 
oligonucleotides, are based on ion-pair, reversed-phase chromatographic principles. An 
efficient charge-based (length-based) oligonucleotide separation was achieved according 
to the protocol provided by the manufacturer. 
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4.3. RNA techniques 
Water used for RNA-related work was ultra-pure water or water treated with DEPC 
(Diethyl-Pyrocarbonat) (0,1%) to eliminate contaminations with RNases. Briefly, DEPC 
was added to water and stirred for 12 hours. For RNase inactivation, water was 
autoclaved by the standard procedure. 
4.3.1. Trizol RNA preparation from eukaryotic cells 
Total cellular RNAs from MDCK, HEK, PBMCs and murine liver cells were isolated by the 
Trizol method according to the protocol provided by the manufacturer. One ml of Trizol is 
sufficient to isolate RNA from 5 - 10 x 106 cells or 10 cm2 of culture dish surface for cells 
grown in monolayer. Trizol contains a mixture of phenol and guanidine thiocynate (GITC) 
in a mono-phase solution, which effectively dissolves DNA, RNA, and protein on 
homogenization or lysis of tissue sample. After addition of the reagent, the cell lysate 
should be passed several times through a pipette to form a homogenous lysate. We 
incubated the cell suspension for 5 min at room temperature. 0.2 ml chloroform were 
added per 1 ml Trizol and shaken for 15 s. After another 2 min of incubation at room 
temperature, the suspension was centrifuged for 30 min at 4°C and 4,000 rpm. The 
mixture separated into three phases: a colorless upper aqueous phase containing RNA, 
an interphase containing DNA and a red organic phase containing proteins. The aqueous 
phase was transferred into a new reaction tube, and RNA was precipitated by adding 0,5 
ml isopropanol per ml Trizol and, after incubation for 10 min at room temperature, 
centrifuged for at least 30 min at 4°C and 4,000 rpm. The pellet was washed once with 70 
% ethanol (at least 1 ml 70% ethanol per ml Trizol), centrifuged for another 15 min and 
air-dried. RNA was dissolved in ultra-pure water, and remaining residual DNA was 
removed by DNase I digest. After digestion, the RNA was phenol/chloroform (4.2.5) 
extracted and ethanol precipitated (4.2.4). Finally, the RNA was dissolved in water and the 








10 Units (1 µl) 
up to 50 µl 
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4.3.2. Isolation of the 18S rRNA from eukaryotic total RNA 
18S rRNA was purified from total eukaryotic RNA using a biotinylated DNA-
oligonucleotide complementary to the 3`-end of ribosomal RNA combined with 
streptavidin-beads (Tsurui et al. 1994). Since avidin bind preferentially to biotin, biotin-
tagged molecules can be extracted from a sample by mixing them with beads which are 
covalently-attached to avidin, and washing away anything unbound to the beads. For 
preparation of the 18S rRNA, 500 µg total RNA (in a final volume of 75 µl) were incubated 
with 25 µl biotinylated DNA-Oligo in 100 µl TAECL (3.6 M) for 5 min at 70°C, in order to 
melt the secondary structure from the rRNA. Then the sample was incubated for 30 min in 
a water bath at 30°C. During this time, the biotinylated DNA-Oligo and the 18S rRNA 
hybridised through complementary base-pairing. Then 50 µl streptavidin-beads in 2,4 M 
TAECL were added and incubated for another 30 min. The hybrid of the biotinylated DNA-
Oligo and the 18S rRNA binded to the streptavidin beads due to the high affinity between 
biotin and streptavidin. After 3 washes with 300 µl 2,4 M TAECL to remove unbound RNA, 
rRNA was eluted with 50 µl 2.4 M TAECl. Then the RNA/DNA-hybrid was melted for 5 min 
at 70°C. Finally, the eluate was dialysed for 2 hours against DEPC water on 25 nm filter, 
in order to purify the RNA from the high molar salt. 
Precipitation was achieved according to the protocol described in section 4.2.4. The 
concentration of the RNA was determined (4.2.3), and the purity of the RNA was analysed 
using agarose elektrophoresis (4.2.1). 
4.3.3. Virus isolation by inoculation in embryonated eggs 
Candling and inoculation of eggs 
Influenza virus strain A/Puerto Rico/8 (A/PR/8) was propagated in the allantoic fluid of 11-
day-old specific pathogen free embryonated eggs (SPF) as described by Nain et al. (Nain 
et al. 1990). Embryonated eggs were incubated for 11 days at 37°C in a relative humidity 
of 40 – 60% and automatically rotated every six hours.  
Eggs were examined with an egg candler and placed blunt-end up into egg trays. Infertile 
eggs and those with cracks were discarded. Then eggs were candled for identification of 
the air sac and vessels and marked for a clear area. Eggs were wiped with an iodine 
solution, and a small hole was drilled into the shell over the air sac without scarifying the 
membrane. Infectious A/PR/8 (A/PR/8 N.Y. Allantois 02.12.96) stock was diluted in sterile 
PBS (1:1000), and 200 µl were inoculated in the allantoic sac with a tuberculin syringe 
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and capillary needle (24 G x 1; 0.55 x 25 mm). The holes punched in the eggs were 
sealed with a drop of glue. Eggs were placed into a humidified incubator at 37°C for 2 
days. The inoculated eggs were observed; deaths were regarded as non-specific, and 
those embryos were discarded.  
Harvesting of inoculated chicken eggs 
The next steps were performed at 4°C under sterile conditions. 
Eggs were chilled at +4°C overnight before harvesting. This led to vessel constriction and 
death of the embryos. The top of each egg was cleaned with 70% ethanol before the shell 
over the air sac was broken and the allantoic membrane pushed away with sterile forceps. 
Allantoic fluid was obtained using a 10 ml syringe and needle (20G x 1,5; 0,9 x 40 mm) 
and was pooled from several eggs. Only clear fluid was collected, cloudy fluids were 
discarded. 7 – 12 ml allantoic fluid was harvested from each egg. 
Purification of influenza A-virus 
To pellet debris, fluid was centrifuged at 6,000 rpm for 30 min at 4°C without break. To 
purify the virus, allantoic fluid was pelleted in an ultracentrifuge in Ultra-ClearTM-Tubes at 
18,000 rpm for 55 min at 4°C without break (Sorvall-Rotor JA-19 in Sorvall-Centrifuge or 
Beckman-Rotor 16250 in Beckman-Centrifuge). Supernatant was discarded, and pellet 
was covered with 500 µl PBSdef, swelled for one hour on ice and resuspended using a 
tuberculin syringe with a capillary needle. A 30-55% gradient from sucrose was made 
from a 60% sucrose parent solution in Ultra-ClearTM-Tubes (treated with 3% H2O2 for 90 
min in the dark). Resuspended virus-pellet was placed on top of the sucrose gradient and 
centrifuged at 24,000 rpm for 16 hours at 4°C without break. The virus was located in a 
white and cloudy coat (near 45% sucrose) and was harvested and filled up with PBSdef in 
order to remove the sucrose. The virus was then pelleted at 24,000 rpm for 45-60 min at 
4°C without break. Finally, the concentrated, purified virus was swelled in 500 µl PBSdef on 
ice for 1 hour and stored at –80 °C. 
Extraction of viral RNA from allantoic fluid 
RNA was extracted from infected allantoic fluid using the Trizol method (4.3.1). 
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Measurement of infectious units 
One of the most important procedures in virology is measuring the concentration of a virus 
in a sample, or the virus titer. This parameter is determined by inoculating serial dilutions 
of virus into host cell cultures. 
Hemagglutination assay 
This assay uses the ability of the influenza virus to cause red blood cell-agglutination as a 
read-out. Members of the family Orthomyxoviridae (among other viruses) contain proteins 
that can bind to erythrocytes (red blood cells); these viruses can link multiple cells, 
resulting in a lattice. This property is called hemagglutination. Influenza viruses contain an 
envelope glycoprotein called hemagglutinin, which binds to N-acetylneuraminic acid-
containing glycoproteins on erythrocytes. This test detects not only infectious but also 
defective virus particles. In practice, 25 µl of the virus suspension was plated in a serial 
1:2 dilution in 96 well round bottom plates and mixed with 25 µl 1% chicken red blood 
cells. After incubation for 30 min at room temperature, the presence of the virus in wells 
was determined by agglutination. The endpoint for this assay was the reciprocal of the 
highest virus dilution at which complete haemagglutination could be detected. Titers were 
calculated as hemagglutinating units (HAU/ml).  
Plaque-Assay 
This test detects infectious virus particles. Therefore, MDCK monolayers were prepared in 
6-well cell culture plates. Once confluent, the cells were washed with PBS++ and 
inoculated with 500 µl of virus dilutions. After adsorption at 37°C for one hour, 3 ml 
nutrient overlay (1.8% Bacto-Agar) were added to each well. Plates were then incubated 
for 4 days at 37°C. When the orginal infected cells release new progeny viruses, the 
spread to neighboring uninfected cells is restricted by the gel. As a result, each infectious 
particle produces a circular zone of infected cells, or plaque. To enhance the contrast 
between the plaque and the surrounding monolayer, the cells were stained with a vital 
dye. Living cells absorbed the stain, and plaque appeared clear against a purple 
background of healthy cells. The titer of a virus stock could thus be calculated in plaque-
forming units (PFU) per milliliter from the dilution of the sample and the amount of plaque 
observed. 
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4.3.4. In vitro transcription 
Human 18S rRNA was amplified from genomic DNA and cloned into pGEM (a kind gift 
from Andreas Kaufmann). pGEM plasmid containing human 18S rRNA was linearized with 
PvuII for 2 hours at 37°C. 
Component Amount 
10 µg DNA x µL 
H20 x µl 
10 x NB Buffer 5 µl 
Enzym Pvu II 2 µl 
 Σ 50 µl 
 
The linearized plasmid was purified according to the MinElute PCR Purification Kit 
Protocol (Peqlab, Erlangen). To confirm that the plasmid was fully linearized, the DNA 
was examined on an ethidiumbromide-stained agarose gel (4.2.1). 
T7 transcription reaction 
The linearized and purified RNA was used as the matrice for the T7 transcription reaction. 
RNA can be transcribed in vitro using DNA-dependent phage RNA polymerases (e.g., T7 
RNA polymerase). T7 RNA polymerase recognises the specific T7 phage promotor 
sequence (5`-TAA TAC GAC TCA CTA TA-3`; sense strand) and starts polymerisation 
immediately downstream in the 5`-3` direction. The in vitro transcription was done 
according to the protocol specified in the AmpliScribeTM T7 Transcription Kit (Epicentre, 
Biozym, Hess. Oldendorf).  
T7 transcription reaction 
All components in the following table were mixed in a 1.5 ml reaction tube, and T7 RNA 
polymerase was added at the end, followed by incubation at 37°C for 3 hours. The 
remaining residual DNA was removed by DNase I digest. For the desalting and removal of 
mononucleotides, samples were purified according to the RNeasy Mini Protocol for RNA 
Cleanup. Transcription efficiency was analysed by agarose gel (4.2.1), and the 
concentration was determined (4.2.3). To obtain large amounts of RNA, preparative scale 
transcriptions were performed. 
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Component Final concentration 
x µl RNase-Free water    
1 µg linearized template with appropriate promoter 
2 µl 10 X AmpliScribe T7 Reaction Buffer            
1.5 µl 100 mM ATP 
1.5 µl 100 mM CTP 
1.5 µl 100 mM GTP 
1.5 µl 100 mM UTP 
2 µl 100 mM DTT 
2 µl AmpliScribe T7 Enzyme Solution              








   - 
Σ 20 µl  
 
4.3.5. Design of the RIG-I ligand 5`-3P RNA 
Synthesis of the RIG-I ligand 5`-3P RNA was performed as described in the Silencer® 
siRNA Construction Kit from Ambion. The Silencer® siRNA Construction Kit overcomes 
the sequence requirements of traditional in vitro transcription strategies by using siRNA 
template oligonucleotides containing a “leader” sequence complementary to the T7 
Promoter Primer included in the kit. The template oligonucleotide should have 21 nt 
encoding the siRNA at the 5`-end and 8 nt at the 3`-end complementary to the T7 
Promoter Primer. The 8 nt at the 3`-end should be the following sequence: 5`-
CCTGTCTC-3`. First, the template oligonucleotide was hybridized to a T7 Promoter 
Primer. Therefore, the components listed below were mixed and heated to 70°C for 5 min. 
Then the mixture was left at room temperature for 5 min. 
 
Component Amount 
T7 Promoter Primer 
DNA Hyb buffer 
Sense template: 
oligonucleotide for RIG-I-ligand 5`-3P RNA 
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Templates for RIG-I-ligand 5`-3P RNA 
Sense Template 
5`-GGG ACC CTG AAG TTC ATC CCC TAT AGT GAG TCG TAC CTG TCT C-3` 
Antisense Template 
5`-TAC GAC TCA CTA TAG GGG ATG AAC TTC AGG GTC CCC CTG TCT C-3` 
 
 
The 3`-end of the hybridized DNA oligonucleotide was extended by the Klenow fragment 
of DNA polymerase to create ds siRNA transcription templates. The following components 
were added to the hybridized oligonucleotides and incubated for 30 min at 37°C 
Component Amount 
10 x Klenow Reaction buffer 








Then the siRNA templates were transcribed by T7 RNA polymerase. The following 
components were mixed and incubated for 2 h at 37°C 
Component Amount 
si RNA template 
Nuclease-free water 
2 x NTP Mix 
10 x T7 Reaction Buffer 







To design the siRNA, the resulting RNA transcripts of sense and antisense templates 
were hybridized to create dsRNA. But for the design of the RIG-I Ligand 5`-3P RNA, this 
step was not necessary. For purification of the RIG-I Ligand 5`-3P RNA, the DNA template 
was removed by digestion with DNase. Therefore, the following reagents were added to 
the last step above and incubated for 2 h at 37°C 
 










The resulting RIG-I ligand 5`-3P RNA was purified by glass fiber filter-binding and elution 
to remove excess nucleotides, short oligomers, proteins, and salts in the reaction. 
4.3.6. Hydrolysis of RNAs with different RNase types  
The treatment of RNA with different RNase types was performed as follows: 
Component Amount 
RNA 






ad 500 µl 
 
The reaction mix was incubated for 1 h at 37°C. Then the solution was subjected to 
phenol/chloroform extraction (4.2.5) followed by ethanol precipitation (4.2.4). The pellet 
was dissolved in RNase-free water and the concentration was determined (4.2.3). 
Alternatively, the RNase-derived fragments were purified by using a Micro Bio-Spin 
column (4.2.6). The RNase-treated RNAs were analyzed either by PAGE (4.2.1) or 
agarose gel electrophoresis (4.2.1). Then immune cells were stimulated with the RNase-
derived fragments by using liposomes (4.5). 
4.3.7. Removing the 2`,3`-cyclic phosphate at the 3`-end of RNA 
The enzyme that catalyses the removal of a 2`,3`-cyclic phosphate (e.g., that generated 








Buffer (500 mM Tris-HCl pH 7.6 at 25°C, 100 
mM MgCl2, 50 mM DTT, 1 mM spermidine 
and 1 mM EDTA) 







ad 19 µl 
 
The reaction mix was incubated for 30 min at 37°C. Then the solution was subjected to 
phenol/chloroform extraction (4.2.5) followed by ethanol precipitation (4.2.4). The pellet 
was dissolved in RNase-free water and the concentration was determined (4.2.3). The 
removal of the phosphate group led to a reduced net charge of the transcript, which, for 
small RNAs (less than 100 nt), could be monitored by a lower electrophoretic mobility of 
the RNA in comparison to the untreated RNA (4.2.1). 
4.3.8. Fragmentation of RNA with Zn2+ or Pb2+ 
Ambion® RNA Fragmentation Reagents contain a buffered zinc solution and are designed 









10 x Fragmentation Buffer 
Mix, spin briefly, and incubate at 70°C in a 
heating block 
Stop Solution (200 mM EDTA pH 8.0) 
20 – 50 µg 
to 18 µl 
2 µl 




to 18 µl 
2 µl 





Pb2+ hydrolysis reactions were started by adding 1 µl of lead acetate solution (100 mM) 
followed by incubation for 60 min at 37°C. 







The fragmentized RNAs were subjected to phenol/chloroform extraction (4.2.5) and 
concentrated by ethanol precipitation (4.2.4). The pellet was dissolved in RNase-free 
water and the concentration was determined (4.2.3). Alternatively, the fragmentized RNA 
was cleaned up by using a Micro Bio-Spin column (4.2.6). Fragmentation was controlled 
by agarose gel electrophoresis (4.2.1). Then immune cells were stimulated with the 
fragmentized RNAs by using liposomes (4.5). 
4.3.9. Ultrasonic treatment 
RNAs were exposed to ultrasound waves for different lengths of time (0 s, 5 s, 10 s, 15 s, 
20 s, 1 min). For this treatment, 40 µg RNA were aliquoted to an end volume with ultra-
pure water of 100 µl in an Eppendorf tube and vortexed. Then the RNA solution was 
exposed to ultrasound waves. The degraded RNAs were analyzed by agarose gel 
electrophoresis (4.2.1), after which immune cells were stimulated with the degraded RNAs 
by using liposomes (4.5). 
4.3.10. RNase III treatment of RNA 
RNase III converts long dsRNA into a heterogeneous mix of short (18-25 bp) interfering 
RNAs (siRNA). We tested two different types of RNase III, one from Epicentre and one 
from BioLabs, in order to exclude an unspecific effect. 
Component Amount 
RNA 






ad 500 µl 
 
RNase III treatment was controlled by agarose gel electrophoresis (4.2.1). Then immune 
cells were stimulated with the RNase III treated RNAs by using liposomes (4.5). 
Component Amount 
RNA 
PbAc 100 mM 
Liposomal buffer 
10 pmol RNA 
1 µl 
4 µl 
  Methods 
 56
4.3.11. CIP treatment 
Calf Intestinal Phosphatase (CIP) catalyses the hydrolysis of terminal 5`-phosphate 








ad 100 µl 
 
The reaction components listed above were mixed and incubated for 1 h at 37°C. Then 
the solution was subjected to phenol/chloroform extraction (4.2.5) followed by ethanol 
precipitation (4.2.4). The pellet was dissolved in RNase-free water and the concentration 
was determined (4.2.3). CIP treatment was controlled by agarose gel electrophoresis 
(4.2.1). Then immune cells were stimulated with the CIP-treated RNAs by using liposomes 
(4.5). 
4.4. DNA techniques 
The polymerase chain reaction (PCR) is a method for the amplification of very small 
amounts of DNA. The following components are required: a thermostable DNA 
polymerase (Pfu polymerase or Taq polymerase); single- or double-stranded DNA (as a 
template); a forward and a reverse DNA primer, a buffer containing Mg2+ and dNTPs. The 
reaction is performed in three basic steps: denaturation of the double-stranded DNA at 
95°C, annealing of primers to the DNA template at a temperature specific for the primers 
used, and elongation at 68 - 72°C for 5' 3' elongation of the annealed primer. The 











































An 5 - 10 µl aliquot of each reaction was checked on an agarose gel (4.2.1). 
4.5. Transfection with DOTAP or Lipofectamine 2000 for 
“in vitro” stimulation 
For stimulation, immune cells (e.g., human PBMCs (4.1.9.2), human HEKs (4.1.2) and 
murine immune cells (4.1.9.1)) were seeded in a range between 2 x 106/ml and 3 x 106/ml 
in 96-well flat bottom plates (100 µl/well). Each stimulation was performed in duplicate. 
Stimulation with RNA or DNA 
Exogenous RNA needs to cross the cell membrane in order to reach the cytoplasm or the 
endosomes. Cationic lipids in the form of liposomes or micelles are an efficient carrier for 
oligonucleotide (ODN) delivery into cells in culture. Cationic lipids are amphiphilic 
molecules, implying that they consist of a hydrophilic and a hydrophobic region, i.e., a 
(charged) cationic (amine) headgroup, attached via a linker (for example glycerol) to 
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usually double hydrocarbon chain. The cationic liposomes form a polyelectrolyte complex 
with the ODN (negatively charged molecules) (Xu and Szoka 1996; Zelphati and Szoka 
1996).  
Stimulation 
Stimulation with RNA oligonucleotides was performed using transfection reagents. RNAs 
were encapsulated with DOTAP (Roche) in a 1:10 ratio for the stimulation of human 
PBMCs and murine immune cells. RNAs were complexed with DOTAP (Roth) in a 1:12,5 
ratio for stimulation of HEKs. RNAs were formulated with Lipofectamine 2000 in a 1:250 
ratio for stimulation of PBMCs and murine immune cells and in a 1:50 ratio for the 
stimulation of HEKs. 
For a repeat determination, the corresponding amount of RNA was dissolved in 50 µl 
optimen in an Eppendorf tube and combined with 50 µl liposomal-mastermix. The mix was 
incubated for 15 min at room temperature before adding 110 µl medium. 100 µl were used 
in the stimulation of a 96-well that contained primary cells in 100 µl complete medium. For 
the stimulation without liposome, the corresponding amount of RNA was dissolved directly 
in 100 µl optimen. As a negative control for the liposomal transfection reagent, the cells 
were stimulated with liposome without adding RNA. 
In order to achieve the desired end concentration, a double-concentrated RNA solution 
was prepared, due to the dilutionary effect from the cells being in 100 µl medium. 
Incubation was performed for 16–20 h in a CO2 incubator at 37°C. Then the cell 
supernatants were harvested (190 µl per well) and stored at -20°C. The supernatants 
were used to detect cytokines by ELISA (4.9). 
Control-stimulation 
Table 4 shows TLR ligands, which were employed as positive controls. 100 µl from 
double-concentrated ligands diluted in medium were added to the cells. As a negative 
control 100 µl medium was added to the cells. 
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4.6. Transfection with LL-37 
For the stimulation of human PBMCs (4.1.9.2), human monocytes (4.1.9.3), human HEKs 
(4.1.2) and murine cultures (4.1.9.1), immune cells were seeded in a range between 2 x 
106/ml and 3 x 106/ml in 96-well flat bottom plates (100 µl/well). Each stimulation was 
performed in duplicate. 
LL-37 (10 µg) was either given directly into cell cultures (50 µg ml-1 = 10 µM) or first 
premixed with 2 µg RNA (peptide:RNA mass ratio of 5:1) in 10 µl of complete medium.  
Non-infected MDCK-RNA or A/PR/8/MDCK-RNA were chosen as RNAs. After 30-minutes 
incubation at room temperature, the mix was added to the cell cultures. (The final 
concentration was 50 µg ml-1 of LL-37 and 10 µg ml-1 of RNA.) 
Supernatants of stimulated cells were collected after overnight culture. Cytokine levels in 
the supernatants were determined by using ELISA kits (4.9). 
4.7. FACS 
To determine the purity of cells, characteristics of surface molecules were stained with 
fluorescence-labelled antibodies and analyzed by flow cytometry or FACS (fluorescence 
activated cell sorter). The most common fluorescent dyes are fluoresceinisothiocyanat 
(FITC), phycoerythrin (PE) and allophycocyanin (APC). Within the flow cytometer, the cell 
suspension is forced through a nozzle. As each cell passes through a laser beam, it 
scatters the laser light, and any dye molecules bound to the cell become excited and 
fluoresce. Sensitive photomultiplier tubes detect the scattered light (forward and side light-
scattering properties), which provides information regarding the size and granularity of the 
cell. This information is used to distinguish different cell types. The result is visualized as 
Stimulus End concentration 
CpG ODN 2216 
LPS 
R848 
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dot plots, coordinate systems that depict distinct cell populations. By using gates, the 
expression analysis is limited to certain cell populations. In addition to detecting scattering 
light, fluorescent signals are measured which give information on the binding of the 
labeled monoclonal antibodies and hence on the expression of cell-surface proteins by 
each cell.  
For extracellular staining against the surface markers of immune cells, 5 x 105 cells were 
transferred into a FACS tube and washed with FACS buffer. After centrifugation for 6 min 
at 4°C and 1,400 rpm, the supernatant was removed, and the cells were incubated with a 
Fc-Block (Antibody against CD16/CD32) and the corresponding antibodies. After a short 
vortexing and an incubation time of 30 min in the dark at 4°C, cells were washed twice 
with 2 ml FACS buffer in order to remove non-binding antibodies. To maintain the cell 
structures for appropriate analysis; 300 µl of a 1% PFA solution in PBS was added, and 
the samples were vortexed. As a control, unstained cells were also analyzed by FACS. 
All probes were measured with a BD FACSCalibur and analyzed with BD CellQuest. 
Table 5: Fluorophore table of absorbance and emission wavelength. 


















4.8. Immunofluorescence staining of LL-37/RNA 
complexes 
The localization of cathelicidin/RNA complexes was analyzed by fluorescence microscopy 
on fixed cells as described in similar analysis (Ahmad-Nejad et al. 2002; Yasuda et al. 
2006). Human monocytes (4.1.9.3) (0.5 x 106/cm2) were plated on 8-well chamber slides 
(1 cm2/well) and rinsed after one hour with 1 x PBS++. They were then stimulated with 
biotinylated LL-37 complexed to A/PR/8/MDCK-RNA as described above (4.6).  
To visualize endosomes the cells were incubated with Transferrin and EEA-1, and to 
visualize lysosomes the cells were incubated with Lysotracker and Lamp. Transferrin (50 
µg/ml) or Lysotracker (1000 nm) were added to the peptide solutions and incubated on the 
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cells for 30 min at room temperature. After washing three times with PBS, the cells were 
fixed with 4% (w/v) paraformaldehyde in PBS for 10 min at room temperature. Further 
stainings were performed with EEA-1 (1:100) or Lamp (1:100) in PBS containing 0,5% 
BSA and 0,5% saponine for 1 h at room temperature. The cathelicin is tracked in its 
biotinylated form by streptavidin-FITC. The streptavidin-FITC antibody is added in a 
1:1000 dilution and incubated for 1 h at room temperature. In order to see the nucleus of 
the cells 4'-6-Diamidino-2-phenylindole (DAPI known to form fluorescent complexes with 
natural ds DNA) is added in a 1:1000 dilution. 
Then cells are washed thrice with PBS/BSA/Saponine and once with ultra-pure water. 
Cells were covered with Mowiol (3.8), and a coverslip was added. The object slides could 
be stored up to two weeks in the dark at 4°C. Cells were analyzed using a Zeiss 
fluorescent microscope. Images were captured by digital image analysis equipment and 
processed with analysis software (AxionVision LE). 
4.9. Cytokine detection by ELISA 
Principle  
A modification of ELISA known as a “capture” or “sandwich” ELISA can be used to 
determine the quantities of secreted cytokines or interferons from cell-free supernatants. 
The sandwich assay uses two different antibodies that are reactive with different epitopes 
on the antigen whose concentration needs to be determined. A fixed amount of one 
immobilized antibody is used to capture an antigen. Test solutions containing antigen at 
an unknown concentration, or a series of standard solutions with known concentrations of 
antigen, are added to the wells and allowed to bind. Unbound antigen is removed by 
washing. The binding of a second, enzyme-linked antibody that recognizes a 
nonoverlapping determinant on the antigen increases as the concentration of antigen 
increases and thus allows quantification of the antigen. A standard curve is constructed by 
adding varying amounts of a known standard preparation; the assay can then measure 
the amount of antigen in unknown samples by comparison with the standard. 
 
Procedure 
Supernatants from overnight cell cultures (4.5/4.6) were collected and stored at –20°C. 
Microtiter plates (Maxi Sorb Nunc Plate) were coated overnight at 4°C with a monoclonal 
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antibody. The purified capture antibodies were diluted in PBSdef, and 50 µl of this solution 
was dispensed into every well. 
To block unspecific binding, 250 µl of a blocking buffer (10% BSA in PBS/Tween20) was 
transferred into every well and incubated at room temperature for 1 h. After 3 washing 
steps with PBS/Tween20, a 50 µl standard sample of the cytokine in question, with a 
defined concentration, was added to the plate, and a serial 1:2 dilution in medium was set 
up for a standard curve. 
The samples to be measured were added to the plate in indicated solutions and incubated 
for 1-2 hours at room temperature. The plates were again washed three times with 
PBS/Tween20. To detect antibody-cytokine complexes, a detection antibody directed 
against the cytokine was diluted in blocking solution, and 50 µl of this solution was 
transferred into each well. The antibody was incubated for 1-2 hours at room temperature 
and washed with PBS/Tween20. 
The detection antibody was either conjugated to an enzyme or was detected indirectly. 
The detection of biotinylated antibodies was performed through incubation with 50 µl of an 
enzyme-conjugated streptavidin dilution, called horseradish peroxidase (HRP). The 
horseradish peroxidase oxidized the substrate diaminobenzidine to produce a brown 
precipitate. For visualization, 100 µl of a colorless substrate (o-Phenylenediamine 
Dihydrochloride Tablet Sets) dissolved in substrate buffer was added and incubated at 
room temperature. The enzyme changes the colorless substrate into a colored reaction 
product. Reaction was stopped with 25 µl 4 N H2S04 and absorbance was measured 490 
nm (reference: 650 nm) using a Microplate ELISA reader and the SOFT Max® program. 
The cytokine concentrations were calculated by comparing the absorbance values of the 
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Used ELISA-Systems 
The used systems are shown in the following table: 
Detectable 





Human-IFN-α     












Standard Recombinant Human Interferon-α Peprotech 20 µg/ml 4 ng/ml 












Heidelberg 500 µg/ml 0.5 µg/ml 
Enzyme Streptavidin-POD conjugate Roche, Mannheim 500 U/ml 0.1 U/ml 
Standard Recombinant Human IL-6 Peprotech 10 ng/µl 10 ng/ml 












Heidelberg 500 µg/ml 1 µg/ml 
Standard Recombinant Human TNF-α R & D 10 µg/ml 5 ng/ml 
Enzyme Streptavidin-POD conjugate Roche, Mannheim 500 U/ml 0.1 U/ml 

















994 µg/ml 0,994 µg/ml 
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Detectable 





Enzyme POD-conjugated goat anti-rabbit IgG Immuno Research 800 µg/ml 0,16 µg/ml 
Standard Recombinant mouse-IFN-α 
PBL, Piscataway, 
NJ, USA 1 x 10
5 U/ml 500 U/ml 
Mouse-IL-6     




500 µg/ml 1 µg/ml 




500 µg/ml 100 ng/ml 
Enzyme Streptavidin-POD conjugate Roche, Mannheim 500 U/ml 0.1 U/ml 
Standard Recombinant mouse-IL-6 
R&D Biosystems, 
Wiesbaden 10 µg/ml 10 ng/ml 
Mouse-IFN-ß     




1 mg/ml 2 µg/ml 




2.5 mg/ml 2.5 µg/ml 
Enzyme anti-rat IgG antibody H&L POD-conjugated Abcam, UK 2 mg/ml 0.5 µg/ml 
Standard Recombinant Mouse Interferon Beta 
R&D Biosystems, 
Wiesbaden 1 x 10
5 U/ml 500 U/ml 
4.10. HPLC (high performance liquid chromatography) 
Principle of HPLC 
High-performance liquid chromatography is used in analytical chemistry to separate, 
identify and quantify compounds. HPLC utilizes a column that holds the stationary phase, 
a pump that moves the mobile phase through the column and a detector (UV or 
fluorescent) showing the retention times of the molecules. Retention time varies 
depending on the interactions between the stationary phase, the analysis of the 
molecules, and the solvent used. The retention time is considered a reasonably unique 
identifying characteristic of a given analyte. Reversed-phase HPLC has a non-polar 
stationary phase and an aqueous polar mobile phase. With these stationary phases, 
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retention time is longer for molecules which are more non-polar, while polar molecules 
elute more readily. A further refinement to HPLC has been to vary the mobile phase 
composition during the analysis, which is known as gradient elution. The retention can be 
decreased by adding a less polar solvent (methanol, acetonitrile) into the mobile phase to 
reduce the surface tension of water.  
 
HPLC run 
For the separation of the nucleosides, a RP-HPLC with a gradient from 5 mM NH4OAc pH 
6 (Buffer A), 40% Acetonitrile (Buffer B) and 66% Methanol (Buffer C) was performed. For 
the stationary phase a LC18-column from SUPERCOSIL (250 x 4.6 mm, 5 µm) was used. 
The run time was 60 min, and the detection was performed via UV-Detector. 
4.11. Immunization 
All animals were kept under specific pathogen-free conditions, and only female mice from 
8-12 weeks of age were used for the experiments. Chicken egg albumin (OVA) was used 
as an antigen. ODN1668 PTO served as a positive control. 
 
Preparation of the Injection 
Animals were divided into groups of 2-3 mice, and 100 µl of the following vaccine 
formulations were injected:  
Controls: 
• liposomal buffer (20 mM HEPES, 150 mM NaCL, pH 7.4), 100 µl/mouse 
• 100 µg OVA in liposomal buffer, 100 µl/mouse 
• 100 µg OVA and 50 µg ODN 1668 PTO in liposomal buffer, 100 µl/mouse 
with DOTAP: 
• 30 µg DOTAP in liposomal buffer, 100 µl/mouse 
• 100 µg OVA and 30 µg DOTAP in liposomal buffer, 100 µl/mouse 
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• 100 µg OVA and 30 µg DOTAP and 100 µg MDCK-RNA, 100 µl/mouse 
• 100 µg OVA and 30 µg DOTAP and 100 µg A/PR/8-MDCK-RNA, 100 µl/mouse 
with CRAMP: 
• 200 µg CRAMP in liposomal buffer, 100 µl/mouse 
• 100 µg OVA and 200 µg CRAMP in liposomal buffer, 100 µl/mouse 
• 100 µg OVA and 200 µg CRAMP and 40 µg MDCK-RNA, 100 µl/mouse 
• 100 µg OVA and 200 µg CRAMP and 40 µg A/PR/8-MDCK-RNA, 100 µl/mouse 
 
Solutions: 
Ova: 5 mg/ml in liposomal buffer 
ODN 1668 PTO: 500 µM - 3,191 µg/µl           50 µg/15,67 µl 
 
4.11.1.1. Injection of mice 
Mice were injected subcutaneously into the tail base with 100 µl of the vaccine 
formulations. 
4.11.1.2. Antibody ELISA 
The principle of ELISA is presented in section 4.9. Incubation times were chosen as 
described there. For antibody detection, serum was obtained from the blood of immunized 
mice 1 week after the second injection. ELISA plates were coated over night with 0.1 
mg/ml OVA. Sera were diluted 1:3,000,000 and for detection the following antibody was 
used: biotin-SP-conjugated AffiniPure goat anti-mouse IgG (1:2,500). A streptavidin-HRP 
(1:5,000) was employed according to the manufacturer's instructions. 
4.12. Electroporation 
The regulation of gene expression is examined by reporter gene assays. For this purpose, 
DNA sequences carrying putative regulatory elements were cloned in front of a reporter 
gene. Here IFN-ß activity was measured using a reporter gene assay, which utilizes a 
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reporter plasmid containing the IFN-ß promoter cloned in front of the firefly luciferase 
gene. The protein encoded by the luciferase gene fluoresces in the presence of certain 
stimuli, making it easy to determine the level of its expression based on the level of 
luminescence. Firefly luciferase (Photinus pyralis) catalyzes the oxidation of luciferin to 
oxyluciferin. During this reaction photons are released at a wavelength of 562 nm. By 
employing a luminometer, the emitted light is measured and quantified. The average 
emitted light is given in Relative Light Units (RLU).  
Polar molecules are allowed to pass membranes by electroporation. For this purpose, 
cells were adjusted to a final concentration of 3 x 106/400 µl in RPMI medium with 25% 
FCS. This suspension was transferred into a sterile 4 mm electroporation cuvette (Biorad) 
and mixed with 700 ng DNA of different types (Luciferase Reporter Plasmid, Plasmid with 
gene of interest, empty vector). The cuvette was placed into the electroporator, and a 
pulse of 220 V, 975 µF and ∞ Ф was carried out. The cells were transferred immediately 
into 10 ml DMEM with 10% FCS and seeded on a 96-well flat bottom plates. Then cells 
were stimulated and incubated for another 20 hours before adding 50 µl 1 x reporter lysis 
buffer. Lysates were shaken for 15 min and then stored at –80°C for 30 min. They were 
then analyzed for luciferase activity. 20 µl of cell-extract were transferred to each well of a 
96-well polystyrene plate. Subsequently, the reaction was started in the luminometer by 
automatic injection of 25 µl Firefly Luciferin, and the emitted light was measured.  
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5. Results 
5.1. Influence of RNA modifications at the 2`-position of 
ribose on immune stimulation 
Recently, GU-rich ssRNA could be identified as a natural ligand for murine TLR7 and 
human TLR7/8 (Heil et al. 2004). In addition, it was shown that not only viral genomic 
ssRNA but also ssRNA-molecules of non-viral origin activate murine immune cells via 
TLR7 (Diebold et al. 2004). Self-RNA, such as ribosomal RNA (rRNA), is not stimulatory, 
due to natural occurring RNA modifications such as base-methylation, pseudouridine and 
2`-O-methyl ribose (Maden 1990). This observation may explain the discrimination of self 
and non-self RNA by TLR7. Ribosomal RNA, which comprises 80% of total RNA, is the 
central part of the ribosome that is composed of two subunits. In eukaryotes, there are 
40S and 60S subunits. The small subunit contains 18S rRNA (approx. 1874 bases), while 
the large subunit contains 28S rRNA (approx. 4718 bases) and two smaller subunits 5,8S 
rRNA (approx. 160 bases) and 5S rRNA (approx. 120 bases). In this study, we compared 
the immunostimulatory potential of ribosomal 18S rRNA with in vitro transcribed 18S rRNA 
and synthesized RNA oligonucleotides with different modifications. The 2`-position of 
ribose was considered critical for immunorecognition, as it is the position at which DNA 
and RNA structurally differ. The aim of this study was to analyse in more detail the 
recognition of ssRNA by TLR7 and TLR8. 
5.1.1. Purified “natural” 18S rRNA in contrast to in vitro 
transcribed 18S rRNA 
To investigate the stimulatory potential of eukaryotic ribosomal RNA, we purified 18S 
rRNA from total HEK293-RNA utilizing a 3`-complementary biotinylated DNA-
oligonucleotide combined with streptavidin-coated beads (4.3.2.). Furthermore, we 
isolated in vitro transcribed 18S rRNA (4.3.4), which is not modified and does not contain 
2`-O-ribose methyl groups. 
Before transfecting cells with RNA, the RNA was purified (4.3.1/4.2.5) and its quality was 
confirmed by agarose gel electrophoresis (4.2.1/4.2.2). In all experiments, only RNA with 
an optical density quotient 260/280 nm of 2.0 or higher (4.2.3) and with high integrity was 
used. The RNAs used for stimulation are shown in Figure 7 A. The agarose gel shows for 
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total HEK293-RNA two bands, the 28S rRNA (4,7 kb) and the 18S rRNA (1,9 kb). 18S 
rRNA was purified from the total HEK293-RNA. As a comparison, we see the band for 







































Figure 7: Analysis of in vitro transcribed 18S rRNA and purified 18S rRNA. A) Samples
were analyzed by 1, 2 % agarose electrophoresis. Marker lane contains an RNA marker. B)
Human PBMCs were stimulated with purified or in vitro transcribed 18S rRNA complexed to
DOTAP. Cytokines were measured 24 hours post stimulation by ELISA. CpG 2216 (1 µM) and
RNA 40 served as positive controls for IFN-α secretion. R848, RNA 40, and LPS served as
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For stimulating immune cells with RNA, the transfection reagent DOTAP was used as 
described in 4.5. The cationic transfection reagent DOTAP (N-[1-(2,3-Dioleoyloxy)propyl]-
N,N,N-trimethyl-ammoniummethylsulfate) protects RNA from RNases and facilitates RNA 
uptake. The aforementioned RNAs were formulated with DOTAP and tested for type-I 
interferon secretion and proinflammatory cytokine induction like IL-6 and TNF-α in human 
PBMC cells (4.1.9.2) by ELISA (4.9). Positive controls for IFN-α secretion were the TLR 
ligands RNA 40 and CpG 2216. RNA 40, R848 and LPS were used as positive controls 
for proinflammatory cytokine secretion. Upon transfection of purified 18S rRNA complexed 
to DOTAP, there was no IFN-α secretion detectable in human PBMC cells, whereas in 
vitro transcribed 18S rRNA strongly induced type-I interferon (Figure 7 B). However, other 
cytokines such as IL-6 and TNF-α were induced by in vitro synthesized as well as by 18S 
rRNA purified from cells.  
In parallel, murine Flt3-derived dendritic cells (4.1.9.1) were stimulated with the described 
RNAs. Flt3-derived dendritic cells were generated from wild-type and TLR7-deficient mice, 
in order to analyze a TLR dependency of the employed RNAs. The differentiation of the 
Flt3-derived dendritic cells was controlled by FACS analysis (4.7). Flt3-derived dendritic 
cells contain two cell types: pDCs and cDCs. Both cell types show characteristic cell 
markers; cDCs can be recognized by the expression of high levels of CD11c, whereas 
pDCs have a combination of B220 and CD11c. As an example, Figure 8 shows a FACS 









Figure 8: Characterisation of Flt3-derived dendritic cells. A representative flow cytometric
analysis of Flt3-derived dendritic cells with anti-CD11c-APC and anti-B220-FITC is shown. A) Gate
of living cells with FSC/SSC. B) Cells concerning the gate described in A. pDCs are shown in the
upper right quadrant, whereas cDCs are shown in the lower left quadrant. 
A) B) 
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The Flt3-derived DCs were stimulated in the same way as described for PBMC cells. The 
supernatants were used for detection of IFN-α and IL-6 (4.9). Figure 9 shows that upon 
transfection of purified 18S rRNA complexed to DOTAP, there was no IFN-α secretion 
detectable in murine Flt3-derived dendritic cells, whereas in vitro transcribed 18S rRNA 
strongly induced type-I interferon in a TLR7-dependent manner. The proinflammatory 
cytokine IL-6 was not induced by purified 18S rRNA complexed to DOTAP. But for 
stimulation with in vitro transcribed 18S rRNA complexed to DOTAP, an IL-6 response 
was detectable in a TLR7-dependent manner. The TLR7-specific control RNA 40 showed 
only a weak IFN-α secretion in TLR7 -/- cells and R848 induced no IL-6 secretion in TLR7  































Figure 9: Analysis of the receptor responsible for recognizing purified or in vitro
transcribed 18S rRNA. Murine Flt3-derived dendritic cells generated from a wild-type or a TLR7-
deficient mouse were stimulated with purified or in vitro transcribed 18S rRNA complexed to
DOTAP. RNA 40 and R848 served as specificity controls for the respective knockout cells.
Cytokines were measured 24 hours post stimulation by ELISA (n = 2, one representative
experiment is shown). 
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5.1.2. 2`-O-ribose methylated synthetic RNA sequences from 18S 
rRNA do not stimulate TLR7, but still stimulate TLR8 
The presence of naturally occuring nucleotide modifications has been proposed to be 
important for RNA-mediated immunorecognition. To further investigate the influence of 2`-
O-ribose methylation on the immunostimulatory activity of rRNA, we synthesized two RNA 
oligonucleotides derived from the 18S rRNA from nucleotides 1488-1499, both with and 
without the naturally occurring 2`-O-ribose methylation. At position 1490, the natural rRNA 
contains a 2`-O-ribose methylated guanosine (5`-CAG2`-O-methylGUCUGUGAU, RNA 63-2`-
O-methyl, 5`-CAGGUCUGUGAU, RNA 63) (Maden 1990; Bachellerie and Cavaille 1997). 
Moreover, we designed RNA oligonucleotides that lack the 2`-oxygen (deoxy derivates) 
and those that feature a fluoro-group at this position (F-derivates). The different 
modifications of the RNA 63 oligonucleotides are shown in Figure 10. 
 
RNA oligonucleotides were formulated with DOTAP and tested for type-I interferon 
secretion and proinflammatory cytokine induction like IL-6 and TNF-α from human PBMC 
cells over a concentration range from 0.2 µg/ml to 10 µg/ml (4.1.9.2), as shown in Figure 
11 A. As controls, the same samples were used as described in section 5.1.1. A dose-
Figure 10: Structures of modified oligonucleotides used in this study. Synthetic RNA 
sequences from 18S rRNA. A) Guanosine without 2`-O-methyl-derivates. B) 2`-O-ribose 
methylated guanosine. C) 2`-deoxy derivates of guanosine. D) 2`-F derivates of guanosine. RNA 
63M (as shown in B) contains a 2`-O-ribose methylated guanosine at position 3 and reflects the
modification occurring in natural 18S rRNA. RNA 63 (as shown in A) has the same sequence but 
contains no modifications. RNA 63 deoxy (shown in C) shows a deoxy group at positon 3 of
guanosine. RNA 63 F (shown in D) contains a fluoro group at position 3 of guanosine. Sequence of
RNA 63: 5`CAGGUCUGUGAU- at position three represent the different modifications of guanosine. 

















A) B) C) D)
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dependent IFN-α secretion was observed which varied between 1 and 4 ng/ml. RNA 63-
2`-O-methyl showed a significantly decreased IFN-α response. Residual IFN-α was only 
detectable at the concentration of 1 µg/ml of RNA. Interestingly, none of the other 
modifications at position 3 of RNA 63, such as 2`-deoxy (RNA 63-2`-deoxy) and 2`-F 
(RNA 63-2`-F), influenced IFN-α production. And surprisingly, RNA 63-2`-O-methyl 
induced IL-6 and TNF-α in human PBMC cells similar to the other tested RNA 
oligonucleotides. 
Next, we tested the RNA oligonucleotides complexed to DOTAP for cytokine induction on 
murine Flt3-derived dendritic cells (wild-type and TLR7-deficient) (4.1.9.1) as shown in 
Figure 11 B. In order to prove TLR7 dependency for the tested RNA oligonucleotides, 
Flt3-derived DCs from a TLR7-deficient mouse were generated. The Flt3-derived DCs 
were stimulated in the same way as described for PBMC cells, and a FACS analysis (as 
described for the Flt3-derived DCs in section 5.1.1) was performed. The supernatants of 
the stimulated cells were used for detection of IFN-α and IL-6 by ELISA (4.9). 
Interestingly, RNA 63 induced IFN-α and proinflammatory cytokine production (TNF-α, IL-
6) in a TLR7-dependent manner. In contrast, RNA 63-2`-O-methyl was not 
immunostimulatory. The proinflammatory cytokine-induced production by RNA 63-2`-O-
methyl which was observed in the human system was not found in murine immune cells. 
Since murine TLR8 itself is non-functional, this may explain the different proinflammatory 
cytokine response for the RNA 63-2`-O-methyl RNA in the human and murine immune 
systems. Indeed, genetic complementation assays in HEK293 cells with human TLR8 















Figure 11: Influence of nucleotide modifications on RNA-mediated immunostimulation. 
Stimulation of human PBMCs (A) and murine Flt3-derived dendritic cells (B) with different modified 
RNA 63 oligonucleotides complexed to DOTAP in the indicated concentrations. RNA 63 was 
transfected with either unmodified (RNA 63), 2`-O-methyl (RNA 63 M), 2`-deoxy (RNA 63 deoxy) or 
with 2`-O-F (RNA 63 F). CpG 2216, RNA 40 and LPS served as positive controls. Cytokines were
measured by ELISA 24 hours after stimulation. In (A) mean values of 6 different donors are shown. 
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5.1.3. Summary 
TLR7 and TLR8 recognize RNA from pathogens and lead to subsequent immune 
stimulation. Self-RNA is either not at all or less immunostimulatory, due to RNA 
modifications such as 2`-O-ribose- or base methylations. Here, we showed that purified 
ribosomal 18S rRNA was not immunostimulatory, whereas in vitro transcribed 18S rRNA 
induced cytokines. A single 2`-O-ribose methylation within a natural fragment of 18S rRNA 
prevented IFN-α production. However, secretion of TNF-α and IL-6 was not impaired in 
human PBMCs. But the induction of the proinflammatory cytokines was not observed in 
murine immune cells. Since murine immune cells do not express a TLR8 receptor, we can 
conclude that a 2`-O-ribose methylation converts a TLR7/TLR8 ligand to a TLR8-specific 
ligand. Interestingly, other modifications at this position such as 2`-deoxy or 2`-F had no 












  Results 
 76
5.2. Analysis of the immunostimulatory capacity of RNA 
from virus-infected cells complexed to cationic 
lipids or natural carriers 
One disadvantage of using RNA as an adjuvant may be the necessity of complexation to 
cationic lipids such as DOTAP for efficient immune stimulation. Since DOTAP is toxic at 
higher concentrations (Romoren et al. 2004), non-toxic or natural carriers for 
immunostimulatory RNA are desirable. Recently, LL-37 has been found as a key factor in 
mediating plasmacytoid dendritic cell (pDC) activation in psoriasis, a common 
autoimmune disease of the skin (Lande et al. 2007; Gilliet and Lande 2008). Accordingly, 
LL-37 forms aggregates with the self-DNA of dying cells, protects it against nuclease 
degradation and converts it into an inducer of type-I interferon production. The binding of 
LL-37 to DNA is driven by both the cationic charges of LL-37 (which interact with the 
negative charges of DNA) and the unique alpha-helical structure of LL-37 (which stabilizes 
these interactions with DNA) (Gilliet and Lande 2008). We investigated whether LL-37 or 
the mouse homolog CRAMP could function as such a carrier for RNA, especially for RNA 
from virus-infected cells as depicted in Figure 12 (4.6).  
Previous studies have indicated that the ssRNA genome of the influenza virus is 
recognized by RIG-I in monocytes (Hornung et al. 2006; Pichlmair et al. 2006). The exact 
structure of RNA detected by RIG-I is currently controversial (Schlee et al. 2009). Several 
authors have reported that RIG-I detects ssRNA containing a 5`-triphosphate (Hornung et 
al. 2006; Pichlmair et al. 2006) as well as short dsRNA (Kato et al. 2008). 
Dephosphorylation of the influenza genome results in a loss of its ability to induce IFN-α, 
suggesting that the recognition of influenza virus RNA by RIG-I is mediated through 5`-
triphosphate ssRNA (Hornung et al. 2006). On the other hand, earlier studies have 
postulated that dsRNA intermediates produced during influenza virus replication induce 
IFN-α (Jacobs and Langland 1996; Majde et al. 1998; Majde 2000). In contrast to these 
earlier findings, Weber et al. found that the recognition of negative ssRNA viruses is not 
accompanied by the formation of immunodetectable dsRNA, as determined using dsRNA-
binding antibodies (Weber et al. 2006; Pichlmair and Reis e Sousa 2007). To address the 
question of which conformation of the influenza genome is responsible for inducing IFN-α, 
we isolated MDCK-RNA (MDCK = Madin-Darby canine Kidney) from non-infected and 
A/PR/8-infected cells (A/PR/8 = Influenza-A-Virus Puerto Rico) (4.1.5/4.3.1) and analyzed 
their immunostimulatory abilities.  













5.2.1. Stimulation with RNA from virus-infected cells 
Interestingly, RNAs from A/PR/8-infected cells (8h) and from non-infected cells were 
indistinguishable when visualized on an agarose gel by ethidium bromide staining (Figure 
13). The eight gene segments for A/PR/8-RNA were not visible in RNA preparations from 
A/PR/8-infected cells as depicted in Figure 13 B. 
For the stimulation of immune cells with RNA, the cationic transfection reagents DOTAP 
and Lipofectamine 2000 were used. The transfection reagent DOTAP (N-[1-(2,3-
Dioleoyloxy)propyl]-N,N,N-trimethyl-ammoniummethylsulfate) enhances the cellular 
uptake of nucleic acids and increases their concentration within the endosomal/lysosomal 
vesicles (Yasuda et al. 2005). On the other hand, the transfection reagent Lipofectamine 
2000 delivers nucleic acids to the cytoplasm (Astriab-Fisher et al. 2004; Dalby et al. 2004; 
Langlois et al. 2005). Moreover, we used natural carriers (cathelicidins) for complexation 
of RNA and analyzed where these natural carriers deliver nucleic acids. 
 
 
Figure 12: Role of LL-37 in a viral infection (modified after (Baumgarth and Bevins 2007)). 
Upon viral infection, LL-37 forms complexes with self-RNA and viral RNA. These complexes trigger 
a strong interferon production in immune cells. 
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5.2.2. The immunostimulatory ability of RNA complexed to 
cathelicidins in human immune cells 
A/PR/8/MDCK-RNA complexed to the cathelicidins LL-37 or CRAMP was tested for its 
ability to induce IFN-α in human PBMC cells (4.1.9.2). PBMC cells were stimulated as 
described in section 5.1 and the supernatants were used for detection of cytokines by 
ELISA (4.9). For PBMCs, the IFN-α secretion was confirmed with the positive controls 
RNA 40 and CpG 2216. Figure 14 depicts the IFN-α response to A/PR/8/MDCK-RNA 
complexed to LL-37, sLL-37 (a scrambled version of LL-37) and CRAMP (murine homolog 
of LL-37) in comparison to A/PR/8/MDCK-RNA encapsulated with DOTAP. For 
A/PR/8/MDCK-RNA complexed to a natural carrier, there was an IFN-α response 
detectable, although the levels of IFN-α were almost 4-fold lower compared to the IFN-α 
response for A/PR/8/MDCK-RNA complexed to DOTAP. Upon transfection of self-RNA 
complexed to cathelicidins, there was no IFN-α response detectable. However, we 
observed for self-RNA in a concentration range of 2 µg/ml complexed to DOTAP a 
RNA M MDCK-RNA






















Figure 13: RNA preparations used for immune stimulation. A) Total RNA from uninfected or 
A/PR/8-infected MDCK cells was isolated and samples were analyzed by 1, 2 % agarose 
electrophoresis followed by ethidium bromide staining. The marker lane contains an RNA marker. 
B) Viral A/PR/8-RNA was visualized by ethidium bromide staining after separation on an 1, 2 % 
agarose gel with an RNA marker. 
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background IFN-α response in human PBMC cells, which, as we will later see, was not 
observed in Flt3-derived dendritic cells (Figure 14/Figure 17). It is remarkable that self-
RNA complexed to LL-37 induced an IL-6 response, whereas the IL-6 response for self-
RNA complexed to DOTAP (and in this experiment also to CRAMP) was variable on 













5.2.3. Monocytes are the main source of IFN-α upon recognition 
of RNA from A/PR/8-infected cells. 
To address the question of which cell types of the human PBMC cells are responsible for 
recognizing the A/PR/8/MDCK-RNA complexed to cationic transfection reagents or to 
cathelicidins, we analyzed the immune activation of monocytes (4.1.9.3) in comparison to 
PBMC cells (4.1.9.2) as shown in Figure 16. Human monocytes were isolated from PBMC 
cells, purified via elutriation followed by MACS separation and stimulated. The purity of 
the monocytes was controlled by FACS analysis (4.7). Monocytes can be recognized by  
Figure 14: Complexation of RNA 
from A/PR/8-infected MDCK cells 
to LL-37 induced type I interferon 
in human PBMC cells. 10 µg of 
total RNA from uninfected or
A/PR/8-infected MDCK cells was 
complexed to 50 µg LL-37, 
scrambled LL-37 or CRAMP and 
used for stimulation of human 
PBMCs at a final RNA 
concentration of 10 µg/ml. As a 
comparison, uninfected and 
A/PR/8/MDCK-RNA (2 µg/ml) was 
complexed to DOTAP. Cytokines 
were measured 24 hours post 
stimulation by ELISA (for 
A/PR/8/MDCK-RNA complexed to 
LL-37 or sLL-37 n = 30, for 
A/PR/8/MDCK-RNA complexed to 
CRAMP n = 8, one representative 
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the expression of high levels of CD14 and CD11b. As shown in Figure 15, the isolated 



























The monocytes were stimulated in the same way as described for PBMC cells. The 
supernatants were used for detection of IFN-α (4.9). Upon transfection of CpG 2216 and 
RNA 40, there was no IFN-α secretion detectable in human monocytes (only a weak 
secretion for RNA 40), whereas these ligands induced type-I interferon in human PBMC 
cells. Stimulation with A/PR/8/MDCK-RNA complexed to LL-37 induced a type-I interferon 
response in human PBMC cells and monocytes. Here, the induced IFN-α response 





Figure 15: Characterization of human monocytes. A representative flow cytometric analysis of 
human monocytes with anti-CD14-PE and anti-CD11b-APC is shown. A) Gate of living 
monocytes with FCS/SSC. B) Cells concerning the gate described in A were stained with anti-
CD14-PE and anti-CD11b-APC. C) Gate of living PBMC cells with FCS/SSC. D) Cells concerning
the gate described in C were stained with anti-CD14-PE and anti-CD11b-APC. 
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there was no IFN-α response detectable. It is remarkable that self-RNA complexed to LL-













5.2.4. Analysis of important RNA features for recognizing the 
A/PR/8/MDCK-RNA 
 
Role of the 5`-triphosphate group for recognizing the A/PR/8/MDCK-RNA 
To determine if the 5`-triphosphate group is involved in the recognition of A/PR/8/MDCK-
RNA, we dephosphorylated the A/PR/8/MDCK-RNA with calf-intestine phosphatase (CIP) 
(4.3.11) and examined its immunostimulatory activity in murine Flt3-derived dendritic cells 
from a wild-type mouse (4.1.9.1). The differentiation of the cells to pDCs and cDCs was 
controlled by FACS analysis (4.7). The TLR ligands RNA 40 and CpG 2216 were used as 
positive controls for IFN-α secretion. The measured IFN-α induction, as presented in 
Figure 17, shows that dephosphorylation of the A/PR/8/MDCK-RNA complexed to DOTAP 
or Lipofectamine 2000 resulted in significant signal abrogation, indicating that its 5`-















Figure 16: Analysis of the cell 
type of human PBMC cells 
responsible for recognizing 
A/PR/8/MDCK-RNA complexed to 
LL-37. A/PR/8/MDCK-RNA 
complexed to Dotap or LL-37 was 
used for stimulation of human 
PBMC cells and monocytes. 
Cytokines were measured 24 hours 
post stimulation by ELISA. CpG 
2216 (1 µM) and RNA 40 served as 
positive controls (for ca. 90 % purity 
monocytes n = 2, for ca. 70 % 
purity monocytes n = 5; one 
representative experiment is 
shown). 
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triphosphate modification was quite efficiently removed. Dephosphorylation of the RIG-I 
ligand 5`-3P RNA complexed to Lipofectamine 2000 also abolished the IFN-α response, 
suggesting that RIG-I signaling in murine immune cells is mediated through the 5`-













The same set of RNA ligands was assayed for their ability to induce IFN-α in human 
immune cells (PBMCs) isolated from healthy donors (4.1.9.2). For PBMCs the IFN-α 
secretion was also confirmed with the positive controls RNA 40 and CpG 2216. Figure 18 
shows that, in contrast to murine Flt3-derived dendritic cells, the IFN-α response to 
A/PR/8/MDCK-RNA complexed either to DOTAP or Lipofectamine 2000 was not 
abrogated after dephosphorylation in human PBMCs, whereas for the RIG-I ligand 5`-3P 
RNA complexed either to DOTAP or Lipofectamine 2000, the IFN-α response was 
reduced after CIP-treatment. The question arises as to whether there are different 
features of RNA responsible for detection of A/PR/8/MDCK-RNA in murine and human 
immune cells. Moreover, we observed for MDCK-RNA in a concentration range of 2 µg/ml 
complexed to DOTAP or Lipofectamine 2000 a background IFN-α response in human 
PBMC cells that was not observed in Flt3-derived dendritic cells (Figure 17/Figure 18). 
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A/PR/8/MDCK-RNA + CIP 
RIG-I ligand 5`-3P RNA 
RIG-I ligand 5`-3P RNA + CIP
Figure 17: Influence of the 5`-
triphosphate end for 
recognizing RNA in murine 
immune cells. RNA from 
uninfected and A/PR/8-infected 
MDCK cells (2 µg/ml) and RIG-
I ligand 5`-3P RNA (0.2 µg/ml) 
were complexed to DOTAP or 
Lipofectamine 2000 that had 
been either mock treated or
treated with CIP and used for 
stimulation of Flt3-derived 
dendritic cells. CpG 2216 and 
RNA 40 served as positive 
controls. IFN-α secretion was 
measured 24 hours post 
stimulation by ELISA (n = 8, 
one representative experiment 
is shown). 














Conformation of the genome of negative-strand viruses 
In order to analyze the conformation of the RNA prepared from A/PR/8-infected cells, we 
treated total A/PR/8/MDCK-RNA with the ds-specific RNase III (4.3.10) and compared 
their immunostimulatory capacity before and after treatment in human and murine immune 
cells (4.1.9). RNase III cleaves dsRNA or hairpin dsRNA regions of ssRNAs (Aliyari and 
Ding 2009). Upon treatment of A/PR/8/MDCK-RNA with RNase III, the RNA was 
complexed to DOTAP and used for stimulation of human PBMC cells. IFN-α induction was 
measured by ELISA and the already described positive controls CpG 2216 and RNA 40 
were used. A/PR/8-infected MDCK-RNA remained immunostimulatory when treated with 
the ss-specific RNase A (data not shown), but signaling was abolished upon treatment 
with the ds-specific RNase III (Figure 19 A). The observed background IFN-α response for 
MDCK-RNA in a concentration range of 2 µg/ml complexed to DOTAP in human PBMC 
cells was also abrogated upon treatment with the ds-specific RNase III.  
For A/PR/8/MDCK-RNA complexed to DOTAP, the same data were obtained in murine 
Flt3-derived dendritic cells (data not shown). Visualization of the virus-infected RNA that 
was either mock-treated or treated with RNase III by ethidium bromide staining did not 
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A/PR/8/MDCK-RNA + CIP 
RIG-I ligand 5`-3P RNA 




A/PR/8/MDCK-RNA + CIP 
RIG-I ligand 5`-3P RNA
RIG-I ligand 5`-3P RNA + CIP 
Figure 18: Influence of the 
5`-triphosphate end for 
recognizing RNA in human 
immune cells. RNA from 
uninfected and A/PR/8-
infected MDCK cells (2 µg/ml)
and RIG-I ligand 5`-3P RNA
(0.2 µg/ml) were complexed to 
DOTAP or Lipofectamine 2000 
that was either mock treated
or treated with CIP and used 
for stimulation of PBMCs. CpG 
2216 and RNA 40 served as 
positive controls. IFN-α 
secretion was measured 24 
hours post stimulation by 
ELISA (n = 6, one 
representative experiment is 
shown). 
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show any differences (Figure 19 B). These results indicate that besides the terminal 5`-























The specificity of RNase III was confirmed by using RNA 40 (a ssRNA). Since RNA 40 
contains 20 bp, it shows the right size for cleavage through RNase III. The minimal 
substrate for RNase III contains 11 base pairs (bp) (Drider et al. 1999; Pertzev and 
Nicholson 2006; Gan et al. 2008). The ethidium bromide staining (Figure 19 B) for the 
RNA M MDCK-RNA ssRNA 40
Infection A/PR/8 + -  
RNase III [U/ml]  - 0.1 0.5 - 0.1 0.5 - 0.1 0.5 
Figure 19: The ds character is 
an important feature for the 
A/PR/8/MDCK-RNA induced IFN-
α production. A) RNA derived 
from MDCK cells either uninfected 
or infected with A/PR/8 (2 µg/ml) 
and ssRNA 40 (10 µg/ml) as a 
control were partially treated with 
RNase III (0.5 U/ml) complexed to 
DOTAP and used for stimulation 
of PBMC cells. IFN-α production 
was measured 24 hours post 
stimulation by ELISA. CpG 2216 
(1 µM) and RNA 40 served as 
positive controls (n = 9, one 
representative experiment is 
shown). B) Different RNAs were 
incubated with varying amounts of 
RNase III. Samples were analyzed 
by 1, 2 % agarose electrophoresis
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either mock- or RNase III-treated ssRNA 40 shows no differences. Furthermore, the IFN-
α-inducing activity of RNA 40 was not abolished upon RNase III treatment (Figure 19 A), 
showing that RNase III had no toxic effect on the immune cells. 
 
The importance of different features of RNA for IFN-α secretion 
Comparing the immunostimulatory capacity of the RNA prepared from virus-infected cells 
with the RIG-I ligand 5`-3P RNA in PBMC cells shows that both require different features 
for IFN-α secretion. After treatment of A/PR/8/MDCK-RNA and the RIG-I ligand 5`-3P 
RNA with either RNase III or CIP, the RNAs were complexed to DOTAP or Lipofectamine 
2000 and used for stimulation of PBMC cells. In Figure 20, IFN-α induction was measured 
by ELISA, and the already described controls were used. For A/PR/8/MDCK-RNA 
complexed to DOTAP or Lipofectamine 2000, phosphatase treatment had no influence on 
the IFN-α inducing ability, but cleavage with the ds-specific RNase III abrogated IFN-α 














Figure 20: For the RIG-I 
ligand 5`-3P RNA the 5`-
triphosphate end is 
important for recognition 
and the ds character has 
no influence. RNA from 
uninfected and A/PR/8-
infected MDCK cells (2 
µg/ml) and RIG-I ligand 5`-3P 
RNA (0.2 µg/ml) were 
partially treated with CIP or 
RNase III, then complexed to 
DOTAP or Lipofectamine 
2000 and used for 
stimulation of PBMC cells. 
IFN-α production was 
measured 24 hours post 
stimulation by ELISA (n = 2, 
one representative 
experiment is shown). CpG
2216 (1µM) and RNA 40 
served as positive controls. 
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In summary, for recognition of the virus-infected RNA the ds character is important. In 
contrast, for the RIG-I ligand 5`-3P RNA complexed to DOTAP or Lipofectamine 2000, 
only the 5`-triphosphate seems to be important, whereas treatment with the ds-specific 
RNase III has no influence for IFN-α secretion.  
5.2.5. Analysis of the receptor recognizing the A/PR/8/MDCK-RNA 
A previous study demonstrated the requirement of TLR7/MyD88 for the recognition of 
ssRNA viruses like the influenza virus in pDCs (Diebold et al. 2004; Lund et al. 2004). On 
the other hand, it was shown that genomic RNA prepared from a negative-strand RNA 
virus and RNA prepared from virus-infected cells triggered a potent IFN-α response in a 
phosphatase-sensitive manner in monocytes. 5`-triphosphate RNA directly binds to RIG-I 
(Hornung et al. 2006). To address the question of whether there is a TLR dependency for 
the recognition of A/PR/8/MDCK-RNA, we analyzed the immune activation of Flt3-derived 
dendritic cells and GM-CSF-derived dendritic cells from corresponding gene-deficient 
mice (TLR7 -/-, Myd88 -/-) (4.1.9.1). Flt3-derived dendritic cells can be regarded as analogs 
to human plasmacytoid dendritic cells. TLR7 and TLR9 expressed in pDCs act via a 
unique pathway to induce IFN-α. Positive controls for IFN-α induction in Flt3-derived 
dendritic cells were the TLR ligands RNA 40 and CpG 2216. The TLR7-specific control 
RNA 40 showed no IFN-α secretion in TLR7 -/- and MyD88 -/- cells. The TLR9-specific 
control CpG 2216 induced no IFN-α in MyD88 -/- cells, whereas for wild-type and TLR7 -/- 
cells IFN-α was detectable. The control RIG-I ligand 5`-3P RNA showed IFN-α secretion 
for wild-type, TLR7 -/- and MyD88 -/- cells. GM-CSF-derived dendritic cells can be regarded 
as analogs to human myeloid dendritic cells. In GM-CSF-derived dendritic cells, IFN-α 
production is mediated by cytosolic helicases and not as described for pDCs, via a unique 
pathway of TLR7 and TLR9. For this reason, upon stimulation with the TLR7-specific 
control RNA 40 and with the TLR9-specific control CpG 2216, there was no IFN-α 
secretion detectable in GM-CSF-derived DCs. But RNA 40 and CpG 2216 induced IL-6 in 
GM-CSF-derived DCs. The TLR9-specific control CpG 2216 showed no IL-6 secretion in 
MyD88 -/- cells, whereas for wild-type cells IL-6 was detectable. Upon transfection of equal 
concentrations of encapsulated A/PR/8/MDCK-RNA complexed to cationic transfection 
reagents or cathelicidins, a strong induction of IFN-α secretion was detected in wild-type 
and knockout dendritic cells from Flt3- and GM-CSF-derived dendritic cells, whereas for 
MDCK-RNA no IFN-α response was detectable. The results suggest that there is no TLR 
dependency for the recognition of A/PR/8/MDCK-RNA in murine immune cells (Figure 21).  
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RIG-I ligand 5`-3P RNA 
Flt3-derived dendritic cells
wild-type
TLR 7 -/- 
MyD88 -/- Figure 21: No influence of 
TLRs for the recognition of 
A/PR/8/MDCK-RNA. A)
Uninfected and 
A/PR/8/MDCK-RNA (2 µg/ml) 
was complexed to DOTAP or 
Lipofectamine 2000 and 
used for stimulation of Flt3-
derived dendritic cells
generated from a wild-type, a 
TLR7- and a MyD88-deficient 
mouse, respectively. RNA 
40, CpG 2216, and the RIG-I 
ligand 5`-3P RNA (0,2 µg/ml 
complexed to Lipofectamine 
2000) served as specificity 
controls for the respective 
knockout cells. IFN-α 
secretion was measured 24 
hours post stimulation by 
ELISA (for TLR7 n = 8, for 
MyD88 n = 4; one 
representative experiment is 
shown). B) 10 µg of total 
RNA from uninfected or 
A/PR/8-infected MDCK cells 
was complexed to 50 µg LL-
37 and used for stimulation 
of GM-CSF- derived dendritic 
cells generated from a wild-
type and a MyD88-deficient 
mouse at a final RNA 
concentration of 10 µg/ml. 
CpG 2216 and the RIG-I 
ligand 5`-3P RNA (0,2 µg/ml 
complexed to Lipofectamine 
2000) served as specificity 
controls for the respective 
knockout cells. For 
comparison, A/PR/8/MDCK-
RNA (2 µg/ml) was 
complexed to DOTAP. IFN-α
and Il-6 secretion was 
measured 24 hours post 
stimulation by ELISA (for 
GM-CSF cultures n = 2, for 
macrophages n = 2; one 
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To investigate whether TLR3, which utilizes the TRIF adaptor protein and not MyD88, is 
important for recognition of A/PR/8/MDCK-RNA, we generated macrophages from wild-
type, TLR7- and TLR7&3 double-deficient mice (4.1.9.1). TLR3 is claimed to be important 
for Poly I:C detection (McCartney et al. 2009). Poly I:C is a synthetic dsRNA clinically 
applied as an immunomodulator (Verdijk et al. 1999). Because the specificity control Poly 
I:C did not work in our murine system, mice deficient for TLR3 were genotyped and 
confirmed for TLR3 deficiency (data not shown). Macrophages were stimulated as 
described in section 5.1, and the supernatants were used for detection of the cytokines 
IFN-ß, IFN-α, and IL-6 by ELISA as shown in Figure 22. In macrophages, IFN-α 
production is mediated by cytosolic helicases and not as described for pDCs via a unique 
pathway of TLR7 and TLR9. For this reason, upon stimulation with the TLR7-specific 
control RNA 40 and with the TLR9-specific control CpG 2216, there was no IFN-α 
secretion detectable in macrophages. But RNA 40 and CpG 2216 induced IL-6 in 
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Figure 22: No influence of TLR3 for the recognition of A/PR/8/MDCK-RNA. Uninfected and 
A/PR/8/MDCK-RNA (2 µg/ml) was complexed to DOTAP or Lipofectamine 2000 and used for 
stimulation of macrophages generated from a wild-type, a TLR7- and a TLR7&3 double-deficient 
mouse, respectively. RNA 40, CpG 2216, R848, LPS, and the RIG-I ligand 5`-3P RNA (0,2 µg/ml 
complexed to Lipofectamine 2000) served as controls for cytokine secretion. Cytokines were 
measured 24 hours post stimulation by ELISA (for macrophages n = 2; for Flt3 cultures n = 4; one 
representative experiment is shown).  
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Upon transfection of equal concentrations of encapsulated A/PR/8/MDCK-RNA 
complexed to either DOTAP or Lipofectamine 2000, a strong induction of IFN-α and IFN-ß 
was detected in wild-type and in the TLR7- and TLR7&3 double-deficient macrophages, 
whereas for uninfected MDCK-RNA no type-I IFN response was detectable. These results 
further demonstrate that there is no TLR dependency for the recognition of A/PR/8/MDCK-
RNA in murine immune cells.  
Moreover, we used Flt3-derived dendritic cells from IPS-deficient mice, which is an 
important adaptor molecule for RIG-I or MDA-5 signaling, in order to investigate if RIG-I or 
MDA-5 are involved in the recognition of the A/PR/8/MDCK-RNA. Positive controls for 
IFN-α induction were the TLR ligands RNA 40 and CpG 2216. The ELISA data in Figure 
23 show that the control RIG-I-ligand 5`-3P RNA failed to induce IFN-α in the respective 
knockout cells, whereas the TLR9-specific control CpG 2216 and the TLR7-specific 
control RNA 40 showed equal amounts of secreted IFN-α in wild-type compared to IPS -/- 
cells. In IPS -/- dendritic cells, IFN-α secretion upon transfection with A/PR/8/MDCK-RNA 
complexed to the cationic transfection reagents or to the cathelicidins was abrogated, 













Figure 23: Relevance of IPS-dependent
receptors for the recognition of
A/PR/8/MDCK-RNA. RNA from A/PR/8-
infected cells (2 µg/ml) was encapsulated
with DOTAP or Lipofectamine 2000 and
used for stimulation of Flt3-derived
dendritic cells generated from a wild-type,
a TLR7- and an IPS-deficient mouse,
respectively. In addition, 10 µg of total
RNA from uninfected or A/PR/8-infected
MDCK cells was complexed to 50 µg LL-
37 or CRAMP and used for stimulation of
murine Flt3-derived dendritic cells at a
final RNA concentration of 10 µg/ml. RNA
40, CpG 2216, and the RIG-I ligand 5`-3P
RNA (2 µg/ml) served as specificity
controls for the respective knockout cells.
IFN-α secretion was measured 24 hours
post stimulation by ELISA
(A/PR/8/MDCK-RNA complexed to
cationic transfection reagents for Flt3
cultures: n = 2 / A/PR/8/MDCK-RNA
complexed to cathelicidins for Flt3
cultures n = 3, for GM-CSF cultures n =
1, for BM cultures n = 1; one
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To analyze whether MDA-5 is involved in the recognition of A/PR/8/MDCK-RNA, we used 
Flt3-derived dendritic cells and bone marrow-generated cells from MDA-5-deficient mice. 
MDA-5 is described to be important for Poly I:C detection (McCartney et al. 2009). 
Because the specificity control Poly I:C did not work in our murine system, mice deficient 
for MDA-5 were genotyped and confirmed for MDA-5 deficiency (data not shown). Positive 
controls for IFN-α induction were the TLR ligands RNA 40 and CpG 2216. IFN-α secretion 
upon transfection with A/PR/8/MDCK-RNA complexed to cationic transfection reagents or 
to cathelicidins was not abrogated in MDA-5-deficient mice (Figure 24), indicating that 
MDA-5 is not involved in the recognition of A/PR/8/MDCK-RNA. These results suggest 
that an IPS-dependent receptor is responsible for recognition of A/PR/8/MDCK-RNA with 
a strong evidence for RIG-I. Because a RIG-I-deficient mouse was not available, we could 
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Figure 24: Relevance of IPS-
dependent receptors and 
MDA-5 for the recognition of 
A/PR/8/MDCK-RNA. A) RNA 
from uninfected and A/PR/8-
infected cells (2 µg/ml) was
encapsulated with DOTAP or 
Lipofectamine 2000 and used 
for stimulation of Flt3-derived 
dendritic cells generated from 
a wild-type, a TLR7- and a
MDA-5-deficient mouse, 
respectively. RNA 40, CpG 
2216, and the RIG-I ligand 5`-
3P RNA (0.2 µg/ml) served as
controls for IFN-α secretion. 
IFN-α secretion was measured 
24 hours post stimulation by 
ELISA (for TLR 7 n = 8, for 
MDA-5 n = 1; one 
representative experiment is 
shown). 
A) 
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To confirm the RIG-I-dependent detection of A/PR/8/MDCK-RNA, human HEK293 cells, 
which lack functional TLRs (with the possible exception of TLR3), were transfected with 
plasmids encoding RIG-I and MDA-5 (4.12) (Yoneyama et al. 2004; Yoneyama et al. 
2005). The normally MDA-5-specific ligand Poly I:C was found to show enhanced IFN-ß 
activation in RIG-I-transfected cells, but when complexed to Lipofectamine 2000 there 
was little detectable increase in IFN-ß reporter activity in MDA-5-transfected cells. The 
question arises as to whether or not our MDA-5 is functional. Cells were transfected with 
MDCK-RNA and A/PR/8/MDCK-RNA, and IFN-ß activation was determined by Dual 
Luciferase Assay. Surprisingly, strong IFN-ß activation for A/PR/8/MDCK-RNA complexed 
to DOTAP or Lipofectamine 2000 was observed in untransfected cells (Figure 25). This 
activation by A/PR/8/MDCK-RNA, possibly observed due to the basal expression of RIG-I 
in untransfected HEK293 cells, was significantly enhanced in RIG-I-transfected HEK293 
cells. We performed a PCR to determine endogenous expression of RIG-I in HEK293 
cells (4.4). Therefore, total HEK293-RNA was assigned in cDNA. We performed one 
reaction by using the enzyme reverse transcriptase and one without this enzyme. To 
prevent amplification of genomic DNA, which has a large number of introns, the primers 
were designed as exon-intron spanning primers. Figure 25 C shows that HEK293 cells 
expressed endogenous RIG-I having a length of 530 bp. As expected, for the negative 
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Figure 24: Relevance of IPS-
dependent receptors and MDA-
5 for the recognition of 
A/PR/8/MDCK-RNA. B) 10 µg of 
total RNA from uninfected or 
A/PR/8-infected MDCK cells was 
complexed to 50 µg LL-37 or 
CRAMP and used for stimulation 
of murine bone marrow cells 
generated from a wild-type, an 
IPS- and a MDA-5-deficient 
mouse at a final RNA 
concentration of 10 µg/ml. The 
RIG-I ligand 5`-3P RNA (2 µg/ml 
complexed to Lipofectamine 
2000) served as specificity control 
for the respective knockout cells. 
IFN-α secretion was measured 24 
hours post stimulation by ELISA 
(for Flt3 cultures n = 1, for BM 
cultures n = 1; one representative 
experiment is shown). 
B) 
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MDA-5-transfected cells showed for A/PR/8/MDCK-RNA complexed to DOTAP or 
Lipofectamine 2000 only a comparable IFN-ß activation like untransfected cells. For the 
respective RIG-I-specific control RIG-I ligand 5`-3P RNA complexed to Lipofectamine 
2000, there was no IFN-ß activation in untransfected HEK293 cells, whereas in RIG-I-
transfected HEK293 cells, there was a strong IFN-ß activation. In untransfected HEK293 
cells, the immune response to A/PR/8/MDCK-RNA was abrogated after 
dephosphorylation and RNase III treatment, whereas in RIG-I-transfected HEK293 cells, 
CIP treatment of A/PR/8/MDCK-RNA had no influence, but RNase III treatment again 
abolished the IFN-α response. For the RIG-I ligand 5`-3P RNA complexed to 
Lipofectamine 2000, the IFN-α response was diminished in RIG-I-transfected cells upon 
CIP treatment. 
To further show that A/PR/8/MDCK-RNA complexed to LL-37 was recognized in an IPS-
dependent way, HEK293 cells were transfected with plasmids encoding for RIG-I and 
MDA-5. RIG-I-expressing HEK293 cells gained responsiveness to the RIG-I-specific 
control RIG-I ligand 5`-3P RNA complexed to Lipofectamine 2000. The A/PR/8/MDCK-
RNA complexed to DOTAP or Lipofectamine 2000 was also recognized in RIG-I-
transfected HEK293 cells. However upon stimulation with A/PR/8/MDCK-RNA complexed 
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A) Figure 25: RIG-I-mediated 
recognition of RNA from 
A/PR/8-infected cells in non-
immune cells. A) HEK293 cells 
were cotransfected with 
plasmids encoding the IFN-ß 
luciferase reporter construct 
(p125Luc), RIG-I and MDA-5 by 
electroporation. Transfected 
cells were treated with Poly IC 
(10 µg/ml), RNA from 
uninfected and A/PR/8-infected 
MDCK cells (2 µg/ml) and RIG-I 
ligand 5`-3P RNA (0.2 µg/ml)
each complexed to DOTAP or 
Lipofectamine 2000 (either 
mock-, CIP- or RNase-III-
treated). IFN-ß activation was 
determined by Dual Luciferase 
Assay (n = 10 for DOTAP and 
Lipofectamine 2000, one 
representative experiment is 
shown). 




























The results obtained by stimulating Flt3-derived dendritic cells from IPS-deficient mice and 
HEK293 cells overexpressing RIG-I with A/PR/8/MDCK-RNA complexed to cationic lipids 
or natural carriers and the phosphatase-dependent induction of IFN-α by A/PR/8/MDCK-
RNA indicate that RIG-I or a yet unidentified IPS-dependent receptor is responsible for the 
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Figure 25: RIG-I-mediated recognition of RNA from A/PR/8-infected cells in non-immune 
cells. B) HEK293 cells were cotransfected with plasmids encoding the IFN-ß luciferase reporter 
construct (p125Luc), RIG-I and MDA-5 by electroporation. Transfected cells were treated with 
uninfected and A/PR/8/MDCK-RNA (2 µg/ml) each complexed to LL-37 and CRAMP. IFN-ß 
activation was determined by Dual Luciferase Assay (n = 3 for LL-37 and CRAMP, one 
representative experiment is shown).C) Ethidium bromide staining of a PCR of cDNA rewrited 
from HEK293-RNA to determine endogenous expression of RIG-I on an 1, 2 % agarose gel. 
Marker lane contains a 1 kbp DNA marker. 
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5.2.6. Influence of the length of antimicrobial peptides for the 
immunostimulatory ability 
In comparison to the long CRAMP version, the shorter CRAMP version failed to induce 
IFN-α in complex with the A/PR/8/MDCK-RNA. We tested murine Flt3-derived dendritic 
cells with the different CRAMP versions (Figure 26) complexed to A/PR/8/MDCK-RNA 
and measured the IFN-α induction (Figure 27). This suggests that a certain length of the 
peptide is necessary for complexation of A/PR/8/MDCK-RNA in order to induce IFN-α in 
immune cells. 
 
Figure 26: Sequences of the different CRAMP versions. Shown are the sequences from the 


























Figure 27: Influence of the length 
from CRAMP for complexation of 
A/PR/8/MDCK-RNA. 10 µg of total 
RNA from uninfected or A/PR/8-
infected MDCK cells was complexed 
to 50 µg LL-37, CRAMP short or 
CRAMP long version and used for 
stimulation of murine Flt3-derived 
dendritic cells generated from a wild-
type mouse at a final RNA 
concentration of 10 µg/ml. IFN-α
secretion was measured 24 hours 
post stimulation by ELISA (n = 3, one 
representative experiment is shown).
 
CRAMP1-39    ISRLAGLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPEQ 
CRAMP                      GLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPEQ 
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5.2.7. Characterization of synthetic LL-37/CRAMP as carrier for 
immunostimulatory RNA 
5.2.7.1. Localization studies of RNA/LL-37 complexes 
We performed localization studies of RNA/LL-37 complexes in human monocytes using 
biotinylated LL-37 (4.8). These experiments demonstrate that LL-37 complexes localize to 
the endosome (EEA-1 positive) and to the lysosome (Lamp positive) (Figure 28). The use 
of Lamp showed a colocalization for the A/PR/8/MDCK-RNA complexed to biotinylated 
LL-37 to the lysosomes. A problem with the use of the lysotracker is that the lysotracker 
alone did not really stain lysosomes, but rather only in combination with A/PR/8/MDCK-
RNA. For the use of EEA1, we first tested the secondary antibody rhodamine alone on the 
cells, in order to exclude an unspecific binding. The addition of biotinylated LL-37 with 
A/PR/8/MDCK-RNA seemed to show colocalization. One problem with this system is that 
the secondary antibody rhodamine also seemed to detect the biotinylated LL-37, or it 
bound unspecifically to the cells. Another marker for the early endosome was transferrin. 













Figure 28: Fluorescence microscopy of human primary monocytes (enriched by counter flow 
centrifugation) and incubated with biotinylated LL-37 complexed to RNA isolated from A/PR/8-
infected MDCK cells for 1h. (A) Cells were fixed and stained with DAPI and an antibody against 
EEA-1 followed by a secondary Rhodamine-labeled antibody and streptavidin-FITC. (B) Cells were 
fixed and stained with DAPI and an antibody against Lamp-1 followed by a secondary Rhodamine-
labeled antibody and streptavidin-FITC. 
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5.2.8. Immunization of mice 
Previous studies have shown the adjuvant function of RNA complexed to the cationic 
transfection reagent DOTAP. RNA induces the secretion of proinflammatory cytokines and 
type-I IFN and works as an adjuvant for the induction of cytotoxic T cells and antigen 
specific antibodies after subcutaneous immunization (Heil et al. 2004; Hamm et al. 2007). 
Others have used in vitro transcribed mRNAs coding for the antigen of choice complexed 
with protamine to induce cell-mediated and humoral immune responses (Scheel et al. 
2006; Probst et al. 2007).  
Because RNA is prone to hydrolysis, RNA molecules have to be protected from 
degradation through interaction with liposomes. Since DOTAP is toxic, we analyzed 
whether cathelicidins could function as a carrier in vaccine formulations. Cathelicidins 
have potent in vivo immunoenhancing effects that make them useful as vaccine 
adjuvants. They enhance antigen-specific humoral and cellular responses. CRAMP can 
enhance antigen-specific immune response to ovalbumin, a commonly used experimental 
model antigen (Kurosaka et al. 2005). 
In the present study, we analyzed whether a mixture of RNA combined with ovalbumin 
complexed to CRAMP (4.11) might function as vaccine formulation in subcutaneous 
injections in the base of tails from mice (Figure 29). Mice were immunized with 100 µg 
ovalbumin, 100 µg RNA complexed to DOTAP or 40 µg RNA complexed to 200 µg 
CRAMP on day 1 and were boosted on day 21. Injections with DOTAP/Ovalbumin and 
CRAMP/Ovalbumin containing no RNA or solely buffer served as negative controls. In 
parallel, immunizations with CpG-DNA 1668 were performed to compare the adjuvant 







day 0 day 21 day 28/29 
1. injection 2. injection ab titer 
Figure 29: Injection scheme and anticipated analysis 
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The RNA-driven humoral response was analyzed by measuring the induction of 
ovalbumin-specific IgG antibodies (4.11.1.2) in the sera of immunized mice 1 week after 
the second injection. 
As expected, CpG-DNA 1668 induced ovalbumin-specific IgG antibodies, although even 
injections of DOTAP/Ovalbumin induced ovalbumin-specific IgG antibodies. In 
combination with MDCK-RNA and A/PR/8/MDCK-RNA there was a little increase in the 
ovalbumin-specific IgG antibody response detectable for serum dilutions 1/3000 and 















As expected, immunization of ovalbumin together with CRAMP enhanced ovalbumin-
specific IgG antibody responses as compared to the immunization with ovalbumin alone. 
In combination with MDCK-RNA or A/PR/8/MDCK-RNA, there was an increase in the 
ovalbumin-specific IgG antibody response detectable for serum dilutions 1/3000 and 
1/30000 (Figure 31). Regarding the high standard deviation for ovalbumin and CRAMP at 
0,0 0,5 1,0 1,5
Medium
Liposomal buffer
Liposomal buffer + Ova





           antibodies
DOTAP
1 / 30.000 
1/ 3.000 
1/ 300 
Figure 30: DOTAP enhancement of ovalbumin-specific humoral immune response. Serum
samples were collected from mice after immunization. Total ovalbumin-specific IgG antibodies
were measured by ELISA (n = 1, one representative experiment is shown). Depicted are the
average ovalbumin-specific IgG antibody titers of each group (n = 2). 
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the dilution 1/300, the ovalbumin-specific IgG antibody response was difficult to compare 
with other stimuli. Future studies should analyze whether an increase in the IgG antibody 
response is measurable by varying the CRAMP concentration. For this experiment, we 
have chosen a similar CRAMP concentration (40 nmol = 176,77 µg) as proposed by 
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OVA-specific IgG Ab titers
CRAMP
1 / 30.000 
1/ 3.000 
1/ 300 
Figure 31: CRAMP enhancement of ovalbumin-specific humoral immune response. Serum 
samples were collected from mice after immunization. Total ovalbumin-specific IgG antibodies were 
measured by ELISA (n = 1, one representative experiment is shown). Shown are the average 
ovalbumin-specific IgG antibody titers of each group (n = 2). 
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5.2.9. Summary 
Upon viral infection, LL-37 might form complexes with self-RNA and viral RNA. These 
complexes triggered a strong interferon production in human and murine immune cells. By 
using Flt3-derived dendritic cells from MyD88-deficient mice, TLRs were ruled out as 
being responsible for this reactivity. To further investigate the recognition mechanism, we 
generated Flt3-derived dendritic cells from IPS-deficient mice, which is an important 
adaptor molecule for RIG-I- and MDA-5-dependent signaling. We observed a strictly IPS-
dependent IFN-α secretion upon transfection with A/PR/8/MDCK-RNA complexed to 
cationic lipids or cathelicidins. However, localization studies showed that LL-37 transfers 
nucleic acids to early endosomal/lysosomal compartments. The localization of LL-37 
currently does not explain how endosomally delivered RNA triggers an IPS-1 dependent 
signaling pathway there. As found by Kurosaka et al., cathelicidins have potent in vivo 
immunoenhancing effects that make them useful as vaccine adjuvants (Kurosaka et al. 
2005). Moreover, we analyzed whether CRAMP complexed to RNA functions as vaccine 
formulation in subcutaneous injections. In combination with differently tested RNAs, there 
was little detectable increase in the ovalbumin-specific IgG antibody response. 
Our findings show that the 5`-triphosphate end of A/PR/8/MDCK-RNA is important for 
inducing IFN-α in murine immune cells and in human HEK293 cells. Dephosphorylation of 
the A/PR/8/MDCK-RNA reduced signaling, suggesting that RIG-I is responsible in Flt3-
derived dendritic cells and in HEK293 cells for inducing IFN-α, and this was further 
demonstrated by using IPS-deficient mice. For human PBMC cells and HEK293 cells 
overexpressing RIG-I, we found only a small decrease in the IFN-α response after 
dephosphorylation. Here, the 5`-triphosphate end seems to play a minor role. Most 
important in this context is the observation that for A/PR/8/MDCK-RNA the ds character of 
RNA plays a major role for activation immune responses. For murine and human immune 
cells, we observed an abrogation for the IFN-α induction upon treatment with the ds-
specific RNase III. Thus, for the ligand A/PR/8/MDCK-RNA, we see two important features 
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5.3. Analysis of the immunostimulatory capacity of self-
RNA 
 
5.3.1. Comparing the immunostimulatory ability of RNA 
fragments generated by different techniques 
 
5.3.1.1. Fragments generated by Ribonucleases 
It has been suggested that small self-RNA fragments derived by RNase treatment be 
considered a non-self structure. In this study, we were interested in identifying the 
mechanism that explains how small self-RNA fragments are recognized by the innate 
immune system. 
Recently, Malathi et al. have described a crucial role for 2`,5`-linked oligoadenylate (2-5A) 
activated RNase L in the degradation of self-RNA and the generation of stimulatory 
ligands of less than 200 nucleotides for MDA-5 and RIG-I (Malathi et al. 2007). We partly 
digested self-RNA with the ubiquitous RNase A (4.3.6) and generated fragments of 20 to 
100 bp, which were visualized by ethidium bromide staining (Figure 32 B / Figure 34). 
These fragments were complexed to DOTAP or Lipofectamine 2000 and used for the 
stimulation of PBMC cells. The supernatants were used for detection of IFN-α by ELISA. 
The TLR ligands CpG 2216 and RNA 40 were taken as positive IFN-α inducers. 
Interestingly, the RNase A-treated self-RNAs complexed to the cationic transfection 
reagent DOTAP were able to mount a type-I interferon response in human PBMCs (Figure 












































Influence of the transfection reagent for the immunostimulatory ability 
of RNA fragments 
The RNase A-treated self-RNAs complexed to DOTAP induced IFN-α in human PBMCs, 
whereas for complexation to Lipofectamine 2000, no IFN-α response was detectable 
(Figure 33 A). RNase A-derived fragments complexed to DOTAP induced IFN-α in a 
concentration range of 5-10 µg/ml. For untreated RNAs complexed to DOTAP, there was 
also a background IFN-α response detectable in a concentration range of 1-2 µg/ml.  
In addition, we tested whether RNase A-derived fragments complexed to cathelicidins like 
LL-37 (presented in section 5.2) induced an immune activation in human PBMC cells. As 
shown in Figure 33 B, there was no IFN-α response detectable. 
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Figure 32: Effects of fragments generated by RNase treatment of self-RNA in human 
PBMCs. A) MDCK-RNA was treated with increasing amounts of RNase A complexed to DOTAP
and used for stimulation of PBMC cells at a final concentration of 10 µg/ml. IFN-α production 
was measured 24 hours post stimulation by ELISA. CpG 2216 (1µM) and RNA 40 served as 
positive controls (n = > 10, one representative experiment is shown). B) Ethidium bromide 
staining of untreated total MDCK-RNA and partially RNase A-treated MDCK-RNA separated on 
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Figure 33: Influence of the 
transfection reagent for RNase 
A- derived fragments in human 
PBMC cells. A) HEK293-RNA 
was treated with RNase A and 
complexed to DOTAP or 
Lipofectamine 2000 and then 
used for stimulation of PBMC
cells at different final RNA 
concentrations. RIG-I ligand 5`-
3P RNA (0.2 µg/ml) complexed to 
Lipofectamine 2000 served as 
positive control for the 
transfection reagent 
Lipofectamine 2000 in human 
PBMC cells. IFN-α production 
was measured 24 hours post 
stimulation by ELISA. CpG 2216 
(1µM) and RNA 40 served as 
positive controls for IFN-α
secretion (n = 3, one 
representative experiment is 
shown). B) RNase A-derived 
fragments were complexed to LL-
37 and used for stimulation of 
PBMC cells at 10 µg/ml final RNA 
concentration. IFN-α production 
was measured 24 hours post 
stimulation by ELISA. CpG 2216 
(1µM) and RNA 40 served as 
positive controls (n = 4, one 
representative experiment is 
shown). 
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Size of RNase A generated fragments 
With the help of a PAA gel (4.2.1), we further characterized the size of the fragments 
generated by RNase treatment of self-RNA. For this, we compared the size of the 
RNase-derived fragments with the size of RNA 40 (containg 20 bp) and RIG-I ligand 5`-
3P RNA (containg 100 bp). In Figure 34, we see a smear of degradation fragments, 












Time dependence for generating immunostimulatory fragments by 
RNase A treatment 
For a more detailed analysis of the fragments derived by RNase A treatment, we 
performed a kinetic analysis. Surprisingly, even after treatment of self-RNA with RNase A 
(4.3.6) for only one minute followed by phenol/chloroform extraction (4.2.5), there was a 
strong IFN-α-inducing activity when the fragments were complexed to DOTAP and used 
for stimulation of human PBMC cells (Figure 35 A). As a positive and negative IFN-α 
inducer, the same samples were chosen as described in section 5.3.1.1. The ethidium 
bromide staining shows that with the increase of time for incubation with RNase A the 













Figure 34: Analysis of degradation fragments by PAA gel electrophoresis. Marker lane
contains a 100 bp marker. 
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Figure 35: Influence of the time on the 
generation of immunostimulatory RNA 
fragments. A) Self-RNA was partially treated
for different lengths of time with RNase A
(0.0075 U/ml) complexed to DOTAP and used 
for stimulation of PBMC cells at a final RNA 
concentration of 10 µg/ml. IFN-α production 
was measured 24 hours post stimulation by 
ELISA (n = 4, one representative experiment is 
shown). CpG 2216 (1µM) and RNA 40 served 
as positive controls. B) At variable time 
intervals, RNase A-treated self-RNAs were 
analyzed by ethidium bromide staining. 
Treatment with RNase A is stopped by 
phenol/chloroform cleanup. RNAs are 
separated on an 1, 2 % agarose gel. Marker 
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Different RNA types are cleaved to immunostimulatory fragments upon 
RNase A treatment  
Next we wanted to examine whether self-RNAs from different sources become 
immunostimulatory upon incomplete RNase A treatment. Therefore, we isolated RNAs 
(4.3.1) from cancer cell lines like MDCK- and HEK293 cells, and, in order to exclude a 
cancer cell line phenomenon, we also tested RNAs from primary cells like murine liver or 
PBMCs (for PBMC-RNA: data not shown). For the stimulation of human PBMC cells we 
used different RNAs, either untreated or RNase A-treated. DOTAP was chosen as 
transfection reagent. CpG 2216 and RNA 40 were used as positive IFN-α inducers. 
Remarkably, the source of the non-immunostimulatory RNAs did not play a role in the 
IFN-α response induced after RNase A treatment in human PBMC cells (Figure 36). The 
fragments derived from RNase A treatment of all tested RNA types complexed to DOTAP 


























































Figure 36: Influence of the RNA 
type on the generation of small 
immunostimulatory self-RNAs. A) 
Different RNA types, either mock or 
RNase A-treated (0.0075 U/ml), were 
complexed to DOTAP and used for 
stimulation of PBMC cells at different 
final RNA concentrations. IFN-α
production was measured 24 hours 
post stimulation by ELISA. CpG 2216 
(1µM) and RNA 40 served as positive 
controls (n = 6, one representative 
experiment is shown).  











Different Ribonuclease-types generate immunostimulatory fragments 
Our initial findings showed that fragments from self-RNAs generated by partial RNase A 
treatment induced an immune response when complexed to DOTAP in human PBMC 
cells. Next, we asked whether other RNase types also render self-RNAs 
immunostimulatory. Therefore, we generated fragments of self-RNA upon treatment with 
different RNase types (4.3.6), complexed them to DOTAP and tested their 
immunostimulatory potential in human PBMC cells. Different ends of the RNA fragments 
were generated, depending on the type of RNase used. Ribonucleases that hydrolyze 
RNA to 3`-phosphomonoester via 2`,3`-cyclic nucleosides are RNase A, RNase T1, and 
RNase T2 (Deshpande and Shankar 2002). Figure 37 B shows the ethidium bromide 
staining for the fragments generated by these ss-specific RNase types. As shown in 
Figure 37 A, the generated fragments with 3`-phosphoryl ends complexed to DOTAP all 
exhibited high immunostimulatory potential for human PBMC cells. Only treatment with 
the ds-specific RNase III did not lead to RNA degradation or generation of 
immunostimulatory self-RNA (Figure 37 A/B).  
To determine if phosphate groups are important features of the RNA fragments, we 
treated the RNase-generated fragments with calf intestine phosphatase (CIP) (4.3.11). 
Dephosphorylation of the fragments showed no influence on the IFN-α response, 
suggesting that the recognition of the RNase cleavage products is not mediated through 
phosphate groups at least in human PBMC cells. 
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Figure 36: Influence of 
the RNA type on the 
generation of small 
immunostimulatory self-
RNAs. B) Ethidium 
bromide staining of 
different RNA types, 
either mock or RNase A- 
treated, separated on an 
1, 2 % agarose gel. 
Marker lane contains a 1  
kbp DNA marker. 
 


















Besides these nucleases, there are ribonucleases like the S1 nuclease from Aspergillus 
oryzae (Desai and Shankar 2003) and the P1 nuclease from Penicillium citrinum (Desai 
and Shankar 2003) that hydrolyze RNA to 5`-phosphomonoester. These are zinc 
metalloproteins and contain three Zn2+ atoms per molecule of the enzyme (McCall et al. 
2000) (1.4). We tested nucleases P and SvP for their ability to generate 
immunostimulatory RNA from self-RNA. Therefore, the fragments were complexed to 
DOTAP and used for stimulation of human PBMC cells. The ethidium bromide staining of 
the generated fragments is shown in Figure 38 B. The Nuclease P treatment was 
performed in a zinc buffer. Because of the metal-induced degradation of RNA, the 
untreated RNA was already degraded as shown in Figure 38 B lane 2. Figure 38 A shows 
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Figure 37: Comparing the ends generated by different RNase types. A) MDCK-RNA was 
partially treated with different RNase types (RNase A 0.0075 U/ml, RNase T1 328.5 U/ml, RNase 
T2 85 U/ml, RNase I 5 U/ml, RNase III 0.5 U/ml), either dephosphorylated or not, complexed to 
DOTAP and used for stimulation of PBMC cells at 10 µg/ml final RNA concentration. IFN-α
production was measured 24 hours post stimulation by ELISA. CpG 2216 (1µM) and RNA 40
served as positive controls (n = 12, one representative experiment is shown). B) RNAs treated 
with different RNase types, either dephosphorylated or not, were analyzed on an 1, 2 % agarose 
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the IFN-α response from human PBMC cells to Nuclease P- and SvP-generated 
fragments complexed to DOTAP. The IFN-α response concerning the RNase types 
generating 5`-phosphate ends seemed to be lower and donor dependent. In conclusion, 
we observed an IFN-α induction with all the RNase types generating 3`-phosphate as well 
as 5`-phosphate RNA ends in human PBMC cells. The IFN-α response was independent 
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Figure 38: Comparing the ends generated by different RNase types. A) MDCK-RNA was
partially treated with different RNase types complexed to DOTAP and used for stimulation of
PBMC cells at 10 µg/ml final RNA concentration. IFN-α production was measured 24 hours post
stimulation by ELISA. CpG 2216 (1µM) and RNA 40 served as positive controls (n = 8, one
representative experiment is shown). B) Ethidium bromide staining of Nuclease P (B.1) and SvP
treated RNAs (B.2) separated on an 1.2 % agarose gel. Marker lane contains a 1 kbp DNA
marker. In lane 2 from picture B.1: untreated MDCK-RNA is degraded because of Zn2+.  
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Another nuclease, called Benzonase, degrades both DNA and RNA, whether ss or ds, 
and shows no base preference (Kariko et al. 2004). It generates 5`-monophosphate-
terminated products (Eaves and Jeffries 1963; Nestle and Roberts 1969). But upon 
stimulation of human PBMC cells with Benzonase generated fragments, there was almost 
no detectable IFN-α response (data not shown). 
 
5.3.1.2. Further techniques for generating RNA fragments 
 
Effect of ultrasound on RNA 
The data presented above describe the ability of RNA fragments generated by RNase 
treatment to induce IFN-α in human PBMC cells. To analyze if fragment size is an 
important feature to induce IFN-α, we generated fragments by different techniques. 
Meidan et al. showed that ODNs clearly undergo chain shortening under the influence of 
ultrasound, suggesting that intramolecular cleavage at the phosphodiester internucleoside 
linkage is occurring. The mechanical (as opposed to the heating) effects of ultrasound are 
responsible for the observed ODN degradation (Meidan et al. 1997). For ultrasonic 
treatment, we exposed self-RNAs for different durations (0 s, 10 s, 30 s and 1 min) to 
ultrasound waves (4.3.9). The ethidium bromide staining in Figure 39 B shows that 
progressive fragmentation due to an increase in the duration of ultrasonic treatment 
resulted in a decrease in the size range of the fragments, reaching 100 - 500 bp in the last 
sample. But when we compared the size of fragments derived by ultrasonic treatment with 
the RNase A-generated fragments (which had a size in the range of 20 - 100 bp), we 
observed that the fragments produced by ultrasonic treatment were longer. The fragments 
derived by ultrasonic treatment were complexed to DOTAP and tested for their 
immunostimulatory potential in human PBMC cells. In contrast to the RNase A-generated 
fragments, the ultrasonic-derived fragments did not induce IFN-α (Figure 39 A). What is 
remarkable is that the background IFN-α response induced by self-RNA in a concentration 
range of 2 µg/ml (5.3.1.1) was reduced with the increase of ultrasonic treatment. This 
suggests that the feature responsible for inducing the background IFN-α response of self-
RNA is destroyed with ultrasonic treatment. Upon treatment of self-RNA with the ds-
specific RNase III, the background IFN-α response was also reduced, as discussed in 
section 5.2.4. 
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Figure 39: Effect of ultrasound waves on self-RNAs regarding immunostimulatory abilities. 
A) MDCK-RNA subjected to ultrasound waves was complexed to DOTAP and used for stimulation
of PBMC cells at different final RNA concentrations. As a comparison, RNase A-treated (0.0075 
U/ml) MDCK-RNA was additionally used at different RNA concentrations. IFN-α production was 
measured 24 hours post stimulation by ELISA. CpG 2216 (1µM) and RNA 40 served as positive
controls (n = 10, one representative experiment is shown). B) Agarose gel electrophoresis patterns 
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Metal ion-induced hydrolysis of RNA 
Concerning the characterization of RNA fragments to induce IFN-α, we further evaluated 
RNA fragments generated by metal ion-induced hydrolysis. Self-RNA was treated with 
metal ions (4.3.8) followed by phenol/chloroform extraction (4.2.5), then complexed to 
DOTAP and used for the stimulation of human PBMC cells. The ethidium bromide staining 
in Figure 40 A and B shows that the fragments generated by Zn2+- or Pb2+-induced 
hydrolysis (4.3.8) were of similar size to the RNase A-derived fragments. The fragments 
produced by Zn2+-induced hydrolysis complexed to DOTAP did not induce IFN-α, whereas 
the fragments produced by Pb2+-induced hydrolysis complexed to DOTAP induced IFN-α 
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Figure 40: Effect of metal-ion induced hydrolysis of RNAs concerning immunostimulatory
abilities. A.1) Fragments generated by Zn2+-hydrolysis from different RNAs were complexed to 
DOTAP and used in the stimulation of PBMC cells at different final RNA concentrations. As a 
comparison, RNase A-treated (0.0075 U/ml) MDCK-RNA was also used. IFN-α production was
measured 24 hours post stimulation by ELISA. CpG 2216 (1µM) and RNA 40 served as positive 
controls (n = 8, one representative experiment is shown). A.2) Agarose gel electrophoresis patterns 
of Zn2+-induced cleavage of self-RNA. Marker lane contains a 1 kbp DNA marker.  


















For the fragments produced by Zn2+-induced hydrolysis, there was only an IFN-α 
response detectable in the concentration range of 2 µg/ml RNA, which was also observed 
for untreated RNAs. The question arose as to whether different ends of the fragments 
were generated by different cleavage mechanisms. 
 
 
5.3.1.3. Role of the 2`,3`-cyclic phosphate at the 3`-end of RNA 
The enzyme T4 polynucleotide kinase (T4 PNK) catalyses the removal of a 2`,3`-cyclic 
phosphate. To analyze whether RNA fragments generated by different methods contain a 
RNA M HEK293-RNA


































Figure 40 Effect of metal-ion induced hydrolysis of RNAs concerning immunostimulatory 
abilities. B.1) Fragments generated by Pb2+-induced hydrolysis from different RNAs were 
complexed to DOTAP and used for stimulation of PBMC cells at different RNA concentrations. As a 
comparison, RNase A-treated (0.0075 U/ml) MDCK-RNA was also used. IFN-α production was 
measured 24 hours post stimulation by ELISA. CpG 2216 (1µM) and RNA 40 served as positive 
controls (n = 5, one representative experiment is shown). B.2) Agarose gel electrophoresis 
patterns of Pb2+-induced cleavage of self-RNA. Marker lane contains a 1 kbp DNA marker.  
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2`,3`-cyclic phosphate group, we treated the fragments with T4 PNK (4.3.7). The ethidium 
bromide staining shows that the removal of the phosphate group led to a reduced net 
charge of the transcripts, which can be monitored for lower electrophoretic mobility of the 
RNA in comparison to the untreated RNA (Figure 41 B). 
First, we treated the fragments derived by RNase A treatment with T4 PNK, complexed 
them to DOTAP and stimulated human PBMC cells. An IFN-α response was detectable 
for either mock- or T4 PNK-treated RNase A-derived fragments (Figure 41 A).  
Next, we treated fragments generated by metal hydrolysis with T4 PNK. But here, T4 PNK 
treatment showed only a variable IFN-α response when complexed to DOTAP and used in 
the stimulation of human PBMC cells (Figure 41 A). 
This result suggests that the 2`,3`-cyclic phosphate group does not play a role for the 















Figure 41: Comparison of 
fragments generated by 
RNase A treatment or by 
metal ion-induced hydrolysis, 
concerning the role of the 
2`,3`- cyclic phosphate group 
at the 3` end. A) RNA 
fragments generated by RNase 
A treatment (0.0075 U/ml) or by 
metal ion–induced hydrolysis 
were either mock- or T4-treated,
complexed to DOTAP and used 
for stimulation of PBMC cells at 
different final RNA 
concentrations. IFN-α production 
was measured 24 hours post 
stimulation by ELISA. CpG 2216 
(1µM) and RNA 40 served as 
positive controls (for RNase A 
treatment n = 4, for metal ion-
induced hydrolysis n = 2; one 
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5.3.2. Characterization of the immunostimulatory nature of self-
RNA fragments 
To gain further insight into the nature of those stimulatory RNA fragments of the ss or ds 
character, we incubated the RNase A-derived fragments with RNase III (4.3.10). 
Treatment of the stimulatory RNase A-derived fragments with RNase III, an enzyme that 
degrades long dsRNA into short dsRNA molecules, abolished the IFN-α response when 
complexed to DOTAP and used to stimulate PBMC cells (Figure 42 A). Ethidium bromide 
staining showed no difference for mock- or RNase III-treated fragments derived from 
RNase A treatment (Figure 42 B). Since RNase III is a ds-specific RNase, we can 
conclude that the stimulatory component of the RNase A-derived fragments is most likely 
double-stranded, whereas the components that are visualized by ethidium bromide 
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Figure 41: Comparison 
of fragments generated 
by RNase A treatment or 
by metal ion-induced 
hydrolysis, concerning 
the role of the 2`,3`- 
cyclic phosphate group 
at the 3` end. B) 
Fragments generated by 
metal ion-induced 
hydrolysis or by RNase A 
treatment were either 
mock- or T4-treated and 
analyzed by 1, 2 % 
agarose electrophoresis. 
Marker lane contains a 
100 bp DNA marker. 


















5.3.3. Immunostimulatory RNA species 
We sought to identify the immunostimulatory RNA species of the RNase A-derived 
fragments mixture and to examine if these species are modified. 
5.3.3.1. Removal of single nucleosides 
We tried to address the question of which fragments of the RNase A digest are 
responsible for the IFN-α inducing capacity. Upon treatment of self-RNA with RNase A, 
the digest contains single nucleosides and various longer RNA fragments. We used Micro 
Bio-Spin columns (4.2.6) in order to purify nucleic acids larger than 20 bases. Single 
RNA M MDCK-RNA
RNase A + + + 
RNase III 
[U/ml] 







Figure 42: Influence of the ds character from fragments derived from partially-treated self-
RNAs for inducing IFN-α. Fragments generated by RNase A treatment were additionally treated
with RNase III, complexed to DOTAP and used for stimulation of PBMC cells at a final RNA 
concentration of 10 µg/ml. IFN-α production was measured 24 hours post stimulation by ELISA. 
CpG 2216 (1µM) and RNA 40 served as positive controls (n = 13, one representative experiment is 
shown). B) Ethidium bromide staining of fragments derived by RNase A that were additionally 
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nucleosides were removed by this technique. Figure 43 shows that the first and second 
purified fractions of the RNase A-derived fragments were visible on an ethidium bromide 
stained gel. For the first fraction, we observed that it seemed more concentrated than the 
complete digest on an agarose gel. This could be explained by the fact that the first 
fraction contained larger fragments which could be better visualized by ethidium bromide 
staining, whereas single nucleosides were removed by Bio-Spin columns. As shown in 
Figure 43, the first fraction of the RNase A-treated self-RNA complexed to the cationic 
transfection reagent DOTAP stimulated human PBMC cells to produce IFN-α, whereas 
the following fractions containing single nucleosides showed no IFN-α secretion in human 
PBMC cells. This shows that fragments longer than 20 nucleotides and not single 
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Figure 43: Fractionated RNAs derived by separating the RNase A digest with the help of
Micro Bio-Spin columns were complexed to DOTAP and used for stimulation of PBMC cells
at a final RNA concentration of 10 µg/ml. A) IFN-α production was measured 24 hours post
stimulation by ELISA. CpG 2216 (1µM) and RNA 40 served as positive controls (n = 2, one
representative experiment is shown). B) Fractionated RNase A-derived fragments were visualized
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5.3.3.2. Oligonucleotide separation by HPLC 
To identify the immunostimulatory RNA species of the RNase A-derived fragments, we 
fractionated the digest into different sizes by using XBRIDGETM OST C18 columns (4.2.7) 
and high performance liquid chromatography (HPLC) (4.10). Figure 44 shows the HPLC 
patterns of fragments derived by RNase A treatment of self-RNA. The obtained fractions 
from the column showed longer RNA fragments as the time increases. The first fraction 








Before we tested which fraction contains the immunostimulatory RNA species, the 
obtained fractions were purified from remaining salts by using Waters C18 SepPak 
columns (4.2.7). Then the obtained fractions were complexed to DOTAP and used for 
stimulation of human PBMC cells. The first fractions (fractions 3-5) containing single 
nucleosides were not able to induce type-I interferon, whereas fractions obtained at a later 
date (fractions 16-19) contained the stimulatory RNA species (Figure 45). Surprisingly, 
these fractions could not be stained by ethidium bromide (Figure 46). Only larger 
fragments (fractions 21-29) could be visualized by ethidium bromide staining, but when 




Figure 44: Characterization of RNA fragments 
obtained by RNase A treatment of self-RNA by 
HPLC analysis. 
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Figure 45: PBMC cells were stimulated with fractionated RNA fragments derived from 
RNase A treatment of self-RNA complexed to DOTAP. After 24 h, cytokines were quantified 
in the supernatant by ELISA (n = 2, one representative experiment is shown). For comparison 
RNase A treated (0.0075 U/ml) HEK293-RNA was additional used. 

















5.3.4.  Identification of cell types recognizing RNase A-derived 
fragments 
 
Monocytes are the main source of IFN-α upon recognition of RNase A-
derived fragments 
To address the question of which cell-types of the human PBMC cells are responsible for 
recognizing the RNase A-derived fragments and in order to induce IFN-α, we analyzed the 
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Figure 46: RNA fragments derived from RNase A treatment were fractionated with 
XBRIDGETM OST C18 columns and high performance liquid chromatography (HPLC) and 
visualized by ethidium bromide staining. Marker lane contains a 1 kbp DNA marker.  
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immune activation of monocytes (4.1.9.3) in comparison to PBMC (4.1.9.2) cells. The 
purity of the monocytes was controlled by FACS analysis (4.7). As shown in Figure 15, the 
isolated monocytes showed a purity of about 90%, whereas PBMCs contained only 28% 
monocytes. The monocytes were stimulated in the same way as described for PBMC 
cells. The supernatants were used for detection of IFN-α. Upon transfection of CpG 2216 
and RNA 40, there was practically no IFN-α secretion detectable in human monocytes (we 
found only a weak secretion for RNA 40), whereas these ligands induced type-I interferon 
in human PBMC cells. Stimulation with fragments derived by RNase A treatment induced 












Influence of the serum concentration for the immunostimulatory ability 
of RNase A-derived fragments 
Our initial findings showed that fragments derived by partially RNase treatment of self-
RNA induced an immune response in human PBMC cells when complexed to DOTAP. 
We then wondered whether different serum concentrations might influence the 
immunostimulatory potential of RNase-derived fragments in human PBMC cells. 
Therefore, we used fragments generated by RNase treatment, complexed them to 










Figure 47: Analysis of the cell type 
of human PBMC cells responsible 
for recognizing RNase A-derived 
fragments. Fragments derived by 
RNase A treatment were complexed to 
DOTAP and used for stimulation of 
human PBMC cells and monocytes. 
IFN-α production was measured 24 
hours post stimulation by ELISA. CpG 
2216 (1 µM) and RNA 40 served as 
positive controls (for ca. 90 % purity 
monocytes n = 2, for ca. 70 % purity 
monocytes n = 1; one representative 
experiment is shown). 
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DOTAP and tested their immunostimulatory potential in human PBMC cells exposed to 
different serum concentrations. As shown in Figure 48, the generated fragments 
complexed to DOTAP showed a serum-dependent IFN-α induction in human PBMC cells. 
The fragments induced the highest IFN-α response in human PBMC cells when using 1-
2% serum, whereas for higher serum concentrations like 10% serum the immune 
response was decreased. With regard to other immune cells, like murine immune cells or 
human HEK293 cells which were maintained in 10% serum, this result is very important 
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Figure 48: Influence of the serum concentration for stimulation of PBMC cells. PBMC cells were 
stimulated at different serum concentrations from 0 % to 10 % with different ligands. IFN-α production 
was measured 24 hours post stimulation by ELISA (n = 2, one representative experiment is shown). 
CpG 2216 (1µM) and RNA 40 served as positive controls.  
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Variable IFN-α responses for RNase A-derived fragments in murine 
immune cells 
To investigate whether RIG-I or MDA-5 mediates the recognition of the fragments derived 
from RNase A treatment; we intended to use Flt3-derived dendritic cells lacking the 
downstream of RIG-I and MDA-5 working adaptor molecule IPS. The ability of the 
fragments to induce IFN-α in PBMC cells was additionally controlled (4.1.9.2).  
First, we analyzed the immune activation of Flt3-derived dendritic cells (4.1.9.1) and 
measured IFN-α secretion by ELISA (4.9). Positive controls for IFN-α induction were the 
TLR ligands RNA 40 and CpG 2216. Upon transfection of RNase A-derived fragments 
complexed to DOTAP, there was always little-to-no IFN-α response detectable in Flt3-
derived DCs. From n = 17 experiments performed in Flt3-derived dendritic cells and bone-
marrow-derived dendritic cells, we observed in n = 5 experiments that the RNase A-
derived fragments were not recognized by TLR7 (data not shown). For all the other 
experiments, there was no IFN-α secretion detectable upon stimulation with RNase A- 
generated fragments in wild-type Flt3-derived dendritic cells. The reason for the variable 
data might be a change in the FCS lot number. Regarding the result we found in human 
PBMC cells (namely, that the IFN-α inducing ability of the RNase A-derived fragments 
was dependent on the serum concentration), we tested different serum concentrations for 
Flt3-derived DCs. PBMC cells were normally stimulated in medium containing 2% AB 
serum, whereas Flt3-derived dendritic cells were cultivated in medium containing 10% 
FCS. For Flt3-derived dendritic cells, we found also a serum-dependent IFN-α induction 
for the fragments derived by RNase treatment (Figure 49). Whereas for serum 
concentrations below 5%, there was an IFN-α response detectable, for 10% serum 






















RIG-I dependent recognition of RNase A-derived fragments in HEK 
immune cells 
To investigate whether RNase-derived fragments are recognized in an IPS-dependent 
way, HEK293 cells which lack functional TLRs (with the possible exception of TLR3) were 







Figure 49: Analysis of the 
influence of serum for the 
recognition of fragments
derived from RNase A treated 
self-RNAs. Either mock- or 
RNase A (0.0075 U/ml)-treated 
self-RNAs were complexed to 
DOTAP and used for stimulation 
of Flt3-derived dendritic cells 
generated from a wild-type mouse
at a final RNA concentration of 10 
µg/ml. RNA 40 and CpG 2216 
served as positive controls. IFN-α
secretion was measured 24 hours 
post stimulation by ELISA (for 
FCS Titration n = 1, one 
representative experiment is 
shown). 
IFN−α (U/ml)
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A) Figure 50: RIG-I-mediated 
recognition of RNA 
fragments in non-immune 
cells. A) HEK293 cells were 
cotransfected with plasmids 
encoding the IFN-ß
luciferase reporter construct, 
RIG-I and MDA-5 by 
electroporation. B) 
summarizes the interesting 
part for RIG-I-transfected 
cells. Transfected cells were 
treated with Poly I:C (10 
µg/ml), RIG-I ligand 5`-3P 
RNA (0.2 µg/ml), uninfected 
and A/PR/8/MDCK-RNA (2 
µg/ml) each complexed to 
DOTAP or Lipofectamine 
2000. In addition, the 
transfected cells were
stimulated with RNase A
(0.0075 U/ml)-derived 
fragments from self-RNA
complexed to Lipofectamine 
2000. These fragments were 
also RNase III- and CIP-
treated. IFN-ß activation was 
determined by Dual 
Luciferase Assay (for RNAs 
in a concentration range 
between 200 ng/ml to 20 
µg/ml complexed to 
Lipofectamine 2000 n = 6, 
one representative 
experiment is shown; for 
RNAs in a concentration 
range between 200 ng/ml to 
50 µg/ml complexed to 
DOTAP n = 7, no 
experiment is shown). 
  Results 
 125
The normally MDA-5-specific ligand Poly I:C was found to show enhanced IFN-ß 
activation in RIG-I-transfected cells, but when complexed to Lipofectamine 2000 there 
was little detectable IFN-ß increase in MDA-5-transfected cells. The question arose as to 
whether our MDA-5 was functional. RIG-I expressing HEK293 cells gained 
responsiveness to the RIG-I-specific control RIG-I ligand 5`-3P RNA complexed to 
Lipofectamine 2000. The A/PR/8/MDCK-RNA complexed to DOTAP or Lipofectamine 
2000 was also recognized in RIG-I-transfected HEK293 cells in a CIP-independent but 
RNase III-dependent way, as described in section 5.2. Upon stimulation with the 
fragments derived from RNase A treatment complexed to Lipofectamine 2000 at a final 
RNA concentration of 1 µg/ml, IFN-ß activation was enhanced. As a control we also 
performed stimulation with untreated self-RNA, but there was no immune induction. The 
observed IFN-ß activation upon stimulation with RNase A-derived fragments was only 
detectable by using the transfection reagent Lipofectamine 2000, but not with DOTAP 
(data not shown). Upon RNase III treatment of the fragments derived from RNase A 
treatment, the immune response was abrogated showing the importance of the ds 
character of the fragments for the RIG-I-dependent immune response. The 5`-
triphosphate has no influence on the recognition of the fragments, because 
dephosphorylation did not reduce IFN-ß activation. Thus, the RNase A-derived fragments 
are recognized in different ways by immune cells. Whereas in human PBMC cells IFN-α 
secretion was observed upon transfection with RNase A-derived fragments complexed to 
DOTAP at a final RNA concentration in the range of 5-50 µg/ml (further concentrations 
have not been tested; data only shown until 10 µg/ml), in human HEK293 cells IFN-ß 
activation was enhanced when the fragments were complexed to Lipofectamine 2000 at a 
final RNA concentration of 1 µg/ml. In conclusion, we could say that, depending on the 
immune cell type, different concentrations of the RNA fragments and different transfection 
reagents are necessary for inducing an immune activation. Regarding the results obtained 
by using HEK293 cells overexpressing RIG-I, we observed that RIG-I is the responsible 
receptor for recognizing RNase A-derived fragments. This result could not be confirmed 
by using respective knockout mice. Reasons for this variable immune response to the 
RNase A-derived fragments on murine immune cells might be that FCS is a problem or 
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5.3.5. Summary 
In this study, we could show that small self-RNAs generated by RNase treatment 
represent an immunostimulatory pattern. These cleavage products complexed to DOTAP 
strongly triggered a type-I interferon response in human PBMC cells. Murine Flt3-derived 
dendritic cells showed a variable immune response to RNase-derived fragments. 
Considering the FCS dependency, optimal conditions for recognizing the RNase A-
derived fragments in the murine system have to be found. However, non-professional 
immune cells were able to mount an IFN-ß response upon stimulation with the RNase-
derived fragments complexed to Lipofectamine 2000. The viral RNA sensor protein RIG-I 
was shown to be responsible for the IFN-ß response in HEK23 cells. Nevertheless, the 
observed immunoactivation in both cells types, PBMCs and HEK293 cells, was not really 
comparable, because different transfection reagents were used. DOTAP facilitates 
endosomal delivery, whereas Lipofectamine 2000 ensures cytoplasmic translocation. At 
the moment, we can only understand the IFN-ß activation upon transfection of RNase-
derived fragments complexed to Lipofectamine 2000 for HEK293 cells. We observed in 
the HEK system a RIG-I mediated immune recognition. The strong secretion of IFN-α 
upon stimulation of PBMCs with fragments complexed to DOTAP, is at the moment, 
difficult to explain. Since RIG-I is expressed in the cytoplasm, the involvement of RIG-I in 
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6. Discussion 
The ability of the host to distinguish between self and foreign nucleic acids is important for 
the recognition of pathogens by pattern-recognition receptors. Viral RNA has been shown 
to represent an immunostimulatory pattern which induces a type-I interferon response in 
immune cells. Under certain circumstances, eukaryotic self-RNA may reach TLR-
containing endosomes allowing for self-recognition. However, several mechanisms have 
evolved to avoid PRR-mediated activation by self-RNA that may result in inflammatory or 
autoimmune responses under other circumstances. Specific modifications are known to 
suppress immune activation when placed in an immunostimulatory RNA. 
6.1. Recognition of 2`-O-ribose methylated RNA 
6.1.1. RNA modifications 
Mammalian RNA contains many modified nucleosides, making them significantly less 
stimulatory via TLR7 and -8 than bacterial RNA (Ishii and Akira 2005; Kariko et al. 2005). 
In eukaryotes, the synthesis and processing of rRNAs take place in the nucleolus (Kiss-
Laszlo et al. 1998). Pre-rRNA molecules undergo a series of processing steps such as 
nucleoside modification in order to become mature rRNA molecules. The modifications 
are of three prevalent types: 2`-O-ribose methylation, pseudouridylation or base-
methylation (Bachellerie et al. 2002). Ribose methylations are directed by snoRNAs (small 
nucleolar RNAs). These are found in the nucleolus and caja bodies (conserved 
subnuclear organelles present in the nucleoplasm), which specify the sites to be modified 
through the formation of a specific duplex at the rRNA modification site, while the catalytic 
function is provided by a common protein enzyme, methylase or pseudouridine synthase 
associated with the snoRNA (Bachellerie et al. 2002). The modifications are restricted to 
the functionally essential regions of mature RNA (Bachellerie et al. 2002). The human 
18S, 5.8 S and 28S rRNAs together carry ~ 110 2`-O-methyl groups and almost 100 
pseudouridines (Kiss 2001). Nucleoside modifications directed by snoRNA guides appear 
dispensable for cell viability or growth in most cases. However, they are likely to play an 
important biological role insofar as they fine-tune a wide range of RNA-RNA and RNA-
protein interactions. Methylation of 2`-hydroxyl groups may protect RNA from hydrolytic 
degradation, enhance hydrophobic surfaces and stabilize helical stems. Due to their 
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flexible C-C glycosyl bonds and increased capacity to form H-bonds, pseudouridines may 
contribute to RNA tertiary structure (Bachellerie et al. 2002). 
6.1.2. Analysis of the immunostimulatory potential of eukaryotic 
and in vitro transcribed 18S rRNA 
First, the immunostimulatory effect of eukaryotic, especially purified 18S rRNA, was 
examined and compared to in vitro transcribed 18S rRNA. It was shown that only in vitro 
transcribed 18S rRNA, but not eukaryotic-purified 18S rRNA stimulated human PBMC 
cells to secrete type-I interferons. In the murine system comparable results were obtained. 
Transfection of 18S rRNA purified from cells was not immunostimulatory or induced only 
low amounts of proinflammatory cytokines in human PBMC cells, whereas in vitro 
transcribed 18S rRNA induced IFN-α and IL-6 when complexed to DOTAP in a TLR7 
dependent manner. Since eukaryotic “natural” rRNA contains modifications in contrast to 
in vitro transcribed rRNA, we conclude that these modifications negatively influence the 
stimulatory potential of rRNA for IFN-α production (Maden 1990; Kariko et al. 2005). After 
in vitro transcription of eukaryotic 18S rRNA, the generated RNA type revealed 
immunostimulatory activity. These results suggest that TLR7 and -8 discriminate between 
"self" and "foreign" RNA-molecules and that this discrimination is due to structural 
modifications of rRNA rather than sequence differences. However, proinflammatory 
cytokines such as IL-6 and TNF-α were induced by in vitro synthesized as well as purified 
18S rRNA. Thus, we can conclude that RNA modifications have a differential influence on 
modulation of cytokine production.  
 
6.1.3. Effect of modifications at the 2`-position of ribose 
concerning the stimulatory potential of ssRNA 
Within this work, it was shown that the introduction of modified nucleotides into RNA 
oligonucleotides derived from eukaryotic 18S rRNA resulted in an altered type-I interferon 
secretion. RNA oligonucleotides containing 2`-O-methoxy residues revealed that the 2`-
position of the ribose is very important for immunorecognition. Ribose-methylation 
abolished or at least impaired the immunostimulatory effect of GU-rich ssRNA 
oligonucleotides. 
Only 2`-O-methoxy-modified nucleosides (and none of the other modified nucleosides) 
were identified as significantly reducing IFN-α secretion in human and murine immune 
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cells. Immune cells responded to RNA 63-mediated stimulation with IFN-α and 
proinflammatory cytokine production (IL-6 and TNF-α) in a TLR7 dependent manner. IFN-
α induction by RNA 63-2`-O-methyl was also significantly reduced, supporting the view 
that TLR7-mediated IFN-α production was abrogated by the 2`-O-ribose methylation of the 
guanosine at position 3. However, RNA 63-2`-O-methyl induced proinflammatory 
cytokines in human PBMC cells but not in murine immune cells. Since murine TLR8 per 
se is non-functional, the RNA 63-driven immunostimulatory activity in murine cells is 
strictly TLR7-dependent. It was shown that resiquimod (R-848) and GU-rich RNA activate 
immune cells via human and murine TLR7 as well as human TLR8 (Hemmi et al. 2002; 
Jurk et al. 2002; Heil et al. 2004). Stimulation of murine immune cells derived from a 
TLR7-deficient mouse and genetic complementation assays in HEK293 cells revealed that 
only human TLR8 conferred responsiveness to R-848, whereas murine TLR8 was not 
active (Hemmi et al. 2002; Bauer et al. 2008). Human TLR7 is expressed in pDCs, 
whereas TLR8 expression is found in monocytes. The cell type-specific expression 
usually results in specific cytokine profiles upon TLR7 (IFN-α production from pDCs) or 
TLR8 (TNF-α production from monocytes) activation (Bauer et al. 2008; Tluk et al. 2009). 
Since human TLR7 and TLR8 differ in their target cell selectivity and cytokine induction 
profile, we hypothesize that RNA 63-mediated IFN-α production is TLR7 dependent, 
whereas production of proinflammatory cytokines such as TNF-α is dependent on human 
TLR8. Indeed, genetic complementation experiments in HEK293 cells demonstrated that 
human TLR8 induces NF-κB upon stimulation with RNA 63 and RNA 63-2`-O-methyl 
(unpublished data). While RNA 63-2`-O-methyl induced proinflammatory cytokines in 
human PBMCs, for eukaryotic-purified 18S rRNA, there was only a weak proinflammatory 
cytokine secretion detectable. The reason for this might be that eukaryotic RNA contains 
further modifications like methylated bases and pseudouridines that inhibit the induction of 
proinflammatory cytokines. 
Tluk et al. found that, by introducing a single 2`-O-methyl modification in self-RNA (U1 
snRNA, which, in contrast to other eukaryotic RNAs, contains only few modifications), the 
immunostimulatory potential is decreased independent of the position of the modified 
nucleotide (Bauer et al. 2008; Tluk et al. 2009). Other studies have described the 2`-O-
ribose methylation as useful RNA modification that destroys the immunostimulatory 
capacity of siRNA, which is widely used to modulate gene expression (Czauderna et al. 
2003; Judge et al. 2006; Sioud 2006; Cekaite et al. 2007; Sioud et al. 2007; Eberle et al. 
2008). It was shown that alternating 2`-O-ribose methylation of the sense strand within a 
siRNA duplex destroys its immunostimulatory function in immune cells, while reduction in 
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target gene expression is functional. Titration experiments with 2`-O-ribose methylated 
ssRNA added to immunostimulatory siRNA demonstrated that 2`-O-ribose methylation 
even acts as an inhibitor for RNA-driven immune stimulation via TLR7. This shows that 2`-
O-ribose-methylated RNA bound stronger to TLR7 than unmodified RNA (Hamm et al. 
2009). 
6.2. Recognition of RNA from influenza-infected cells 
6.2.1. Recognition of an influenza virus infection 
Historical accounts of influenza infections date back centuries, and the ever-changing 
nature of the influenza genome has ensured that influenza infections remain a continuing 
major public health problem to this day. Influenza A viruses belong to the 
Orthomyxoviridae family and have a segmented ssRNA genome coding for different viral 
proteins (Lamb and Krug 1996). Influenza viruses are unusual among RNA viruses 
because all viral RNA synthesis – transcription and replication - occur in the nucleus of the 
infected cell (Flint et al. 2004). Virus infection elicts immune responses in all cells intended 
to contain the spread of the virus before intervention by the adaptive immune system 
(Pichlmair and Reis e Sousa 2007). The route of infection determines the cell types 
responsible for type-I IFN production (Takeuchi and Akira 2008). Macrophages and cDCs 
play critical roles in IFN-α production, particularly during the course of local RNA virus 
infection. pDCs function when the first line of defense is broken and play an important role 
in the production of IFN-α during systemic IFN-α infections (Takeuchi and Akira 2007). In 
the following, different receptors are discussed that recognize the RNA of influenza 
viruses infecting different cell types. 
Viral RNA is sensed by receptors belonging to the TLR and RIG-like receptors (Diebold et 
al. 2004; Lund et al. 2004; Kato et al. 2006). These receptors target structures that are 
characteristic for viral RNA, such as ds conformation (Kato et al. 2008) or the presence of 
an accessible 5`-triphosphate (Hornung et al. 2006). Of course, it is possible that there are 
additional, as yet undefined, distinguishing features, which are recognized by the innate 
immune system. Recognition of endogenous RNA is limited by the restriction of TLRs to 
endosomal compartments, which only come into contact with RNA molecules that have 
been taken up via the endocytotic pathway. Besides this compartmentalization, it has 
been shown that nucleotide modifications as they occur in eukaryotic RNA are able to 
reduce immunostimulation (Kariko et al. 2005; Kato et al. 2006; Kariko and Weissman 
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2007). Besides the aforementioned receptors, the NLRP3 inflammasome mediates host 
defense against influenza infection through the sensing of viral RNA (Allen et al. 2009; 
Ichinohe et al. 2009; Owen and Gale 2009; Thomas et al. 2009). NALP3 has also been 
described as a cytosolic RNA sensor for bacterial RNA (Kanneganti et al. 2006; Eberle et 
al. 2009). NLRs represent the largest family of PRRs in humans (Ting and Davis 2005). 
They are further grouped into NODs and NALPs. NOD-like (nucleotide binding 
oligomerization domain) receptors are implicated in the recognition of bacterial 
components and activate the transcription factor NF-κB (Leber et al. 2008). NALPs reside 
in the cytosol in an inactive form. Upon activation, NALPs form multimeric protein 
complexes called inflammasomes. ACS (apoptosis-associated speck-like protein) 
represents an essential adaptor molecule for inflammasome signaling. It subsequently 
leads to the activation of pro-caspase-1, which leads to the processing of pro-IL-1ß and 
pro-Il-18 to produce mature cytokines (Tschopp et al. 2003; Martinon et al. 2007; Martinon 
2008).  
Moreover, the dsRNA-activated protein kinase (PKR) has been shown to have antiviral 
functions. PKR is a cytoplasmic serine-threonine kinase that is ubiquitously expressed 
and activated by binding dsRNA. Active PKR catalyzes phosphorylation of the eukaryotic 
initiation factor 2 (eIF-2), which inhibits translation initiation, thus preventing pathogen 
replication. Activation of PKR also induces type-I interferon induction (Balachandran et al. 
2000; Bergmann et al. 2000; Barchet et al. 2005). 
It is notable that monocytes required CD14 for influenza A virus-induced cytokine and 
chemokine production (Pauligk et al. 2004). CD14 might play an important role for the 
IPS-dependent recognition of A/PR/8/MDCK-RNA complexed to cationic lipids or to 
cathelicidins. It would be interesting to analyze the influence of CD14 on the recognition of 
A/PR/8/MDCK-RNA in CD14-deficient immune cells. 
In addition to viral RNA recognized by the immune system, virion components are also 
pyrogenic as virosomes depleted of RNA but including viral lipid, haemagglutinin and 
neuraminidase induced fever (Brydon et al. 2005). 
6.2.2. Role of cathelicidins in viral infections and autoimmune 
diseases 
The role of LL-37/CRAMP in viral infections has not been thoroughly studied. LL-37 
exhibits known selective antiviral activity against vaccinia virus (Howell et al. 2004) and 
may have potential antiviral properties against HSV-1 (Yasin et al. 2000) and HIV-1 
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(Bergman et al. 2007). But its role for the immune response against the influenza virus or 
other RNA viruses has not been analyzed. Previous studies have indicated that the 
release of antimicrobial proteins by neutrophils contribute to an early host defense against 
influenza virus infection. Treatment of mice infected with the influenza virus with LTB4, a 
lipid mediator of inflammation, led rapidly to the secretion of the human cathelicidin LL-37 
and further antiviral peptides from neutrophils, reducing the viral load in their lungs 
(Flamand et al. 2007; Gaudreault and Gosselin 2008). In this study, it was investigated if 
LL-37 or its mouse homolog CRAMP could function as a carrier for RNA from A/PR/8-
infected MDCK cells. We found that A/PR/8/MDCK-RNA complexed to LL-37 induced a 
type-I interferon response in human PBMC cells, whereas a scrambled form of LL-37 
(sLL-37) conferred no immune activation. Upon transfection with self-RNA, there was no 
IFN-α response detectable when complexed to cathelicidins. In some rare cases the IFN-
α response induced by A/PR/8/MDCK-RNA complexed to cathelicidins was variable in 
human PBMC cells. One possible explanation for the variable IFN-α response is that it 
was donor-dependent. Furthermore, as discussed in section 6.2.10, we have to consider 
that human plasma was found to completely block the antimicrobial activity of LL-37. It is 
possible that a formation of a complex between LL-37 and RNA was negatively influenced 
by human plasma, such that sometimes only variable IFN-α responses could be detected. 
Recently, it was found that self-RNA-LL-37 complexes activate in human pDCs TLR7 and 
trigger the secretion of IFN-α (Ganguly et al. 2009). Furthermore, it was described that 
self-RNA complexed to LL-37 also trigger the activation of human classical myeloid 
dendritic cells (mDCs). This occurs through TLR8 and leads to the production of TNF-α 
and IL-6. We found that self-RNA complexed to LL-37 did not induce the secretion of IFN-
α in human PBMC cells, but we observed an IL-6 and TNF-α secretion. Considering that 
we used another cell type than Ganguly et al., the induction of proinflammatory cytokines 
in PBMC cells by self-RNA complexed to cathelicidins is an interesting observation. In 
inflammatory or autoimmune situations, a variety of nucleotide-binding proteins such as 
autoantibodies, antimicrobial peptides and high mobility group box 1 (HMGB-1) are 
complexed with self-nucleic acids. The complex of self-nucleic acids and proteins may 
become resistant to degradation and reach the endolysosome, thereby inducing the 
secretion of cytokines.  
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6.2.3. Monocytes are responsible for recognition of RNA from 
A/PR/8-infected cells 
To analyze the cell type within the PBMC cells responsible for recognizing A/PR/8/MDCK-
RNA complexed to cationic lipids or cathelicidins, we isolated monocytes. Little is known 
about the contributon of pDC-independent IFN-α production capacity of human peripheral 
blood. So far, TLR-expressing DCs, primarily pDCs, are known as the principal IFN-α 
source in the immune system. Based on the discovery of cytoplasmatic helicases like 
RIG-I and MDA-5, the question arose as to how much IFN-α can be produced by non-DCs 
in peripheral blood. Stimulation of monocytes with A/PR/8/MDCK-RNA showed that 
monocytes represent the cell type responsible for recognizing the A/PR/8/MDCK-RNA 
complexed to cationic lipids or cathelicidins. The obtained monocytes had a purity of 
about 90%. Since monocytes do not express TLRs like TLR9 or TLR7 (Iwasaki and 
Medzhitov 2004; Barchet et al. 2008), but instead express cytosolic helicases, this result 
might give us a first indication of the responsible receptor. In order to exclude an 
involvement of pDCs, which are present in very low frequency in PBMC cells (0.2-0.5%), 
another approach might be to isolate pDCs by either magnetic or fluorescent cell sorting 
and to test their immunostimulatory ability upon stimulation with A/PR/8/MDCK-RNA 
complexed to cationic lipids or cathelicidins. Recent studies have already shown that 
human monocytes are highly susceptible to influenza A virus infection and release 
different cytokines like TNF-α, IL-6 and IFN-α (Nain et al. 1990; Kaufmann et al. 2001). 
Hansmann et al. were able to show that monocytes are the main IFN-α source after Poly 
(I:C)/DOTAP stimulation, suggesting that monocytes might represent an underestimated 
source of IFN-α in human peripheral blood (Hansmann et al. 2008). 
 
6.2.4. Features of RNA from virus-infected cells which are 
important for induction of IFN-α 
 
Contribution of the terminal 5`-triphosphate of RNA for RIG-I signaling 
Previous studies have indicated that the 5`-triphosphate is a structural feature responsible 
for IFN-α-inducing activity of in vitro transcribed RNA and flu vRNA in monocytes, bone 
marrow-derived DCs and HEK293 cells transfected with IFN-ß reporter. 
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Dephosphorylation of the 5`-triphosphate end completely abrogated the IFN-α response in 
the aforementioned cells. However, pDCs showed no decrease in IFN-α secretion upon 
dephosphorylation of oligonucleotides. Triphosphate RNA-mediated IFN-α induction 
neither required endosomal maturation nor TLR7 (Hornung et al. 2006; Pichlmair et al. 
2006).  
Our findings showed that the 5`-triphosphate end of A/PR/8/MDCK-RNA complexed to 
DOTAP or Lipofectamine 2000 was important for inducing IFN-α in murine immune cells. 
Dephosphorylation of the A/PR/8/MDCK-RNA reduced signaling, suggesting that RIG-I 
senses the A/PR/8/MDCK-RNA in a 5`-triphosphate dependent manner in Flt3-derived 
dendritic cells. For the RIG-I ligand 5`-3P RNA complexed to Lipofectamine 2000, we 
observed the same behaviour as for A/PR/8/MDCK-RNA; the IFN-α induction was 5`-
triphosphate dependent. 
However, for human PBMC cells we observed only a minor decrease in the IFN-α 
response upon dephosphorylation of A/PR/8/MDCK-RNA complexed to DOTAP or 
Lipofectamine 2000. In contrast, for the RIG-I ligand 5`-3P RNA complexed to 
Lipofectamine 2000, the IFN-α response was abrogated upon dephosphorylation. We 
hypothesize that human immune cells express more RIG-I proteins than murine immune 
cells, so that in the human system a higher number of putative binding sites between RIG-
I and the A/PR/8/MDCK-RNA are available, and the 5`-triphosphate end is no longer 
important for interaction. For the RIG-I ligand 5`-3P RNA, the nucleic acid length from 100 
bp is not sufficient in order to have interactions with RIG-I proteins in a 5`-triphosphate 
independent way. Another possibility is that the murine RIG-I molecule and the human 
RIG-I molecule are different in the dependency of the 5`-triphosphate end. But the results 
obtained with the RIG-I ligand 5`-3P RNA complexed to Lipfectamine 2000 argue against 
the idea that the murine and the human RIG-I molecules behave differently as regards the 
5`-triphosphate ends. 
In untransfected HEK293 cells, the immune response to A/PR/8/MDCK-RNA complexed 
to DOTAP or Lipofectamine 2000 was abrogated after dephosphorylation, whereas in 
RIG-I-transfected HEK293 cells dephosphorylation of A/PR/8/MDCK-RNA had no 
influence. The RIG-I ligand 5`-3P RNA complexed to Lipofectamine 2000 induced IFN-ß 
activation only in RIG-I-transfected HEK293 cells, and the IFN-ß response was diminished 
after dephosphorylation. It seems that the A/PR/8-infected MDCK-RNA shows more 
putative binding sites even for only lowly expressed RIG-I proteins in untransfected 
HEK293 cells than the RIG-I ligand 5`-3P RNA. As discussed for PBMCs, we hypothesize 
that immune cells expressing more RIG-I proteins contain a higher number of putative 
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binding sites for the ligands and that, in this case, the 5`-triphosphate end is not important 
for recognition of the RNA through RIG-I. But further experiments are required, like 
radioactive labeling of the RNAs to prove that the phosphate group was efficiently 
removed.  
 
Influence of the ds character of RNA for RIG-I signaling 
The "panhandle" conformation of the A/PR/8/MDCK-RNA represents a second 
independent target structure for RIG-I signaling. Schmidt et al. have found that RIG-I 
ligands require base-paired structures in conjugation with a free 5`-triphosphate to trigger 
a type-I interferon response (Schmidt et al. 2009). We could show that immunostimulatory 
RNA from virus-infected cells was sensitive to ds- but not ss-specific RNases. The ds-
specific RNase III abolished signaling of A/PR/8/MDCK-RNA complexed to DOTAP or 
Lipofectamine 2000 in human and murine immune cells, which indicates that the 
A/PR/8/MDCK-RNA contain base-paired regions. 
In the past, most studies suggested that single-stranded 5`-triphosphate RNA is sufficient 
to bind to and activate RIG-I (Pichlmair et al. 2006). These studies used in vitro 
transcription for generation of 5`-triphosphate RNA without analyzing the purity of those 
RNA molecules. In fact, an unintended formation of dsRNA is the cause of RIG-I activity of 
the in vitro transcribed RNA (Schlee et al. 2009; Schmidt et al. 2009). Even for negative-
strand RNA viruses known to activate RIG-I, it was shown by Schlee et al. that they 
contain 5` and 3` sequences that form a short ds with a perfect blunt end (panhandle) 
(Schlee et al. 2009). Interestingly, Myong et al. showed that RIG-I translocates on 
synthetic double-stranded RNA molecules and that this movement is enhanced in the 
presence of 5`-triphosphate (Myong et al. 2009). Some studies suggested that for ssRNA-
viruses no dsRNA can be detected (Hornung et al. 2006; Pichlmair et al. 2006; Weber et 
al. 2006). However, the antibody used to demonstrate the absence of dsRNA (Weber et 
al. 2006) is limited to the detection of dsRNA longer than 40 bases (Bonin et al. 2000; 
Schlee et al. 2009). In contrast, other studies demonstrated that the most widely 
postulated triggers for cytokine induction on influenza virus infection are dsRNA 
intermediates produced during replication (Jacobs and Langland 1996; Majde 2000). Long 
dsRNA molecules are absent from uninfected cells. Madje et al. showed that dsRNA is 
released from dying influenza virus-infected cells (Majde et al. 1998). 
Comparing the ligands A/PR/8/MDCK-RNA and the RIG-I ligand 5`-3P RNA in human 
PBMC cells with regard to the features important for recognition, we observed the 
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following: For A/PR/8/MDCK-RNA complexed to DOTAP or Lipofectamine 2000, 
phosphatase treatment had no influence on the IFN-α-inducing ability, but cleavage with 
the ds-specific RNase III abrogated IFN-α secretion in human PBMC cells. This shows 
that, for the recognition of RNA from virus-infected cells, the ds character or at least a 
"panhandle" conformation by pairing complementary 5` and 3` ends is important. In 
contrast, for the RIG-I ligand 5`-3P RNA complexed to DOTAP or Lipofectamine 2000, 
only the 5`-triphosphate seemd to be important, whereas treatment with the ds-specific 
RNase III had no influence for IFN-α secretion in human PBMC cells. A possible 
explanation is that for longer ligands the ds character is sufficient to induce IFN-α, and 
even after phosphatase treatment they remain immunostimulatory. In contrast, shorter 
ligands like the RIG-I ligand 5`-3P RNA need a 5`-triphosphate end for IFN-α secretion. At 
the moment, it is not clear whether dsRNA or hairpin dsRNA regions of the virus-infected 
RNA are responsible for inducing IFN-α. It is also possible that the RIG-I ligand 5`-3P 
RNA shows hairpin dsRNA regions, but that for inducing IFN-α a 5`-triphosphate end is 
necessary. Thus, we conclude that for the ligands A/PR/8/MDCK-RNA and RIG-I ligand 
5`-3P RNA two important features for RIG-I signaling are necessary: the ds character and 
the 5`-triphosphate end. On the other hand, some studies indicate that RNase III cuts 
ssRNA specifically and seems to degrade dsRNA rather nonspecifically (Dunn 1976). In 
contrast, Sun et al. demonstrated that RNase III retains strict specificity for dsRNA (Sun et 
al. 2001). At the moment, it is not clear whether RNase III is a ds-specific RNase. Further 
analysis is required in order to prove that the ds character of the A/PR/8/MDCK-RNA is 
responsible for inducing IFN-α. 
6.2.5. TLR-independent recognition of A/PR/8/MDCK-RNA 
It is possible that ssRNA from viruses is recognized through the receptors TLR7 and/or 
TLR8 (Diebold et al. 2004; Heil et al. 2004). IFN-α production by pDCs from TLR7-
deficient mice is impaired after infection with influenza virus or vesicular stomatitis virus 
(VSV) (Diebold et al. 2004; Lund et al. 2004). In this study, it was shown that 
A/PR/8/MDCK-RNA was recognized in a TLR7-independent way in Flt3-derived DCs, 
which consists of pDCs and cDCs. By using Flt3-derived DCs from TLR7- and MyD88-
deficient mice and GM-CSF-derived DCs from MyD88-deficient mice, we showed that 
IFN-α secretion upon transfection of A/PR/8/MDCK-RNA complexed to cationic lipids or 
cathelicidins was not reduced in comparison to wild-type DCs. TLR7 does not seem to 
play an essential role in the innate immune response to RNA virus infection in vivo. There 
is not a significant difference between MyD88 -/- and wild-type mice in the susceptibility to 
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intranasal influenza virus infection and type-I IFN response (Barchet et al. 2005; 
Eisenacher et al. 2007). 
The dsRNA-sensing TLR3 is localized in endosomes and is preferentially expressed in 
phagocytic cells. Thus, it is possible that after dendritic cells take up apoptotic bodies of 
virus-infected cells, dsRNAs are delivered into vesicles, where they are recognized by 
TLR3. Moreover, TLR3 is expressed on pulmonary epithelial cells and contributes to the 
immune response of respiratory epithelial cells (Guillot et al. 2005). Upon infection with 
influenza A virus in a TLR3-dependent manner, human lung epithelial cells express 
proinflammatory cytokines including IL-6 and IL-8 (Le Goffic et al. 2007). In this study, it 
was shown that A/PR/8/MDCK-RNA was recognized in a TLR3-independent way in 
murine immune cells. By using murine macrophages from TLR3-deficient mice, we 
demonstrated that IFN-α and IFN-ß secretion upon transfection of A/PR/8/MDCK-RNA 
complexed to DOTAP or Lipofectamine 2000 was not reduced in comparison to wild-type 
macrophages. Murine macrophages were chosen because murine pDCs do not express 
TLR3. The unaltered course and pathogenesis of influenza- and other negative-strand 
RNA virus infections in TLR3 -/- and MyD88 -/- mice (Edelmann et al. 2004; Lopez et al. 
2004; Barchet et al. 2005) also argues against such a generalized role for TLRs as 
antiviral effectors. In addition, plasmacytoid dendritic cells (pDCs), which do not express 
TLR3, when isolated from the bone marrow of mice and infected in vitro with the influenza 
A virus, were found to secrete wild-type levels of IFN-α (Lund et al. 2004). The fact that 
GM-CSF-derived DCs and macrophages can be induced to produce IFN-α in response to 
RNA from virus-infected cells shows that this IFN-α response is mediated via TLR7 and 
TLR9 independent pathways (Fancke et al. 2008). 
6.2.6. IPS-dependent recognition of A/PR/8/MDCK-RNA 
It was found that the ubiquitously expressed RNA helicases play essential roles in the 
recognition of RNA viruses in various cell types, such as fibroblasts and conventional 
dendritic cells (cDCs) (Takeuchi and Akira 2008). The critical role of RIG-I in influenza A 
virus infection of epithelial cells was also shown (Siren et al. 2006; Le Goffic et al. 2007; 
Opitz et al. 2007). In this study, it could be shown that A/PR/8/MDCK-RNA was 
recognized in a RIG-I dependent way. The cytosolic helicase RIG-I is a key sensor of viral 
infections and is activated by RNA containing a triphosphate at the 5`-end (Hornung et al. 
2006). However, the exact structure of RNA-activating RIG-I remains controversial 
(Schlee et al. 2009). By using Flt3-derived dendritic cells from IPS-deficient mice, which is 
an important adaptor molecule for RIG-I or MDA-5 signaling, we observed that IFN-α 
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secretion upon transfection of A/PR/8/MDCK-RNA complexed to cationic lipids or 
cathelicidins was significantly reduced in comparison to wild-type dendritic cells. We could 
rule out MDA-5 as a possible receptor for A/PR/8/MDCK-RNA complexed to cationic lipids 
or cathelicidins by using Flt3-derived DCs and bone-marrow derived DCs from MDA-5-
deficient mice. Stimulation of HEK293 cells overexpressing RIG-I with A/PR/8/MDCK-RNA 
complexed to DOTAP or Lipofectamine 2000 resulted in a strongly enhanced IFN-ß 
response in comparison to untransfected HEK293 cells. In contrast, A/PR/8/MDCK-RNA 
complexed to LL-37 induced no detectable IFN-ß activation in RIG-I-transfected HEK293 
cells, despite appropriate positive controls, which suggested either that the HEK293 cells 
lack some cofactor specifically required for A/PR/8/MDCK-RNA complexed to LL-37-
induced activation of IFN-ß, or that the IFN-ß luciferase reporter used for these assay 
might be not sensitiv enough to detect the A/PR/8/MDCK-RNA complexed to LL-37. 
In order to further prove the involvement of RIG-I for the recognition of A/PR/8/MDCK-
RNA complexed to cationic lipids or cathelicidins, an analysis of immune activation of cells 
from RIG-I-deficient mice is necessary. But as mentioned earlier, RIG-I-deficient cells 
were not available at the time. 
It is still not known which viral RNAs are sensed by RIG-I during influenza infection. 
Influenza virus RNA can trigger RIG-I activation in vitro, but it is difficult to explain how this 
happens during infection when the genome segments are coated by viral nucleoproteins 
and have the viral polymerase bound to their 5`-ends (Lamb and Krug 1996). For RIG-I to 
interact with the genome and the critical 5`-triphosphate moiety, these viral proteins need 
either to be displaced or to dissociate from the vRNA. The former process could be 
facilitated by the ATP-driven helicase activity of RIG-I, whereas the latter may occur 
naturally as part of an equilibrium reaction (Takahasi et al. 2008). A recent study observed 
that viral genomes are the major trigger for RIG-I in cells infected with negative-sense 
single-stranded RNA viruses (Rehwinkel et al. 2010). 
6.2.7. Escape mechanism of viruses 
Viruses have developed different strategies to evade or inhibit key elements of antiviral 
immunity. The nonstructural protein 1 (NS1) of some strains of the influenza virus 
possesses a dsRNA-binding site and sequesters dsRNA (Min and Krug 2006; Hale et al. 
2008). However, this site also allows binding to ssRNA and the formation of a complex 
with RIG-I in the presence of 5`-triphosphate RNA (Pichlmair and Reis e Sousa 2007). 
This suggests that NS1 protein blocks type-I IFN induction by targeting RIG-I (Guo et al. 
2007; Mibayashi et al. 2007; Opitz et al. 2007). Recently, it was shown that the influenza 
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A virus nonstructural protein 1 (NS1) specifically inhibits TRIM25-mediated RIG-I CARD 
ubiquitination, thereby suppressing RIG-I signal transduction (Gack et al. 2009). 
For some negative-strand RNA viruses (e.g., Hantaan virus, Crimean-Congo hemorrhagic 
fever virus and Borna disease virus), it was shown that they process the 5`-termini to 
avoid RIG-I-dependent interferon induction (Habjan et al. 2008). 
6.2.8. Localization studies of RNA/LL-37 complexes 
We have performed localization studies of RNA/LL-37 complexes in human monocytes 
using biotinylated LL-37 (4.8). These experiments demonstrated that LL-37 complexes 
localized to the endosome (EEA-1 positive) and to the lysosome (Lamp positive). Of note 
is that we observed only the biotinylated LL-37 in the cells. We do not know if the 
complexes of LL-37 and the RNA could be detected in the endosome and the lysosome, 
or if the RNA was released earlier from the complex. This analysis has to be further 
extended to various human and murine immune cells, including tracking of fluorescence-
labeled RNA.  
A recent study showed that LL-37 retains DNA in the early endocytic compartments of 
pDCs (Lande et al. 2007). In contrast, another group showed that LL-37 transfers bacterial 
DNA to the nuclei of mammalian host cells (Sandgren et al. 2004). In this context, the 
influence of serum on the localization of LL-37 was discussed. It was shown that, in the 
absence of serum, LL-37 became localized to the nucleus in epithelial cells. When LL-37 
was observed in the presence of human serum, it was only detected in cell-associated 
aggregates (Lau et al. 2006).  
However, the localization of DOTAP and cathelicidins to early endosomal/lysosomal 
compartments does not currently explain how endosomally delivered RNA triggers an 
IPS-1 dependent signaling pathway there (Yasuda et al. 2005). Since RIG-I is expressed 
in the cytoplasm and has no access to the endosome, the involvement of RIG-I in RNA 
recognition is questionable. However, small amounts of RNA transported from the 
endosome in the cytoplasm might be sufficient for inducing an RIG-I dependent immune 
signaling. Moreover, it can be postulated that an unidentified IPS-dependent receptor may 
localize to the endosome and recognize immunostimulatory RNA. Alternatively, a 
previously unrecognized localization for RIG-I in the endosome is a possibility. The 
involvement of RIG-I has to be clarified through analysis of immune cells from RIG-I-
deficient mice. Another possibility is that DOTAP transfers nucleic acids not only to the 
endosome, but also to the cytoplasm. For cationic liposomes, it was shown that the 
complex initiates a destabilization of the endosomal membrane that results in a flip-flop of 
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anionic lipids that are predominately located on the cytoplasmic face of the membrane. 
The anionic lipids laterally diffuse into the complex and form charge-neutralized ion pairs 
with cationic lipids. This displaces the ODN from the complex and the ODN can diffuse 
into the cytoplasm (Xu and Szoka 1996; Zelphati and Szoka 1996). For the transfection 
reagent Lipofectamine 2000, which delivers nucleic acids to the cytoplasm where RIG-I 
and MDA-5 reside, an IPS-dependent recognition of the A/PR/8/MDCK-RNA is 
comprehensible. Further localization studies with fluorescence-labeled RNA and 
biotinylated LL-37 will clarify where the cathelicidin/RNA complexes are transferred. 
6.2.9. Immunization with natural carrier for RNA 
Because RNA is prone to hydrolysis, RNA molecules have to be protected from 
degradation through interaction with liposomes. Since DOTAP is toxic, we analyzed if 
cathelicidins could function as a carrier in vaccine formulations. Previous studies have 
shown the adjuvant function of RNA complexed to the cationic transfection reagent 
DOTAP (Heil et al. 2004; Hamm et al. 2007). Cathelicidins have potent in vivo 
immunoenhancing effects that make them useful as vaccine adjuvants. CRAMP could 
enhance antigen-specific immune response to ovalbumin, a commonly used experimental 
model antigen (Kurosaka et al. 2005). In the present study, it was analyzed whether a 
mixture of RNA combined with ovalbumin complexed to CRAMP (4.11) can serve as a 
vaccine formulation in subcutaneous injections. Immunization of ovalbumin together with 
CRAMP enhanced ovalbumin-specific IgG antibody response compared to the 
immunization with ovalbumin alone. In the combination of the different RNAs, either 
uninfected self-MDCK-RNA or A/PR/8/MDCK-RNA, there was an increase in the 
ovalbumin-specific IgG antibody response detectable. Further studies should analyze if, 
by varying the CRAMP concentration, an increase in the IgG antibody response is 
measurable. Induction of cytotoxic T cells has to be analyzed by staining spleen cells with 
ovalbumin-peptide-specific tetramers. The antigenic ovalbumin-peptide is presented via 
MHC molecules and has the sequence SIINFEKL. 
Since cathelicidins interact with the immune system receptors involved in chemotaxis and 
IL-1ß release (De et al. 2000; Elssner et al. 2004), it is important to study the contribution 
of cathelicidins to gene expression in a vaccine formulation. Its influence on gene 
expression (Affymetrix gene arrays) has to be analyzed and the cytokine production in 
primary immune cells or fibroblasts with cathelicidin/RNA complexes has to be compared 
to the induction patterns of DOTAP/RNA complexes. 
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6.2.10. Relevance of LL-37/RNA complexes and the influence of 
the microenvironment  
In the experiments we performed, cathelicidin/RNA complexes are formed in vitro and 
then added to the cells. In order to assess the in vivo role of cathelicidin/RNA complexes, 
it is important to consider facts like the concentrations and the activity of the cathelicidins 
in vivo. Since LL-37 is cytotoxic at high concentrations, there is a need for tight control of 
the release of this peptide (Johansson et al. 1998). In plasma, the concentration of LL-37 
is measured by ELISA to be 1.18 µg/ml (Sorensen et al. 1997). The microenvironment is 
critical for the activities of antimicrobial peptides (Gudmundsson and Agerberth 1999). 
Interestingly, human plasma is found to completely block the antimicrobial activity of LL-
37, and apolipoprotein A-I is identified as the scavenger of LL-37 (Wang et al. 1998; 
Sorensen et al. 1999). The serum components provide a physiological mechanism to 
protect blood cells from potentially harmful effects of the peptide (Zanetti 2005). 
In water, LL-37 exhibits a disordered structure. In physiological salt solutions, LL-37 forms 
a stable α-helical structure. The extent of helicity correlates with the antibacterial activity 
(Johansson et al. 1998). The ability of LL-37 to form α-helical aggregates can be 
rationalized by the Hofmeister effect. Here, the increasing ionic strength of the solvent 
makes it more and more unfavourable for the peptide to expose hydrophobic faces (Durr 
et al. 2006). The main determinants for the folding are certain anions as SO4-, HCO3-, and 
CFOO-. In contrast, the Cl- anion and cations have much less effect on the folding 
(Johansson et al. 1998). But it is observed that cathelicidins lose antimicrobial activity in 
vitro with the addition of physiological NaCl concentrations (Dorschner et al. 2006). In 
cystic fibrosis (CF), antimicrobial peptides are deactivated by increased salt 
concentrations because of a defective ion channel (Bals 2000; Bals and Hiemstra 2004). 
Gene transfer resulting in four-fold overexpression of LL-37 in a cystic fibrosis xenograft 
model succeeded in restoring bacterial killing to normal levels, suggesting that LL-37 may 
protect against bacterial lung infections and providing a possible therapeutic strategy for 
such infections (Bals et al. 1999). Ganguly et al. have found that RNA/LL-37 complexes 
are rapidly dissolved by the addition of sodium chloride (Ganguly et al. 2009). The 
influence of the microenvironment concerning the cathelicidin activity, make it difficult to 
judge the role of cathelidin/RNA complexes in vivo, for example in viral defense. 
To further analyze the role of cathelicidins for the immune response against the influenza 
virus and other RNA viruses, wild-type and CRAMP-deficient mice should be intranasally 
infected with sublethal and lethal doses of A/PR/8, and survival, weight loss and influenza 
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titers in the lung should be analyzed. Since we hypothesize that cathelicidins are involved 
in RNA-mediated immune stimulation upon viral infection, this would demonstrate whether 
or not synthetic CRAMP reconstitutes an effective immune response in CRAMP-deficient 
mice and accelerates the anti-influenza immune response in wild-type mice. 
 
6.3. Immunorecognition of self-RNA 
6.3.1. Discrimination of self- versus non-self-nucleic acids 
For DNA, CpG motifs in eukaryotic DNA have been identified (Bird 1986; Krieg et al. 
1995). For rRNA, the major constituent of total cellular RNA, known modifications include 
modified nucleotides such as conversion of uridine to pseudouridine, methylation of 2`-
hydroxyls (2`-O-methylation) and methylation of bases at different positions (Maden 1990; 
Decatur and Fournier 2003). However, the overall frequency of 2`-O-methylated bases is 
rather low and the distribution is not random (Maden 1990). These nucleic acid 
modifications of DNA and RNA represent a structural feature, which enables the immune 
system to distinguish self from non-self-nucleic acids (Krieg 2002; Diebold et al. 2004; Heil 
et al. 2004; Ganguly et al. 2009). However, it has recently become clear that this 
discrimination is primarily achieved by the intracellular localization of the TLRs, which 
allows the recognition of viral nucleic acids released into endosomal compartments 
(Barton et al. 2006). In contrast, self-nucleic acids are rapidly degraded in the extracellular 
environment and fail to access endosomal compartments (Barton et al. 2006). A possible 
exception to this situation may be the case of apoptotic cells, which might protect RNA 
from extracellular degradation and deliver it to the endosomes of phagocytes (Diebold et 
al. 2006).  
Thus, responses to extracellular self-RNA are normally prevented by the endosomal 
seclusion of nucleic acid-recognizing Toll-like receptors (TLRs). The question arises as to 
whether self-nucleic acids can become a potent trigger of pDC activation when aberrantly 
transported into TLR-containing endosomes. Recently, it was found that self-RNA 
complexed to LL-37 activates TLR7 and triggers the secretion of IFN-α (Ganguly et al. 
2009). Diebold et al. showed that both viral and self-RNA can trigger TLR7 activation 
equally efficiently, if delivered to endosomes. This suggests that TLR7 discriminates 
between viral and self-ligands on the basis of endosomal accessibility and uracil content 
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rather than sequence (Diebold et al. 2006). Also for DNA, the concept of self- versus non-
self discrimination based on the presence of unmethylated CpG motifs was changed 
(Haas et al. 2008). Although synthetic phosphothioate DNA depends on unmethylated 
CpG motifs to induce TLR9 activation, phosphodiester DNA depends on the 2`-
deoxyribose backbone. The ability for phosphodiester DNA to activate TLR9 depends on 
the formation of multimeric aggragates, indicated by the finding that eukaryotic DNA 
becomes immunostimulatory under certain circumstances that promote efficient DNA 
uptake such as DNA/antibody immune complexes, transfection or complexation to the 
antimicrobial peptide LL-37 (Boule et al. 2004; Lande et al. 2007). Recently, it was shown 
that a chimeric TLR9 that localized to the cell surface is able to recognize self-DNA which 
does not stimulate endosomal TLR9 (Barton et al. 2006). 
We can conclude that both modification of the nucleic acid and compartimentalization of 
the receptor allow one to discriminate self versus non-self-nucleic acids in concert.  
6.3.2. RNase treatment of self-RNAs 
For the first time, we were able to show that immunologically inert self-RNA can be 
converted to immunostimulatory RNA by treatment with RNase A and that it is as 
immunostimulatory as RNA from virus-infected cells. It is already described how cellular 
RNA serves as a ligand that stimulates the RLR pathway during viral infection. Viral RNA 
stimulates 2`-5` oligoadenylate synthetase (2`-5` OAS) to promote activation of an 
endonuclease, RNase L, which subsequently cleaves self-RNA to make small RNA 
species. The cleaved RNA, which contains a 3`-monophosphate group, serves as the 
ligand for RIG-I and MDA-5 to initiate signaling leading to type-I IFN production (Malathi et 
al. 2007; Silverman 2007). These observations suggest that this RLR-mediated 
recognition may be a host defense mechanism to efficiently amplify type-I IFN responses 
(Kawai and Akira 2008). 
Normally, it is found that RNase A, which cleaves both ssRNA and dsRNA at pyrimidine 
residues in low salt conditions, leads to the complete degradation and loss of activity of 
RNA (Libonati et al. 1980; Libonati and Sorrentino 1992; Aksoy et al. 2005).  
In our current work, we tested self-RNAs of different species upon partial RNase A 
treatment for their immunostimulatory potential. The RNA preparations were formulated 
with DOTAP to increase endosomal delivery and Lipofectamine 2000 to ensure 
cytoplasmatic translocation and were tested for immune stimulation. Furthermore, 
phenol/chlororform purification of RNase-derived fragments showed no reduction of the 
immunostimulatory potential indicating that putative contaminations did not play a role for 
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recognition. We observed that RNA fragments of 20 to 100 bp derived by RNase A 
treatment of self-RNA complexed to DOTAP induced a type-I interferon response in 
human PBMCs, whereas the generated fragments complexed to Lipofectamine 2000 or 
alone induced no immune activation. Since DOTAP transfers the nucleic acids to the 
endosome, an endosomal receptor should be responsible for recognition of the RNase A-
derived fragments. It seemed that the IFN-α response to the RNase A-derived fragments 
depends on the aberrant transport into endosomes, since the RNase A-derived fragments 
induced an immune activation only in combination with DOTAP but not alone or with 
Lipofectamine 2000. However, for different untreated RNA types complexed to DOTAP, 
there was an IFN-α response detectable when using them in a concentration range of 2 
µg/ml. The reason for this phenomenon is unclear at the moment, especially as to why 
there was only an immune induction when using them in a concentration range of 2 µg/ml. 
This immune induction was only achieved in combination with DOTAP but not when given 
alone. Therefore, it must depend on an aberrant transport into the endosome. Ganguly et 
al. found that self-RNA-DOTAP and self-RNA-LL-37 complexes activate TLR8 by using 
HEK293 cells transfected with TLR8 (Ganguly et al. 2009). This finding might explain why 
self-RNA complexes only induce an immune activation in human PBMC cells and not in 
murine immune cells, which express only a non-functional TLR8. In addition, we observed 
that the RNase A-derived fragments complexed to cathelicidins induced no immune 
activation on PBMC cells. Since cathelicinds are already described for transferring nucleic 
acids to endosomal compartments, it is unknown why these RNA/cathelicitin complexes 
induce no IFN-α. It is possible that the size of the fragments generated by RNase 
treatment is too small for complexation to cathelicidins, since RNA 40 (20 bp) complexed 
to cathelicindis was also not able to induce IFN-α in human PBMC cells (data not shown). 
Gel analysis revealed that the self-RNA was only partially digested. Upon complete 
digestion of self-RNA, there was no immune activation in human PBMC cells. A kinetic 
experiment showed that stimulatory fragments were even generated upon treatment with 
RNase A for only one minute. For complete degradation of the self-RNA, we had to add a 
higher amount of RNase A; a mere increase in time was not sufficient. The question 
arises as to whether the remained fragments are modified in such a manner that they 
become resistant for further cleavage by RNase A. 
As the source of self-RNAs (either cancer cell lines or primary cells) did not play any role 
in the immunostimulatory potential of the RNase A-derived fragments, we concluded that 
the immunostimulatory capacity of the RNase A-derived fragments depends on the RNA 
itself and is not associated, for example, to the RNA of cancer cells. 
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In section 5.1, the impact of natural occurring modifications in ribosomal RNA on its TLR-
dependent immune effects was investigated. Other studies might show that, for TLR7 
signaling, 2`-modified RNA suppresses RNA immune activation even when co-incubated 
with a stimulatory unmodified RNA. Upon RNase A treatment of self-RNA, the digest 
contains a mixture of unmodified stimulatory self-RNAs and modified non-stimulatory self-
RNAs. Since we think that the recognition of the generated self-RNA fragments depends 
on cytoplasmic receptors like RIG-I and MDA-5, the influence of RNA modifications on the 
activation of cytoplasmic receptors such as RIG-I and MDA-5 have to be further 
investigated. It is already discussed the fact that RNA modifications such as base-
methylation, pseudouridine and 2´-O-methyl ribose as described in section 6.1.1 decrease 
RIG-I stimulatory activity when incorporated into 5`-triphosphate RNA oligonucleotides 
(Hornung et al. 2006). 
The question arose regarding whether the IFN-α-inducing ability of RNase-derived 
fragments is due to the presence of foreign nucleic acids. A recent study showed a 
striking viral inhibition by heterologous RNA with a smaller inhibition than with homologous 
RNA, suggesting that the IFN-α production occurs as a reaction of cells to foreign nucleic 
acids (Rotem et al. 1963). In order to exclude the possibility of foreign nucleic acids for the 
IFN-α inducing ability of RNase A-derived fragments it should be analyzed whether or not 
RNA fragments from one PBMC donor also induce IFN-α on PBMC cells from the same 
donor. 
 
6.3.3. Fragments generated by different techniques 
The sites attacked in the RNA molecules by various treatments are expected to be 
different, corresponding to the different specifities of the enzymes and the basically 
different mode of action like ultrasonication or hydrolysis by metals. Although the 
degradation products were always heterodisperse, conditions could be controlled so as to 
yield breakdown within a given size range. This was checked in each experiment by 
agarose gel electrophoresis. 
The various ss-specific ribonuclease types we tested generated different ends for the 
RNA fragments. Ribonucleases that hydrolyze RNA to 3`-phosphomonoester via 2`,3`-
cyclic nucleosides are RNase A, RNase T1, and RNase T2 (Deshpande and Shankar 
2002). Most ribonucleases cleave only after specific residues. Since RNase A specifically 
degrades RNA at C and U residues by cleaving the phosphodiester bond between the 5`-
ribose of a nucleotide and the phosphate group attached to the 3`-ribose of an adjacent 
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pyrimidine nucleotide, certain RNA sequences should be enriched in the partial digest. But 
considering the ability of RNase I to degrade ssRNA to individual nucleoside 3`-
monophosphates by cleaving every phosphodiester bond; it can be concluded that special 
sequences enriched in the partial digest are not responsible for the IFN-α inducing ability. 
Treatment with all the aforementioned ss-specific ribonuclease types resulted in the 
fragmentation of self-RNAs and the generation of immunostimulatory fragments when 
complexed to DOTAP on human PBMC cells. Only treatment with the ds-specific RNase 
III did not lead to RNA degradation and generation of immunostimulatory self-RNA. 
Besides these nucleases, we tested the ribonucleases S1 from Aspergillus oryzae (Desai 
and Shankar 2003) and the P1 nuclease from Penicillium citrinum (Desai and Shankar 
2003) that hydrolyze RNA to 5`-phosphomonoester. They generated fragments that 
induce a lower IFN-α response by PBMC cells. Furthermore, we have also to consider 
donor-dependent effects. For fragments generated by Benzonase, a nuclease which 
degrades both DNA and RNA, whether ss or ds, and shows no base preference, there 
was no IFN-α response detectable.  
In conclusion, there was an IFN-α response detectable upon treatment with all the RNase 
types generating 3`-phosphate as well as 5`-phosphate ends on human PBMC cells. The 
IFN-α response seemed to be independent from the phosphate end. Dephosphorylation of 
the fragments showed no influence concerning the IFN-α response, suggesting that the 
recognition of the RNase-derived fragments was not mediated through phosphate ends at 
least in human PBMC cells. But consider the results for A/PR/8/MDCK-RNA from section 
5.2, which showed no influence upon dephosphorylation for the immunostimulatory 
potential in human PBMC cells, whereas in murine cells and untransfected HEK293 cells 
the IFN-α response was abrogated upon dephosphorylation. This fact leaves it open as to 
whether RNase A-derived fragments would show a changed immunostimulatory potential 
in other immune cells upon dephosphorylation. In addition, we have to consider that we 
had no control for effective dephosphorylation. In the future, radioactive experiments will 
be necessary in order to show that the phosphate group is removed completely. 
Fragments generated by ultrasonic treatment of self-RNA were not able to induce an IFN-
α response when complexed to DOTAP in human PBMCs. Through intermolecular 
cleavage at the phosphodiester internucleoside linkage, the RNAs undergo chain 
shortening (Meidan et al. 1997). Ultrasonic degradation of DNA results in DNA fragments 
of 100-500 bp with a phosphorylated 5`-end and a free alcohol at the 3`-end (Elsner and 
Lindblad 1989). With increases in time for ultrasonic treatment of the self-RNAs, the 
generated fragments became smaller, reaching 100-500 bp. Although they were not in the 
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size range of the RNase A-derived fragments (20-100 bp), it seems that fragment size is 
not an important feature to induce IFN-α. It is remarkable that the IFN-α response induced 
by untreated self-RNAs in a concentration range of 2 µg/ml was reduced both with the 
increase of ultrasonic treatment and with RNase III treatment. It is possible that through 
the degradation of the self-RNA the structure responsible for inducing IFN-α is destroyed. 
We hypothezise that ultrasound treatment and incubation with the ds-specific RNase III 
destroyed the double-stranded structure of RNA. In the literature, self-RNA molecules, in 
particular those rich in uridine and guanosine and those in small nuclear ribonucleoprotein 
(snRNP), were shown to trigger pDCs to produce type I IFNs through TLR7 when 
delivered to endosomes by DOTAP at a concentration range of 3-10 µg/ml (Vollmer et al. 
2005; Savarese et al. 2006). For mRNA complexed to PEI at a concentration range of 0.3-
1 µg/ml an immune induction was also observed. Our experiments showed for the first 
time that a ds character of self-RNA or at least intermolecular secondary structures of self-
RNA might be responsible for immune recognition. DsRNA is found only in minute 
amounts in normal cells and represents a danger signal when aberrantly transferred to the 
endosome (Majde et al. 1998; Weber et al. 2006). Edy et al. showed that fragmentation of 
double-stranded RNA either by RNase A, RNase III treatment or ultrasonic irradiation led 
to a significant fall in the capacity of RNA to induce the formation of circulatory interferon 
in the mice (Edy et al. 1974).  
The IFN-α-inducing activity of self-RNA at a concentration of 2 µg/ml, which can not be 
observed for further higher or lower concentrations, can be described by a Heidelberger 
curve. Also for titration of A/PR/8/MDCK-RNA a Heidelberger curve could be observed 
(data not shown). Complexation of an increasing amount of nucleic acids led to a 
decrease in the initial zeta potential value of liposomes, and this influenced the 
transfection efficiency of the liposomes (Almofti et al. 2003). A change in the zeta potential 
upon forming different charge ratios of nucleic acids to liposomes might explain the 
Heidelberger curve. Moreover, a change in the zeta potential might also be a reason for 
self-RNA becoming immunostimulatory upon RNase A treatment. 
Fragments generated by metal-induced hydrolysis of self-RNAs showed the same size as 
RNase A-derived fragments. For fragments derived by Zn2+-induced hydrolysis, there was 
no IFN-α response detectable when complexed to DOTAP in human PBMCs. However, 
for fragments derived by Pb2+-induced hydrolysis, there was an IFN-α response detectable 
when complexed to DOTAP in human PBMC cells. It is difficult to explain the different 
behaviour of the fragments generated by metal-ion induced hydrolysis. Pb2+-induced 
cleavage occurs preferentially in bulges, loops and other ssRNA regions (Hartmann et al. 
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2005). Since Zn2+ is a component of the single-stranded specific enzymes S1 nuclease 
and P1 nuclease (McCall et al. 2000), we can conclude that Zn2+ like Pb2+, preferentially 
cleaves ssRNA. Both metal ions might cleave the phosphodiester bond by generating a 
2`,3`-cyclic phosphate and 5`-hydroxyl groups as cleavage products (Matsuo et al. 1995; 
Yashiro et al. 2002; Hartmann et al. 2005; Wang et al. 2007). Thus, Pb2+ and Zn2+ behave 
in a similar way concerning the cleavage of RNA. 
A further question arises as to whether fragments derived by ultrasonic treatment or Zn2+-
induced hydrolysis really do not show any stimulatory potential in PBMC cells. Further 
concentrations of the fragments need to be tested. In addition, it should be controlled 
regarding whether or not they induce an immune response when complexed to 
Lipofectamine 2000. Moreover, a novel method has to be developed in order to analyze 
and compare the different ends of the fragments generated by the different techniques. It 
has to be analyzed what makes the difference between the fragments generated by Pb2+  
and Zn2+-induced hydrolysis. 
The removal of the 2`,3`-cyclic phosphate of RNase A-derived fragments or metal-induced 
fragments also did not change the stimulatory properities. We checked if the 2`,3`-cyclic 
phosphate is either responsible for the IFN-α-inducing ablilities of RNase A-derived 
fragments or if the 2`,3`-cyclic phosphate might inhibit the stimulatory potential of 
fragments generated by Zn2+-induced hydrolysis.  
It is also interesting to note that proteasomes show endonuclease activity (Pouch et al. 
1995; Petit et al. 1997). The best characterized properties of proteasomes are their 
multiple endopeptidase activities (Petit et al. 1997). Surprisingly, two distinct α-type 
subunits of 20S proteasomes (subunit zeta and iota) have been identified that are 
associated with RNase activity. Proteasome subunits zeta and iota hydrolyzed tobacco 
mosaic virus RNA, whereas none of the other subunits degraded the RNA under the same 
conditions (Petit et al. 1997). Furthermore, it was shown that proteasomal endonuclease 
activity is rather RNA specific, since 5S rRNA, 9S globin mRNA and lysyl-tRNA were not 
degraded by proteasomes (Pouch et al. 1995). It was claimed that proteasomes might be 
involved in the destabilisation of cytokines mRNAs containing AUUUA sequences as well 
as of viral mRNAs (Jarrousse et al. 1999; Gautier-Bert et al. 2003). It has also been 
observed that 18S rRNA fragments are degraded by proteasomes (Petit et al. 1997; 
Horikoshi et al. 1998). It would be very interesting to analyze whether self-RNA becomes 
immunostimulatory upon incubation with proteasomes. Since proteasomes are located in 
the cytoplasm (in addition to the nucleus), RNA fragments could be detected for example 
by the cytosolic helicases upon incubation with proteasomes.  
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6.3.4. Double-stranded character is important for IFN-α signaling 
The conformation of the RNase A-derived fragments (either ss or ds) was analyzed by 
treatment with the ds-specific RNase III. The RNase A-derived fragments were treated in 
different ways, then complexed to DOTAP and used for the stimulation of PBMC cells. 
The effect of the treatment was controlled by agarose electrophoresis. We were able to 
show that immunostimulatory RNase A-derived fragments were sensitive to ds-specific 
RNase III. RNase III abolished signaling by RNase A-derived fragments complexed to 
DOTAP in human immune cells. Schmidt et al. have found that RIG-I ligands require 
base-paired structures in conjugation with a free 5`-triphosphate to trigger a type-I 
interferon response (Schmidt et al. 2009). The ds character gives the first indication of 
RIG-I-dependent immune signaling. Since ethidium bromide staining showed no 
difference for mock or RNase III-treated RNase A-derived fragments, we can conclude 
that only the stimulatory fraction of the digest shows ds character, whereas other 
components of the digest are of an ss nature. It can be hypothesized that some of the 
fragments derived by RNase A digest have the propensity to form ds structures that are 
recognized by immune cells, whereas most of them are of ss conformation. 
In conclusion, the RNase III treatment of RNase A-derived fragments showed that the 
stimulatory principle of the digest might be ds. Regarding the observation that RNase III 
also cuts ssRNA (Dunn 1976), further analysis is required in order to analyze the 
conformation of RNase A-derived fragments. 
 
6.3.5. Identification of the immunostimulatory RNA species 
Self-RNA is highly methylated and contains numbers of pseudouridines, which have been 
shown to lack the ability to activate endosomal TLRs (Kariko et al. 2005; Robbins et al. 
2007). Host-derived RNA contains many modifications, but nucleotide modifications are 
usually found in clusters, leaving a significant number of RNA nucleotides unmodified. In 
18S rRNA approximately 40 positions are modified by 2`-O-methyl groups (4.3% modified 
nucleosides), and the occurrence is clustered (Maden 1990). Since the sequence of rRNA 
contains numerous stretches rich in guanosine and uridine, it is unclear why these non-
modified sequences within rRNA do not activate immune cells. Our finding that fragments 
derived by RNase treatment of self-RNA can activate the immune system indicates that 
non-modified sequences in mammalian RNA are sufficient to induce immune activation if 
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RNA is protected from extracellular degradation and transported into endosomal 
compartments. 
The ethidium bromide staining of the RNase A-derived fragments on a PAA gel shows a 
smear of degradation fragments, showing a size in the range from < 20 bp to 100 bp. 
However, below the marker size of 100 bp we were able to observe a pattern of ca. 3 
distinct bands. The production of such specific fragments indicated that splitting of the 
RNA was not a random process. Concerning the conditions employed for the digest—
either mild conditions (low concentration of the enzyme, short incubation time) or stronger 
conditions—the band pattern showed some variability from one experimental series to 
another. The long smear in the gel is a result of unspecific random degradation. The RNA 
bands might be responsible for the IFN-α inducing activity of the RNase A-derived 
fragments. To test this, the RNA bands should be eluted from the PAA gel and tested for 
their immunostimulatory ability as described by Edy et al. (Edy et al. 1976). The various 
data in the literature on partial or complete digestion of RNA by RNases are difficult to 
compare, as different conditions (time, enzyme:substrate ratio) of digestion and different 
assays have been used by different authors. Depending on the conditions for the RNase 
A digest, there was either a band pattern (Edy et al. 1976) or no specific cleavage 
products generated (Wreschner et al. 1981). 
In order to address the question regarding which fragments of the RNase A digest are 
responsible for the IFN-α inducing capacity, we used Micro Bio-Spin columns which purify 
nucleic acids larger than 20 bases by removing single nucleosides. The first fraction, 
which contains larger fragments, when complexed to the cationic transfection reagent 
DOTAP, stimulated human PBMC cells to produce IFN-α, whereas the subsequent 
fractions containing single nucleosides showed no IFN-α secretion in human PBMC cells. 
This showed that fragments longer than 20 nucleotides and not single nucleosides are 
responsible for the immunostimulatory potential. 
To identify the immunostimulatory RNA species of the RNase A-derived fragments, we 
fractionated the digest into different sizes by using XBRIDGETM OST C18 columns and 
high performance liquid chromatography (HPLC). The obtained fractions from the column 
showed longer RNA fragments with the increase in time. The first fractions (fractions 3-5) 
containing single nucleosides were not able to induce type-I interferon when complexed to 
DOTAP in human PBMC cells, whereas fractions obtained at a later time (fractions 16-19) 
contained the stimulatory RNA species. Surpisingly, these fractions could not be stained 
with ethidium bromide. These fractions might be of an ss character, since ssRNA 
fragments cannot be stained with ethidium bromide. Only larger fragments (fractions 21-
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29) could be visualized by ethidium bromide staining, but these fractions showed no ability 
to induce IFN-α in human PBMC cells when complexed to DOTAP. The finding that the 
stimulatory fragments could not be stained with ethidium bromide could explain the 
behaviour of the RNase A-derived fragments upon RNase III treatment. Whether the 
sample was mock- or RNase III-treated could not be visualized by ethidium bromide 
staining. Another possibility might be to try the staining of the fragments with Syber Gold 
(Invitrogen), which shows a high sensitivity to nucleic acids. 
The IFN-α response induced by the fractionated fragments was only low in comparison to 
the complete digest. It is possible that the stimulatory capacity of the fragments is lost 
after passing through several columns or that an interplay between different fractions is 
necessary for inducing a high IFN-α response. Remembering the FCS sensitivity of the 
RNase A-derived fragments, it becomes apparent that the immunostimulatory activity of 
the fragments is very subtle. 
The identified fragments should be used to create a RNA (cDNA) sequence library, 
followed by T/A-cloning and sequencing. Identified sequences will be validated for their 
immunostimulatory potential after in vitro transcription or chemical synthesis and 
complexation to DOTAP in human PBMC cells. 
So far, only the immunostimulatory capacity of a mixture containing ribosomal RNA, 
transfer RNA and mRNA has been demonstrated. It is currently unknown whether certain 
RNA species or RNA sequences mediate immune stimulation. For this reason, various 
RNA species from total RNA such as ribosomal RNA (rRNA), transfer RNA (tRNA) or 
messenger RNA (mRNA) have to be purified and analyzed for their immunostimulatory 
potential after partial RNase A treatment.  
6.3.6. Monocytes are responsible for recognition of RNase A-
derived fragments 
Comparing the immunostimulatory ability of the fragments derived from RNase treatment 
in human monocytes and PBMC cells showed that monocytes represent the cell type 
responsible for recognizing the RNase-derived fragments. Thus, as shown by Hansmann 
et al. for stimulation with Poly (I:C)/DOTAP, we observed also that monocytes have the 
capacity to produce high amounts of IFN-α upon stimulation with RNase A-derived 
fragments complexed to DOTAP (Hansmann et al. 2008). The obtained monocytes had a 
purity of about 90%. Since monocytes do not express TLRs like TLR9 or TLR7, but 
instead express cytosolic helicases, this result might give us a first indication of the 
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responsible receptor. In order to exclude an involvement of DCs, another approach might 
be to analyze whether depletion of myeloid and plasmacytoid DC subsets via antibodies 
from PBMC cells actually reduce the IFN-α producing capacity of human PBMCs upon 
stimulation with RNase-derived fragments. 
6.3.7. Receptor for recognition of fragments from self-RNA 
Very little is known about small self-RNA recognition. TLRs could be involved due to (1) a 
possible decreased number of nucleotide modifications in the cleavage products 
compared to the full length eukaryotic RNA, or (2) the presence of particular sequence 
patterns of a certain length. Furthermore, the cytosolic RNA-helicases RIG-I and MDA-5 
might detect the fragments generated by RNase digest due to the fact that (1) the 
cleavage products show the right ends like phosphates and thereby represent a possible 
target structure for RIG-I, or (2) the fragments form structures that display partial ds 
conformation. For small self-RNAs produced by the action of RNase L on cellular RNA it 
was shown that the signaling involves RIG-I, MDA-5 and IPS-1 (Malathi et al. 2007). 
To investigate whether TLRs or cytosolic helicases mediate the recognition of the 
fragments derived from RNase A treatment; we planned to use Flt3-derived dendritic cells 
from respective knockout mice. But for Flt3-derived dendritic cells, it was observed that 
there was often only a very low or no IFN-α response to the RNase-derived fragments, 
although the fragments were controlled parallel on PBMC cells. It is possible that the IFN-
α response induced by RNase A-derived fragments in Flt3-derived dendritic cells was 
below the threshold of the ELISA. For future experiments, it should be analyzed whether 
the RNase A-derived fragments induce an expression of the activation marker CD69 in 
Flt3-derived dendritic cells. Another important aspect may be that the RNase A-derived 
fragments do not contain a 5`-triphosphate end, which murine immune cells need more for 
RIG-I dependent signaling than do human immune cells (6.2.4). The possibility that the 
immune induction of RNase A-derived fragments is species-specific, which in our case 
would means that it only works for human PBMC cells and not for murine immune cells, is 
excluded by the observation that RNase L-derived fragments of self-RNA induced an IPS-
dependent immune activation in murine MEF cells (Malathi et al. 2007). Since some 
experiments indicate that the recognition of partially digested self-RNA fragments is IPS-
dependent (Malathi et al. 2007), the Flt3-derived dendritic cells expressing TLR 7 and 9 
may represent the wrong cell type for recognizing the fragments derived by RNase A 
digest. But in GM-CSF and M-CSF derived cells, which are regarded as analogs to human 
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myeloid dendritic cells, there was also no IFN-α response detectable upon transfection of 
fragments derived from RNase treatment (data not shown).  
Using HEK293 cells transfected with RIG-I expression vectors along with IFN-ß reporter 
plasmid, we observed that the fragments derived by RNase A treatment activated RIG-I 
when complexed to Lipofectamine 2000 but not when complexed to DOTAP or given 
alone. Upon RNase III treatment of RNase A-derived fragments complexed to 
Lipofectamine 2000, the immune response was abrogated, showing that the ds character 
of the fragments was important for the RIG-I dependent immune response. The 
phosphate end had no influence for the recognition of the fragments, because 
dephosphorylation did not reduce IFN-ß activation. But here again the question arose as 
to how efficient the dephosphorylation method was. 
Regarding the FCS sensitivity of the RNase A-derived fragments, it becomes apparent 
that the immunostimulatory activity of the fragments is very subtle. The generated 
fragments complexed to DOTAP showed a serum dependent IFN-α induction in human 
PBMC cells. The fragments induced the highest IFN-α response in human PBMC cells 
when using 1-2% serum, whereas for higher serum concentrations like 10% serum the 
immune response was decreased. The exact composition of FCS (proteins, antibodies, 
growth factors) is generally less defined and can vary from batch to batch. For example, a 
higher titer of antibodies binding to the RNA fragments might attenuate the 
immunostimulatory potential of the RNase A-derived fragments. With regard to other 
immune cells, e.g., murine immune cells or human HEK293 cells maintained in 10% 
serum, this could explain the variable IFN-α response for RNase A-derived fragments on 
murine and human HEK293 cells. For Flt3-derived DCs, we did find that the IFN-α 
response to RNase A-generated fragments was increased by testing lower serum 
concentrations, but unfortunately this result was not reproducible. Further experiments 
with GM-CSF and M-CSF derived cells should show whether fragments generated by 
RNase treatment induced an immune response by using lower serum concentrations. If 
this were the case, the responsible receptor for recognizing the fragments derived by 
RNase treatment could be identified by using the respective knockout mice. Considering 
the serum sensitivity of the fragments, we also tested different serum concentrations in 
HEK293 cells and observed an increase in the IFN-ß response for fragments complexed 
to Lipofectamine 2000 but not for DOTAP by using lower serum concentrations (data not 
shown). 
The data obtained by stimulating human monocytes already exclude an involvement of 
TLR9 or TLR7, so only the responsibility of the cytosolic helicases has to be tested. 
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6.3.8. Cell types and transfection reagents 
The RNase A-derived fragments were recognized by immune cells in different ways as 
shown in Table 6. Whereas in human PBMC cells IFN-α secretion was observed upon 
transfection with RNase A-derived fragments complexed to DOTAP at a final RNA 
concentration in the range of 5-50 µg/ml (further concentrations were not tested), in 
human HEK293 cells, overexpressing RIG-I IFN-ß activation was enhanced when the 
fragments were complexed to Lipofectamine 2000 at a final RNA concentration of 1 µg/ml. 
For murine immune cells, we could only observe a variable IFN-α response. In conclusion, 
we can say that, depending on the immune cell type, different concentrations of the RNA 
fragments and different transfection reagents are necessary for inducing an immune 
activation. 
 
Table 6: Influence of the cell type and the transfection reagent for the recognition of RNase 
A-derived fragments (LF 2000 = Lipofectamine 2000) 
 
6.3.9. Relevance of the recognition of self-RNA fragments 
Extracellular self-RNA normally does not lead to innate immune activation because it is 
rapidly degraded by RNases and fails to access endosomal compartments of dendritic 
cells. However, in some autoimmune diseases, self-nucleic acids gain access to 
endosomal compartments by the help of autoantibodies or antimicrobial peptides (Gilliet et 
al. 2008). For example, in systemic lupus erythematosus (SLE), self-RNA and self-DNA 
are complexed with autoantibodies, which deliver the nucleic acids into endosomal 
compartments of pDCs via FcyRII-mediated endocytosis (Ronnblom and Alm 2003; Barrat 
Cell type PBMC cells 
and monocytes 





























IFN-α - - 
low 
IFN-α 
- - IFN-ß 
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et al. 2005; Means et al. 2005), leading to an aberrant IFN-α production (Theofilopoulos et 
al. 2005; Banchereau and Pascual 2006). DC activation by immune complexes formed by 
U1snRNP and SLE-IgG or isolated U1snRNA in complex with cationic liposomes is largely 
mediated by TLR7 (Vollmer et al. 2005; Savarese et al. 2006). In psoriasis, self-DNA 
forms complexes with the cationic antimicrobial peptide LL-37, which gain access to 
endosomal TLR9 (Lande et al. 2007). Recently, it was found that LL-37 also forms 
complexes with self-RNA (Ganguly et al. 2009). These complexes are highly protected 
from RNase degradation and gain access to endosomal compartments, where they trigger 
TLR7. Moreover, it should be noted that self-RNA could activate the RIG-I pathway under 
specific circumstances, for example, when excess RNA is not properly degraded by 
nucleases or mitochondrial RNA is released (Krug 2008). An important protective 
mechanism is the rapid clearance of apoptotic material and degradation of excess nucleic 
acids by nucleases. Severe autoimmune diseases develop in mice and humans with 
defects in these enzymes. For example, the Aicardi-Goutieres syndrome shows four 
mutations: one affects the DNAse III, and the other three were relocated to the RNAseH2 
(Crow et al. 2006; Rigby et al. 2008). Furthermore, it is possible that RNA degraded 
during apoptosis and delivered to endosomes activated immune cells (Diebold et al. 
2006).  
The data obtained in this work regarding self-RNA fragments, which induced an IFN-α 
response in human PBMC cells upon complexation to DOTAP or an IFN-ß activation in 
HEK293 cells upon complexation to Lipofectamine 2000, clearly demonstrates the 
possible role of self-RNA fragments generated by incomplete RNase treatment in 
autoimmune diseases. 
For future work, it would be interesting to use the ability of the self-RNA fragments 
complexed to cationic lipids to induce IFN-α. A pratical approach would be to analyze their 
role for vaccination studies. 
To further gain insight into changes in immune cells induced by RNase-derived fragments, 
their global transcriptional profile could be analyzed with Microarray chips. This method 
allows the observation of the expression of thousands of genes and their coordinate 
change in a given condition. Therefore, RNA has to be isolated from immune cells after 
stimulation with RNase-derived fragments or medium alone, and hybridized to the 
Affymetrix chip. So, different expressed genes which are induced following stimulation 
with RNase A-derived fragments could be identified. 
 
  Summary 
 156
7. Summary 
RNA provides a stimulus for innate immunity either by activating the endosomal TLRs (3, 
7 and 8) or by triggering cytosolic RNA sensors (RIG-I and MDA-5). RNA recognition 
results in the secretion of type-I interferons and / or proinflammatory cytokines. 
Recognition of foreign RNA is thought to occur due to the presence of non-self strucures, 
such as abundance of nucleotide modifications, ds conformation or the presence of a 
terminal 5`-triphosphate. Discrimination between self and non-self-RNAs is very important 
to prevent constant induction of type-I IFNs which would lead to autoimmune responses. 
However, the exact structural requirements for RNA recognition are still mainly 
unidentified. Within this work, the influence of RNA modifications and the 
immunostimulatory potentials of RNA from influenza-infected cells, small self-RNAs and 
cathelicidin/RNA complexes were analyzed. 
The first part of this thesis identified the 2`-position of the ribose as crucial for TLR7-
mediated immunorecognition by introducing nucleotide modifications in RNA. We were 
able to show that a single 2`-O-ribose methylation within a natural fragment of 18S rRNA 
prevented IFN-α production, however secretion of proinflammatory cytokines was not 
impaired in human immune cells but in murine immune cells. Since murine TLR8 is non-
functional, the RNA 63-induced immunostimulatory activity in murine cells was strictly 
TLR7-dependent.  
In the second part of this thesis we introduced the human antimicrobial peptide LL-37 
and its murine homolog cathelicidin-related antimicrobial peptide (CRAMP), which function 
as carriers for RNA from virus-infected cells and induce innate immune activation. In the 
past, it was shown that ss-synthetic oligonucleotides (ORN) complexed to the cationic 
transfection reagent DOTAP induce antigen-specific cytotoxic T cells and antibodies in a 
TLR7-dependent manner. Since DOTAP is toxic, we analyzed whether cathelicidin/RNA 
complexes could function as carriers in vaccine formulations. Moreover, we investigated 
the characterictics of RNA extracted from influenza-infected cells, which was recognized 
as having a non-self structure. Immune cells are potently activated by viral RNA but not by 
mammalian total RNA, which is abundant in modified nucleosides. It was demonstrated 
that the 5`-triphosphate moiety of RNA from influenza-infected cells is not the only target 
structure for RIG-I but that the ds character of RNA from influenza-infected cells represent 
a second structural feature that activate RIG-I. 
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The third part of this thesis concentrated on the interesting observation that RNase A 
treatment of non-immunostimulatory self-RNA rendered it immunostimulatory. First, we 
determined the size of the fragments and the responsible receptor for recognizing the 
cleavage products. In addition, we tested other RNase types, especially concerning their 
generated ends. In order to determine whether the conformation of the stimulatory RNA 
fragments were ss or ds, we treated the RNase digest with the ds-specifc RNAse III. 
Moreover, we generated RNA fragments of similar size by ultrasonic treatment and metal-
induced hydrolysis and analyzed their ability to induce IFN-α. The immunostimulatory 
potential of self-RNA fragments may be useful as a possible vaccine formulation. Besides 
the possible advantages of RNA fragments, their possible role in autoimmune diseases 
have to be considered. 
Finally, on the basis of the results obtained up to this point, we have generated 
convincing data concerning the immunostimulatory capacity of RNA and cathelicidin 
complexes. A key finding of this thesis was the observation that self-RNA became 
immunostimulatory upon RNase treatment. Further investigations will show whether, 
besides RIG-I, additional immune system receptors are involved in the recognition of 
fragments generated by RNase treatment of self-RNAs and whether cathelicidin/RNA 
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8. Zusammenfassung 
RNA stellt einen Stimulus für das angeborene Immunsystem durch die Aktivierung der 
endosomalen TLRs (3, 7 und 8) oder der zytosolischen RNA Sensoren (RIG-I und MDA-
5) dar. Die Erkennung von RNA resultiert in der Sekretion von Typ-I Interferonen und / 
oder proinflammatorischen Zytokinen. Fremd-RNA wird über das Vorhandensein von 
"Nicht-Selbst" Strukturen, wie gehäufte Nukleotidmodifikationen, doppelsträngige 
Konformation oder eine terminale 5`- Triphosphategruppe, erkannt. Diese Unterscheidung 
zwischen Selbst- und Fremd-RNA verhindert eine permanente Typ-I Interferon Sekretion 
und somit Autoimmunerkrankungen. Jedoch ist nach wie vor wenig über die strukturellen 
Einzelheiten der RNA Erkennung bekannt. In dieser Arbeit wurde der Einfluss von RNA-
Modifikationen und das immunstimulatorische Potential von RNA aus Influenza-infizierten 
Zellen, Selbst-RNA Fragmenten sowie von Cathelizidine/RNA Komplexen analysiert. 
Der erste Teil der Arbeit identifizierte durch die Einführung entsprechender 
Modifikationen die 2`-Position der Ribose als entscheidende Struktur für die Erkennung 
durch TLR7. Es konnte gezeigt werden, dass die Methylierung der Ribose innerhalb eines 
natürlichen Fragmentes der 18S rRNA die Induktion von IFN-α in humanen und murinen 
Immunzellen sowie die Sekretion von proinflammatorischen Zytokinen in murinen 
Immunzellen, nicht jedoch in humanen Immunzellen, unterdrückte. Die RNA 63 induzierte 
immunstimulatorische Aktivität in murinen Immunzellen ist TLR7 abhängig, da der murine 
TLR8 nicht funktionell ist. In humanen Immunzellen verwandelte eine 2`-O-Methylierung 
einen TLR7/TLR8 Liganden zu einen TLR8-spezifischen Liganden und induzierte 
proinflammatorische Zytokine. 
Im zweiten Teil dieser Arbeit führten wir das antimikrobielle Peptid LL-37 und sein 
murines Homolog CRAMP ein, welche als Träger für RNA aus virus-infizierten Zellen 
fungieren und eine Immunantwort auslösen. In der Vergangenheit wurde gezeigt, dass 
einzelsträngige synthetische Oligonukleotide (ORN) komplexiert mit dem kationischen 
Transfektionsreagenz DOTAP antigen-spezifische zytotoxische T-Zellen und Antikörper in 
einer TLR7 abhängigen Weise induzierten. Da DOTAP toxisch ist, analysierten wir, ob 
Cathelizidine/RNA Komplexe in Impfstoffen eingesetzt werden könnten. Außerdem 
untersuchten wir die Charakteristika von RNA, welche aus Influenza-infizierten Zellen 
isoliert und als "Nicht-Selbst" Struktur erkannt wurde. Immunzellen werden durch virale 
RNA aktiviert aber nicht durch eukaryotische RNA, welche gehäuft 
Nukleotidmodifikationen enthält. Es konnte gezeigt werden, dass eine terminale 5`-
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Triphosphatgruppe nicht die einzige Erkennungsstruktur in RNA aus Influenza-infizierten 
Zellen darstellt, sondern auch die Doppelstrangkonformation von RNA als unabhängiger 
Stimulus für RIG-I fungiert. 
Der dritte Teil dieser Arbeit konzentrierte sich auf die Beobachtung, dass eine RNase A 
Behandlung von nicht-immunstimulatorischer Selbst-RNA dieser immunstimulatorische 
Eigenschaften verleiht. Zuerst analysierten wir die Größe der RNA Fragmente und den 
verantwortlichen Rezeptor, der die RNA Spaltprodukte erkennt. Zusätzlich testeten wir 
andere RNase Typen hinsichtlich der generierten Enden und ihrer immunstimulatorischen 
Eigenschaften. Um die Konformation der stimulatorischen RNA Fragmente zu bestimmen, 
d.h. ob sie einzelsträngig oder doppelsträngig vorlagen, behandelten wir den Verdau mit 
der Doppelstrang-spezifischen RNase III. Zusätzlich generierten wir RNA Fragmente 
gleicher Größe durch Ultraschall-Behandlung und Metall-induzierter Hydrolyse und 
analyzierten ihre Fähigkeiten, IFN-α zu induzieren. Das immunstimulatorische Potential 
von Selbst-RNA Fragmenten könnte als mögliches Adjuvantium Verwendung finden. 
Allerdings müsste hierbei neben den möglichen Vorteilen von RNA Fragmenten, auch 
deren eventuelle Rolle in Autoimmunerkrankungen bedacht werden. 
Auf der Basis der bisher erzielten Ergebnisse haben wir überzeugende Daten bezüglich 
der immunstimulatorischen Kapazität von RNA und Cathelizidine Komplexen gewonnen. 
Die Haupterkenntnis dieser Arbeit war, dass Selbst-RNA durch RNase Behandlung 
immunstimulatorisch wird. Weitere Untersuchungen werden zeigen, ob neben RIG-I 
weitere Rezeptoren des Immunsystems an der Erkennung von RNA Fragmenten beteiligt 
sind, und ob RNA/Cathelizidine Komplexe als Adjuvantien fungieren können. 
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10. Abbreviations and Units 
°C celsius 
µ micro (10 -6) 
A adenosine 
A260 absorption at 260 nm 
AA amino acids 
APC allophycocyanine 
APS ammonium persulfate, (NH4)2S2O8 
Bp base pair(s) 
BPB bromphenol blue 
BSA bovine serum albumin 
C cytosine 
Cardif Caspase activation recruitment domain inducing IFN-ß 
CD cluster of differentiation 
cDNA complementary desoxyribonucleic acid 
cEnd end concentration 
cStock stock concentration 
DAPI 4,6 Diamin-2-phenylindoldihydrochlorid 
DC dendritic cell 
DEPC diethylpyrocarbonat 
DMEM Dulbecco’s Modified Eagles Medium 
DNA deoxyribonucleic acid 
DNase deoxyribonuclease 
DOTAP N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-trimethyl-ammoniummethylsulfate 
dNTP deoxynucleoside triphosphates 
ds double-strand 
DTT dithiothreitol 
EDTA ethylenediamine tetraacedic acid 
ELISA enzyme-linked Immunosorbent Assay 
FACS fluorescence-activated cell sorting 
FCS fetal calf serum 
FITC fluoresceinisothiocyanat 
  Abbreviations and Units 
 177
Flt3 Fms-like tyrosine kinase 3-ligand 
FSC forward scatter 
g gram 
G guanosine 
GM-CSF granulocyte macrophage-colony stimulating factor 
h hour(s) 
HEK293 human embryonic kidney cells 
HEPES N-2-Hydroxyethylpiperazin-N`-2-ethane sulfonic acid 
HPLC high performance liquid chromatography 
HRP horseraddish peroxidase 
IFN interferon 
IKB  inhibitor KB 
IKK IKB kinase 
IL interleukin 
IPS-1 interferon-ß promoter stimulator 1 
IRAK IL-1-receptor-associated kinase 
IRF interferon regulatory factor 





LGP2 Laboratory of genetics and physiology 2 
LRR leucine-rich-repeats 
LTA Lipoteichoic acid 
m milli (10 -3) 
M molar [mol/l] 
mA millampere 
MAVS mitochondrial differentiation-associated gene 5 
MDA-5 melanoma differentiation-associated gene 5 
MDCK Madin Darby canine kidney 
mDC myeloid dendritic cell 
MHC major histocompatibility complex 




mRNA messenger RNA 
MOPS 3-(N-morpholino)-Propansulfonsäure 
MW molecular weight 
MyD88 myeloid differentiation primary response protein 88 
n nano (10-9) 
n.t. not tested 
NF-κB nuclear factor κB 
NLR NOD (nucleotide-binding and oligomerization domain)-like receptor 
nt(s) nucleotide(s) 
NTP ribonucleosidtriphosphate 
OD optical density 
ODN oligodeoxyribonucleoside 
OPD o-Phenylendiamin Dihydrochloride 
p.a. pro analysis 
PAA polyacrylamide 
PAGE polyacrylamide gel electrophoresis 
PAMP pathogen-associated molecular pattern 
PBSdef phosphate buffered saline -deficient of calcium and magnesium 
PBS++ phosphate buffered saline with calcium and magnesium 
PBMC peripheral blood mononuclear cell 
PCR polymerase chain reaction 
pDC plasmacytoid dendritic cell 
PE phycoerythrin 
Poly (I:C) polyinosine-deoxycytidylic acid 
PRR pattern recognition receptor 
PTO phosphothioate 
R-848 resiquimod 
RIG-I retinoic acid inducible gene I 
RLR RIG-I-like receptors 
RNA ribonucleic acid 
rRNA ribosomal RNA 
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RNase ribonuclease 
RP-HPLC reverse phase high performance liquid chromatography 
rpm rounds per minute 
RPMI 1640 Roswell Park Memorial Institute 
RT reverse transcriptase 
RT room temperature 
s second 
SDS natriumdodecylsulfate 
ss single-strand  
SSC side scatter 
T thymine 
TAE Tris/Acetate/EDTA 




TLR toll like receptor 
Tm melting temperature 
TNF Tumor-Necrosis-Factor 
tRNA transfer RNA 
Tris tris-hydroxymethylaminomethan 
U Unit(s) (unit for enzyme activity) 
VISA virus induced signaling adaptor 
WT wild-type 
XCB xylene cyanol blue 
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